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CT densitometry is the method of quantifying emphysema using specialised 
software programs, and its ability to assess emphysema has been validated clinically 
and pathologically. However, the technique has yet to be standardised and its 
clinical utility remains unclear. The systematic review performed highlighted the 
strong relationship to clinically relevant parameters, but demonstrated that vast 
heterogeneity that exists between studies using CT Density. This heterogeneity was 
overcome when only studies using the same software program, reconstruction 
algorithm and slice thickness were meta-analysed.  
The variability the two leading software programs, PULMO and Pulmonary 
Workstation was calculated, and showed that where the same slickness and 
reconstruction algorithms were used, the two programs showed directly comparable 
results for volume and PD15. The difference between -910HU and -950HU is likely 
clinically negligible but requires further consensus, and the difference between 
different slice thicknesses will require adjustment. 
Analysis of CT scans performed within the Birmingham AAT registry confirmed the 
strong relationship between CT and lung function and quality of life measures. For 
the first time it was also shown that PD15 and -950HU whole lung are both 
predictive of mortality. Through a variety of methods the MCID for annual CT 
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 Introduction Chapter 1
 
1.1. Chronic Obstructive Pulmonary Disease 
 
Chronic Obstructive Pulmonary Disease (COPD) is a common and preventable 
respiratory disease, characterised by a chronic inflammatory response in the lung 
tissue secondary to inhaled noxious gases or particles, most commonly tobacco 
smoke(1). It is currently the 4th leading cause of death worldwide and projected to be 
the third by 2020(2, 3). Diagnosis is made on the presence of symptoms of 
breathlessness, chronic cough and exacerbations together with spirometry. The 
degree of inflammatory response varies between patients, with only a few who 
smoke going on to develop severe airflow limitation and a diagnosis of COPD(4). 
There are multiple factors involved besides environmental exposure (e.g. cigarettes, 
air pollution) such as genetic abnormalities such as Alpha one Antitrypsin Deficiency 
(AATD) or abnormal lung development(5). Patients with COPD suffer the effects of 
chronic airway inflammation even after smoking cessation, which cause the 
symptoms of chronic bronchitis, airways obstruction and emphysema (6-8). 
1.1.1. Anatomy of the airways 
 
Moving distally from the trachea, the airways sequentially divide over 23 
generations into smaller and smaller divisions down to the terminal and then 
respiratory bronchioles.16 divisions occur before the respiratory bronchioles, 
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constituting the conducting zone, and a further 7 more distally in the transitional and 
respiratory zones (see Figure 1.1)(9). High Resolution Computed Tomography 
(HRCT) is able to visualise to around 2mm, which equates to the 7th-9th order airway, 
or the inner two thirds (10).  






1.1.2. Anatomy of the parenchyma  
 
The lung parenchyma is the area of the lung responsible for gas exchange i.e. from 
the respiratory bronchioles down to the alveoli (pulmonary acinus). These are 
fenestrated with alveolar ducts , and continue to subdivide until the final alveolar 
ducts/sacs (12). Histologically in the centre of the acinus is the bronchiole and its 
adjacent bronchial artery, with the venous and lymphatic drainage on the periphery 
of the unit(13). The adjacent alveoli are separated by the interlobular septae with 
communicating fenestrations. The alveoli remain patent and compliant through 
trans-pulmonary pressures and the alveolar surfactant. Proteins including elastin, 
proteoglycans and collagen make up the alveolus and therefore the presence of 
proteases, and imbalance between proteases and anti-proteases, damages their 
structure and function(14); this leads to emphysema.  
1.1.3. Spirometry 
 
Spirometry measures volume of air over time during a forced expiratory manoeuvre. 
The Forced Expiratory Volume in 1 second/Forced Vital Capacity (FEV1/FVC ) ratio 
measures the degree of resistance to airflow during expiration over one second 
compared to their full capacity, and a ratio <70% indicates airflow obstruction. The 
FEV1 alone is then used to grade the severity of the obstruction, with the Global 
initiative for chronic Obstructive Lung Disease (GOLD) guidelines using thresholds 
of 80%, 50% and 30% to diagnose mild, moderate and severe disease(1). Appendix 1 
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shows the formulae used to calculate predicted normal values, which vary with age, 
height and sex, and also show racial variation. Airways measuring less than 2mm 
have been shown to be the largest contributor to airflow resistance, likely due to the 
inflammation and elastin degradation overcoming the smaller airways’ ability to 
maintain normal integrity and elastic recoil(15).  
1.1.4. Gas Transfer 
 
DLCO (Diffusing capacity of the Lung for Carbon Monoxide) measures the ability of 
gas to transfer across from the alveoli in to the circulation. Changes to alveolar 
ventilation and its blood supply, thickening of the interstitium or the haemoglobin 
can all affect it.  KCO (Carbon Monoxide transfer coefficient) is calculated by DLCO 
divided by the alveolar volume (see also Appendix 1)(16). Breathless patients with 
parenchymal lung damage may sometimes exhibit a low DLCO with a relatively 
preserved FEV1(17). In those with very severe COPD FEV1 decline slows down 
(Figure 1.2) (18), making its use as a disease marker less relevant in the later stages of 
disease, particularly because DLCO continues to decline, and does so more rapidly in 
the later stages (19).  
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Figure 1.2. Rate of annual FEV1 decline in patients with AATD 
  
1.1.5. Lung Volumes 
 
Where there is increased expiratory flow limitation (EFL) the length of time to 
complete lung emptying is prolonged, and if this time exceeds the drive to next the 
next breath in, the lungs do not fully empty such that the Residual Volume (RV) will 
rise (20). This effect is exacerbated by dynamic hyperventilation during episodes 
where the minute ventilation is increased (e.g. infective exacerbation, panic attacks) 
or where there is an increase in airflow resistance (e.g. bronchospasm). The volume 
of lung subsequently occupied by the RV reduces the inspiratory capacity, and 
increases the total lung capacity (TLC). Lung volumes increase even in the early 
stages of COPD and increase further with severity stages of disease (21). Air trapping 
is the radiological feature of increased RV seen on CT, more prominently seen in 
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expiration; there is a decrease in the lung attenuation in a mosaic pattern relative to 
where there is regional small airways disease(22).  
1.2. Pathology 
1.2.1. Airways Disease 
 
The pathology of airways disease seen in COPD consists of an exaggerated 
inflammatory response with abnormal tissue response to injury and airway 
remodelling (6, 23, 24). There is an accumulation of inflammatory cells within the 
airway wall contributing to increased airway wall thickening and airway 
resistance(25, 26). Proliferation of goblet cells and mucus glands also occurs which 
contributes to airway occlusion, and the hyper-proliferative state risks mucus and 
squamous cell metaplasia (25-27) (see Figure 1.3). This airway narrowing particularly 
affects the conducting airways measuring 2mm or less, and has been demonstrated 







Figure 1.3. Histology slides of small airways disease in COPD.  
 
A) Airway with empty lumen for comparison. B) Lumen partially filled with mucus 
plug with a few epithelial cells. C) Active inflammatory process, exudate extends 
into the lumen. D) Narrowed airway from deposition of inflammatory infiltrate in 
the peri-bronchiolar space  
1.2.2. Emphysema 
 
Emphysema is the permanent abnormal dilatation of air spaces distal to the terminal 
bronchiole accompanied by destruction of their adjoining walls (28). The protease 
anti-protease theory addresses the direct tissue loss secondary to tobacco smoke, 
meaning there is destruction of the membranes responsible for gas transfer as well as 
the elastin that gives each alveolar duct/sac its structural integrity (29, 30). 
Inhalation of tobacco smoke is a noxious stimulus which triggers a subsequent 
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inflammatory cascade that involves the recruitment of neutrophils (31, 32). During 
the inflammatory process they release neutrophil elastase (NE) which if unopposed 
causes elastin breakdown in the lung tissue. Alpha one antitrypsin (AAT) is one of 
the key anti-proteinases, and if deficient, the individual has an increased risk of 
emphysema. The presence of elastases causes the collagen and elastin networks to 
become tortious and damaged in emphysema (see Figure 1.4)(33). The adjoining 
walls become degraded and airspaces coalesce causing airspace enlargement, which 
together with reduced elasticity of the tissues causes reduced elastic recoil (34, 35).  
The abnormal dilatation and hyperinflation reduces alveolar surface area, impacting 
on its ability to take part in oxygenation. In CT studies that account for the volume 
effects of hyperinflation, there is still a density reduction and therefore likely direct 
tissue loss(36).  
Figure 1.4. Histology slides to demonstrate normal lung parenchyma and that 
affected by emphysema 
 




1.2.3. Alpha One Anti-trypsin Deficiency  
 
AAT is a type of serine protease inhibitor (SERPIN) coded for on SERPINA1 gene on 
chromosome 14q (37, 38). The enzyme has a major role in inactivating NE, and in 
AATD there is subsequent unopposed degradation of lung tissue by elastases 
resulting in emphysema(39). The enzyme additionally has anti-inflammatory 
properties, regulating pro-inflammatory cytokines such as TNF, IL-6 and IL-8(40). 
The M alleles indicate normal function, and the Z allele causes a severe deficiency in 
enzyme levels. Therefore MM represents a normal phenotype and ZZ would cause 
AATD(41). A number of other rarer alleles can cause deficiency and are summarised 
in Table 1.1. Specifically the mutation responsible for abnormal function in the Z 
allele is an amino acid substitution of lysine for glutamic acid on position 342, and 
accounts for 95% of the clinically significant cases(41). Levels of AAT above 
11µmol/L are largely considered protective, and levels below are often associated 




Table 1.1. Rarer Alleles responsible for AATD 
Allele Genetic Defect Cellular defect 
Deficient 
Z Amino acid substitution from 
glutamic acid to lysine 
AAT polymers form 
inclusion bodies in the 
liver, instead of being 
released into 
circulation(38) 
S Slower polymer formation resulting 
from the same amino acid 
substitution 
Slower rate of 
polymerisation as the 
structural change is not as 
profound(38) 
Mmalton Phenylalanine deleted position 52 Polymerisation of AAT(38) 
Siiyama Serine substitution from serine to 
phenylalanine position 53 
Polymerisation of AAT(38) 
Mprocida Point mutation and an amino acid 
substation of proline for leucine and 
intracellular degradation 
Mildly reduced neutrophil 
elastase function(43) 
Mheerlen Point mutation and an amino acid 
substation of leucine for proline and 
intracellular degradation 
Abnormal processing of 
the secondary and tertiary 
structure of the AAT 
protein(44) 
Null 
Null groups all result from mutations causing the formation of stop codons(45) 
 
 
QO granite falls 
1 base pair deletion Absence of AAT due to 
premature stop codon and 
unstable mRNA 
QO hong kong 2 base pair deletions Premature stop codon and 
truncated protein 
QO Isola di 
procida 





Single amino acid substitution Lack of neutrophil elastase 
inhibition, with 
intracellular aggregates 
Pi Pittsburgh Single amino acid substitution Low NE activity and an 




1.3. Types of Emphysema 
1.3.1. Centriacinar emphysema 
 
In emphysema secondary to dust/smoke inhalation, there is an increase in the 
airspace of the proximal bronchioles, with relative sparing of the distal alveolar 
ducts/sacs (see Table 1.2) (25, 46). Airspaces this small cannot be visualised on CT 
but the adjacent bronchial artery can and therefore changes can be seen around the 
tip of the pulmonary artery (47). This type of emphysema is typically in the upper 
lobes or superior segment of the lower lobe, and is more core than peripheral (48, 
49).  
1.3.2. Panacinar emphysema 
 
Unlike centriacinar emphysema where the airway dilatation is limited to the 
proximal element of the acinus, in panacinar emphysema there is dilatation of the 
respiratory bronchiole evenly distributed from the bronchiole to the alveolar ducts 
and sacs(50). The distribution of panacinar emphysema is more frequently in the 
lower lobes, and associated with more airway narrowing/inflammation(50, 51). 
Causes include alpha one antitrypsin deficiency as well as Swyer-James syndrome 
and Ritalin abuse (52, 53).  
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distal alveolar sacs 
Panlobular 
  
Uniform dilatation of 
all air spaces from the 





enlarged airspaces at 
the periphery of each 
acini 
1.3.3. Paraseptal/distal acinar. 
This is the least common form of emphysema, and is characterised by enlarged 
airspaces at the periphery of the acinus usually on the dorsal surface of the upper 
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lobes(50). The main risk to the patient is due to the lesion adjacent to the pleura and 
disruption of the surrounding tissue can lead to pneumothoraces (54).  
1.4. COPD and Phenotypes 
1.4.1. Clinical Phenotypes 
 
A phenotype in COPD is described as “a single or combination of disease attributes 
that describe differences between individuals with COPD as they relate to clinically 
meaningful outcomes like symptoms, exacerbations, response to therapy, rate of 
disease progression, or death” (55). The aim of phenotyping is to be able to identify 
subgroups of patients who share similar underlying biological or physiological 
mechanisms and therefore targeted therapy can be prescribed(56). FEV1 fails to 
describe the disease heterogeneity in COPD, and explains less than 25% of the 
disease impact on quality of life measures such as symptoms and quality of life (55). 
How best to include the heterogeneity into clinically useful phenotypes is still up for 
debate, with multiple methods of phenotyping proposed.  
Historically “blue bloaters” and “pink puffers” identified those with hypoxaemia, 
CO2 retention and cor pulmonale versus breathlessness, hyper-inflated and low CO2 
respectively (57, 58). Exacerbations in COPD are of particular interest as they are 
associated with accelerated decline in lung function, reduced quality of life and 
increased mortality(59) Certain patients exacerbate repeatedly whilst others do not 
suffer with any. The ECLIPSE study was a prospective observational study of 2138 
patients with moderate to severe COPD followed up over 3 years. 23% of patients 
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did not suffer with any exacerbations whereas 60% of those with 2 or more 
exacerbations went on to have frequent exacerbations in the subsequent year. The 
stability of this ‘exacerbator phenotype’ indicates that this group may well have 
susceptibility to repeated exacerbations and therefore tailoring their investigations 
and management could improve care (60, 61).  
1.4.2. Cluster analysis 
 
Statistical modelling has been applied to patients with COPD in order to identify 
clusters and therefore phenotypes. An example of such a study that attempted this is 
by Burgel et al who performed a Principal Component Analysis (PCA) using 8 
commonly used clinical variables in COPD was performed in 322 COPD 
patients(62). Variables used were age, cumulative smoking, FEV1, BMI, 
exacerbations, the Medical Research Council (MRC) breathlessness score, St George’s 
Respiratory Questionnaire (SGRQ) and Hospital Anxiety and Depression Score 
(HADS). 4 clinical phenotypes were identified, that would not have been found 
using GOLD classification, demonstrating that FEV1 alone is ineffective for 
categorising patients who for the same value can have markedly different 
phenotypes. 
A systematic review regarding the derivation and validation of clinical phenotypes 
in COPD by Pinto et al however demonstrated that the reproducibility and reliability 
of these clustering studies was only modest, with such a variety of methods used 
that a quantitative analysis was not possible(63). A large cohort study of COPD 
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heterogeneity and clustering was recently performed by Castaldi et al (64). This 
involved 17 countries, 146 individuals from 11 different cohorts including 
COPDGene and ECLIPSE and again showed only modest reproducibility of 
clustering analyses, and concluded the heterogeneity was better described as 
continuous disease rather than mutually exclusive groups. However the authors 
recognised that certain clusters do tend to reoccur. The first common cluster is that 
of with severe COPD with low FEV1, low BMI, dyspnoea and extensive CT 
emphysema (LAA950 ≥19.7%). The other being an ‘airway predominant’ cluster 
have moderately impaired FEV1, elevated BMI and relatively little CT emphysema 
with thickened airway walls (LAA950 ≥4.7% and ≤Pi10 3.75% respectively). Other 
ways of phenotyping have been investigated such as resting inspiratory capacity and 
exercise tests, though this is beyond the scope of this chapter(65).  
1.4.3. Radiological phenotyping 
 
Imaging, and in particular CT, can be used to identify clinically important 
subgroups. For example those with upper vs lower zone emphysema or 
homogenous vs heterogeneous (see section 1.6.3 for further detail). Those with either 
predominant airways disease or emphysema can be identified using simply visual 
inspection or quantitative methods. Multiple studies have sub-grouped patients in to 
these radiologically defined phenotypes and demonstrated they have significant 
clinical difference between them (see Table 1.3).  For example in the Emphysema 
versus Airways (EvA) trial (66) those with predominant airways disease had higher 
BMI, lesser degree of airflow obstruction, and less hyperinflation. In addition, there 
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was a negative correlation between CT lung density and airway wall thickening, 
which replicates similar findings from previous studies (67, 68). Therefore these two 




Table 1.3. Summary of studies dividing patients into HRCT defined phenotypes 
Author and 
Year 
HRCT defined phenotypes  Variables studied Significant variable difference 
Kitaguchi 2006 
(69) 
A: little or none of either 
emphysema or BWT 
E: emphysema but no BWT 





Response to beta-agonist 
Response to treatment with 
ICS  
Sputum cell differentiation 
 
A: ↑ BMI 
↑DLCO ↓ hyperinflation. 
 ↑reversibility.   
↑response to ICS  
↑ % of sputum eosinophils 
E: No response to ICS 
M: ↑response to ICS.  
↑% of sputum eosinophils. 
Fujimoto 
2006(70) 
A: little or none of either 
emphysema or BWT 
E: emphysema but no BWT 







Response to beta-agonist 
Symptoms 




From derivation set, created 
new validation set Group A 
and B 




A:  ↓ FEV1, ↑ TLC ↓DLCO. ↑pixel index (threshold --950HU).  
B: ↑BMI  
purulent sputum  
worse bronchial wall thickening 
Han 2011(72) Emphysema Predominant or 
Airway Predominant 
BWT 




Emphysema Predominant (>35% --950HU):  
↓ FEV1 and 6MWD.  
↑SGRQ and MRC grade. 
For every 5% ↑ in emphysema, 1.18 fold ↑ exacerbation frequency. 
Airways Predominant: 






airways disease dominant, 









Compared with airway disease dominant group,  emphysema 
dominant group had ↑ lung volumes, ↓gas transfer ↓ pO2 +pCO2 
↓BMI ↑Hb  
 
No difference between age, and smoking history between the 
groups. 
DaSilva 2016(73) Emphysema or airways 
disease 
Clinical +functional evaluation 
HRCT 
Emphysema group: 
↑ airflow obstruction 
↓BMI ↓ 6MWD 
The table shows significant differences in clinical and physiological parameters between the stated groups (p<0.05).  
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1.4.4. Management Guided by CT phenotypes 
1.4.4.1. Medical Management 
 
Table 1.4 summarises up to date evidence with regards to COPD management, 
subdivided into airways and emphysema predominant changes. These are 
subdivided into those clinical features shown to be statistically associated with one 
CT phenotype over the other.
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Table 1.4. Treatment of COPD as defined by CT phenotypes. 
CT Phenotype CT feature Clinical features Management Reference 
Predominant 
Emphysema 







Low BMI Nutritional Support in a 
community rehabilitation 
program 















Sciurba et al, 2016(76) 
Davey et al 2015(77) 
Reduced exercise 
tolerance, and higher 
SGRQ 
Pulmonary Rehabilitation Cochrane Systematic 




Hypoxia LTOT NOTT trial(79)  
MRC trial(80) 
Lower FEV1 Bronchodilators including 
LAMA +/-LABA 
D’Urzo et al 2014 (81) 





Lower wall area/Body Surface 
Area ratio (WA/BSA) 
Lower luminal area/BSA 
Higher %WA 
 
Higher BMI Weight loss 
CPAP if associated OSA 
OSA Taskforce 
2009(83) 
Increased response to 
steroids 
Inhaled steroids Cochrane Systematic 




Oral or inhaled steroid Brightling CE et al 
2005(85) 
Siva. R et al 2007 (86) 





Calverley et al 
2009(87) 
Cochrane Systematic 








1.4.4.2. Alpha One Augmentation Therapy 
 
Unopposed NE in AATD produces emphysema like lesions, and therefore logically 
replacement of the enzyme might restore protective function in the lungs and slow 
down disease progression(90). Alpha one Proteinase Inhibitor given intravenously 
can increase serum levels of alpha one antitrypsin above 11µMol/L and a recent 
meta-analysis demonstrated slower disease progression in treatment vs placebo 
(p=0.002) as measured by CT density(91, 92).  However, the outcome measures used 
in clinical trials of alpha one augmentation therapy still remain controversial. In the 
recent systematic review by Edgar et al, there was found to be no significant 
improvements in lung function (as measured by FEV1 percent predicted and DLCO 
mmol/min/kPa) in those patients receiving augmentation therapy, and a small but 
significant increase in the annual exacerbation rate. The systematic review on 
intravenous alpha one augmentation therapy by Gotzche et al concluded further 
studies should aim to demonstrate a relevant clinical effect, namely reduction in 
mortality(93). However, most patients diagnosed with AATD are non-smokers, or 
stop smoking at diagnosis, and therefore rate of decline is reasonably slow. For this 
reason mortality cannot be expected to change within the short period of a trial, 
where patients are often very motivated and carefully selected(94).  
The rate of decline seen on CT scanning is small but significant and evidence from 
the RAPID extension (RAPID-OLE (Open Label Extension)) indicates slowing of 
decline in density loss whether or not a patient has previously received alpha one 
augmentation therapy. The density loss in the placebo arm of the original RAPID 
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trial at TLC was -2.19/L/year versus -1.45g/L/year in the treatment arm. RAPID-
OLE saw all patients receive active drug, with the two groups now defined as 
delayed and early start respectively. In both arms there was significant reduction in 
the annual density loss (-2.26g/L versus 1.51g/L) but the rate of tissue loss was 
slower in the early treatment group emphasising the importance of early initiation 
(95).  
1.4.4.3. Lung Volume Reduction Surgery (LVRS) 
 
Using CT measurements both visually and quantitatively allows for a more 
informed decision when considering patients with COPD for LVRS. By carefully 
selecting patients appropriately for surgical treatments who suffer with severe 
emphysema but remain dyspnoeic on maximal medical therapy, LVRS can reduce 
the associated symptoms and mortality.  The surgery aims to resect areas of the lung 
most severely affected by emphysema, with a view to reducing reduce the total lung 
volume by up to 60% (96, 97).  The mechanisms proposed are improved elastic recoil 
and expiratory airflow in the remaining lung (75, 98-100). Gas transfer is increased, 
dynamic hyperinflation is decreased, and an improvement in the movement and 
synchronicity of diaphragm and inspiratory muscle movements occurs (75, 101, 102).  
The procedure is carried out via a median sternotomy, VATS or staged thoracotomy 
approach, with VATS now being the most common. The unwanted lung tissue is 
isolated and stapled using buttressed sutures with the remaining lung then allowed 
to re-inflate (See Figure 1.5)(97, 103, 104). The current NICE guidelines advise 
consideration of LVRS if still symptomatic despite maximum medical therapy, and 
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meeting all the recommended criteria: FEV1>20%, PCO2 <7.3, upper lobe 
predominant emphysema and TLCO >20%. (35) There is a pre-requisite that 
participants should have completed pulmonary rehabilitation first, and should have 
a TLC >100% predicted, and an RV >150%. (75) 
Figure 1.5. Illustration of lung wedge resection performed during Lung Volume 
Reduction Surgery (LVRS). 
 
 
1.4.4.3.1. LVRS Clinical trials 
A systematic review was performed in 2016 of all RCTs examining the improvement 
of health outcomes in patients receiving LVRS vs standard medical therapy (75). This 
included the long term follow up outcomes from National Emphysema Treatment 
Trial (NETT) 2003, a large scale RCT comparing surgery with medical therapy, 
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which accounted for 68% of the patients included in the review (1218 participants). 
(96)  
A meta-analysis of 5 clinical trials comparing LVRS versus standard medical care 
was performed to assess 90 day mortality, which showed a significantly higher 
number of deaths in the LVRS arm as a result of post-op complications (Odds Ratio 
6.16, p<0.0001). However, the 36 month mortality favoured the LVRS arm; 307 
events recorded in the LVRS arm versus 350 events in usual medical care 
respectively (OR 0.76, p=0.01).  
The NETT authors re-analysed those patients at risk of early mortality by comparing 
high risk versus low risk patients. After identifying those at high risk i.e. FEV1<20% 
and/or DLCO<20% and homogenous emphysema, the 24 month mortality remained 
significantly high in the high risk group (OR 2.00, p=0.04), whereas there was no 
difference in mortality in the low risk group, (OR 0.86, p=0.29). The long term NETT 
data collected at 14 years showed that nearly all included patients randomised to 
either LVRS or usual care had died. Although 90 day mortality was higher in the 
LVRS group, the mortality curves of LVRS and usual care crossed at 4.4 years and 
showed a non-significant trend favouring the LVRS group.  
The systematic review included analysis of change in SGRQ from baseline in 
surviving patients, combining data from the NETT study with a smaller study from 
2005 of 83 patients(105). This demonstrated a mean change of -13.78 SGRQ units 
favouring LVRS (<0.0001). The NETT study alone chose a threshold of 8 points on 
the SGRQ scale to represent an improvement in quality of life. This was chosen over 
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the MCID of 4 points to justify the high risks of surgery. At 24 months, analysing all 
surviving patients, 121 patients out of 371 in the LVRS had an improvement of their 
SGRQ of 8 points or more, vs just 34 out of 378 in the usual medical care (OR 4.9, 
p<0.001). 
1.4.4.4. Bronchoscopic valve reduction surgery (BRVS) 
1.4.4.4.1. Endobronchial Valves 
 
In an attempt to reduce the morbidity and mortality of LVRS, bronchoscopic 
techniques are being increasingly used. Zephyr valves are one way valves 
endoscopically placed under bronchoscopic vision (see Figure 1.6)(106). They allow 
trapped air and mucus to leave but not enter, and therefore cause distal collapse and 
atelectasis. The fissures must remain intact with no collateral ventilation from 
adjoining lobes so therapeutic collapse/atelectasis can take place, hence collateral 
ventilation must be actively assessed to determine eligibility (107). Figure 1.7 
demonstrates a CT scan of a patient with severe AATD in whom the fissures can be 









Figure 1.6. Endoscopic view of Zephyr valve in situ. 
 
   
 






The 2017 Cochrane systematic review of bronchoscopic volume reduction 
procedures meta-analysed 5 studies with a total of 703 participants (108). Table 1.5 
lists all relevant endobronchial valve trials, with those included in the Cochrane 
review highlighted in bold. A more recent Endobronchial Valve (EBV) RCT has since 
been published (LIBERATE) that followed up randomised patients to EBV or 
Standard of Care (SOC) for a longer time period of 12 months (109). The Cochrane 
review concluded those patients who were randomised to EBV versus SoC had a 
significant improvement in FEV1, 6MWD, RV and SGRQ with no significant 
difference in mortality. However, adverse events such as pneumothorax were more 
common in the EBV group (OR 5.85). The NICE guidelines published in the same 
year were satisfied there was enough evidence to support their use clinically, and 
that patient selection should be done through an MDT (110). Patients are expected to 
have completed pulmonary rehabilitation first, and valves should only be placed in 
target lobes with no collateral ventilations. PFTs need to demonstrate severe 
obstruction and hyperinflation, and collateral ventilation should be assessed either 




Table 1.5. Summary of endobronchial valve trials since 2010. 













2010 220 6m 1:1 randomisation to 





FEV1 and 6MWD FEV1% increased by 4.3% 
in EBV group versus -
2.5% in the control.  
6MWD increased by 2.5% 
in EBV group, and 
decreased by 3.2% in 
control arm.  
VENT EU 
(112) 
2012 171 6m 1:1 randomisation to 







FEV1 and 6MWD EBV patients had a 
significant improvement 
in FEV1 compared to SoC 
(7% vs 0.5% change).  
The average distance 
change in 6MWD 
between groups was 
comparable (15m versus 




2015 50 3m Single centre 1:1 double 
blind EBV vs sham 
controlled trial in 
patients with 
heterogeneous 
emphysema and intact 
FEV1 FEV1 increased 8.77% in 
EBV arm vs 2.88% in 
control group. Significant 
complications including 2 
deaths and a prolonged 
pneumothorax in EBV 
30 
 
interlobar fissures. arm 
LIBERATE 
(109) 
2018 190 12m 2:1 randomisation (EBV 
to SoC) to assess 
effectiveness and safety 









from baseline of 
>15% 
47.7% EBV patients vs 
16.8% SoC had achieved 
change in FEV1 >15%.  
 
Differences between the 
two groups at 12m were 
also significant for 




2017 97 3m  Single centre 2:1 RCT 
EBV vs SOC. 
FEV1 improvement 
from baseline 12% 
or greater.  
55.4% EBV group met 
sufficient FEV1 
improvement, compared 
with 3.2% in SoC patients.  
 
Mean change of FEV1 at 
6m was 20% vs -8.6%. 
89.8% EBV patients at 




2015 64 12m Previously treated EBV 
patient were 
prospectively followed 
up for 1 year 
 EBV patients had a 17% 
improvement in FEV1, 
687ml reduction in RV 
and 11 point reduction in 
SGRQ at 12m.  
 
17% however underwent 
valve replacement and 




IMPACT (115) 2016 93 3m Prospective multicenter 
1:1 RCT of EBV vs SoC., 
in patients with 
homogenous emphysema 
with absence of collateral 
ventilation assessed by 
Chartis 
FEV1 at 3m related 
to baseline. 
In the ITT population the 
improvement in FEV1 
from baseline was 13.7% 
in EBV group versus -
3.2% in SoC group.  
 
SGRQ change:-8.63 vs 
+11.25 in EBV/SoC 
groups.  
In the EBV group, 97.2% 
achieved volume 









1.4.4.4.2. Endobronchial Nitinol Coils 
 
Nitinol coils are passed through the bronchoscopic channel in a straightened 
position and once released into the lung tissue, they spring back into their coil shape, 
pulling in and collapsing surrounding tissue (See Figure 1.8). This aims to reduce the 
lung volume and therefore improve overall ventilation. Two RCTs published in 2016 
randomised patients to either endobronchial coils or usual care (415 patients in 
total), both showing small improvement in FEV1 that did not meet clinical 
significance (76, 116). There was a significant improvement of the SGRQ in the coils 
arm of the REVOLENS trial (-10.6 points at 12 months in the coil group) but for both 
studies, the rate of complications is as high as 35% and therefore this procedure is 
















A) Flexible bronchoscope is passed through and wedged into a segment of the RUL. 
B) The coil which is held in the straightened position within the bronchoscopic 
channel is pushed out into the lobe 
C) The coil quickly springs into its original shape 
D) This pulls in surrounding lung tissue to reduce the volume of the segment of lung 









1.5. Prognosis as guided by Quantitative CT 
1.5.1. Disease distribution  
 
Emphysema as a result of smoking/inhalation of noxious gases most frequently 
results in the centriacinar distribution of emphysema which begins predominantly in 
the upper zones. Due to the nature of emphysema originating from inhalation and 
local destruction of lung tissue, there is a higher %LAA centrally rather than 
peripherally. When emphysema is divided into core and rind, studies show a higher 
association with predominant core emphysema and a lower FEV1 and higher MRC 
(118). As the core has a greater %LAA this could also explain why there is a stronger 
association with gas transfer here versus peripherally (49).  Findings by Parr et al 
demonstrated that in AATD patients basal distribution is associated with greater 
impairment of FEV1 (p=0.002), but less impairment of gas exchange (p=0.016), and 
Aa gradient (p=0.007)(119).  Given the lung function variation between different 
lung regions the authors warn of using a single physiological parameter as a 
measure of severity as it may introduce bias. 
Castaldi et al found that panacinar rather than centriacinar distribution was 
associated with stronger associations with lung function and quality of life than CT 
lung density, demonstrating that the distribution of disease has an independent 
effect on severity (120). AATD typically occurs in a panacinar distribution with basal 
predominance, and Dawkins et al showed that for these patients, basal distribution 
carried a higher mortality risk (121). Finally, in patients randomised to the medical 
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arm of NETT, the authors demonstrated that a greater proportion of emphysema in 
the lower lung zone vs upper lung zone was predictive of mortality (p=0.005). (122) 
1.5.2. Predicting post-operative FEV1. 
 
CT density masking to quantify the severity of emphysema is linked to favourable 
post-operative outcomes in a range of procedures. In a small study of 9 patients 
Sverzellati et al applied a density mask to COPD patients awaiting lobectomy for 
lung cancer, along with spirometry. With specific equations, they predicted the post-
operative FEV1 using both values and found quantitative CT was superior to lung 
function (r=0.97)(123). Gierada et al used various LAA measurements and 
determined that a 75% LAA or greater for -900HU threshold, or 25% at --950HU 
were associated with improved outcomes post-operatively in patients undergoing 
LVRS, including a >50% improvement in FEV1 and 2 fold increased six minute walk 
distance(124, 125). 
Finally the ratio of upper to lower lobe emphysema is of particular importance in 
assessing predicted post-operative FEV1 following bilateral LVRS. Consistent with 
the fact that upper lobe predominance is associated with better outcomes, Flaherty et 
al found that the CT emphysema ratio (CTR) was the best single predictor of a 
successful 12% increase in FEV1 (absolute value 200ml). Importantly, the highest 
CTR scores (>2.5) were associated with a greater than 90% specificity at each time 
point up to 36 months, although the sensitivity was low (126). The positive 
predictive value (PPV) of this threshold was at least 75% up to 36 months after 
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surgery. The negative predictive value (NPV) remained moderate at all thresholds 
throughout 36 months of follow-up.  
1.6. Quantifying Emphysema using Computed Tomography 
1.6.1. Computed Tomography 
 
There was early recognition that CT scanning could provide useful information 
about the severity of COPD and before more sophisticated software was available to 
formally quantify the level of emphysema, there were numerous scoring systems to 
help visually grade disease. Two of the more commonly used methods are the 
Thurlbeck method and the modified Goddard system (127, 128). These score 
emphysema 0-100 and 0-4 respectively and correlate with pulmonary function tests. 
However the correlation is not as strong as that performed quantitatively with CT 
densitometry and the greater inter- and intra-observer variability means the results 
are less reliable and reproducible(129). 
1.6.2. CT Densitometry.  
 
CT densitometry is the method of quantifying the severity of emphysema using 
dedicated software. Figure 1.9 demonstrates how the CT images are digitally 
produced. X-rays are emitted and passed through the subject and received by 
detectors that calculate how much the intensity has been reduced by the tissue. 
These attenuation coefficients are then converted into a digital image in the form of a 
matrix consisting of many small data sets. Each small square in the matrix is a pixel, 
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and in 3D with volume adjustment is a voxel. Each pixel is assigned a value in 
Hounsfield Units (HU) from -1000 representing the least possible 
density/attenuation i.e. air and 1000 representing the highest, i.e. solids. These pixels 
or voxels can be plotted on a histogram as shown in Figure 1.10. There are two ways 
of reading the severity from this histogram. The first is the value of where the 15th 
percentile point lies on the curve (PD15) and is the most preferred value in trials 
quoting density, as it is most accurate and sensitive to change(36, 119, 130, 131). The 
second method is to calculate the percentage under the curve that represents the low 
attenuation area for a selected threshold e.g. --910HU or --950HU. These and other 
values are used in studies quoting density, and Table 1.6 demonstrates trials that 
have sought to ascertain the most valid method in both AATD and COPD. 
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X-rays are passed through the patient and received by the detectors that rotate 360⁰ 
around the patient (A). The reduced intensity of the XR beam passed through the 
subject is calculated as an “attenuation coefficient” or a numerical value received by 
the computer (B). A software program will ‘reconstruct’ this data into a digital image 
(C). In the 2D format these individual units are known as pixels, and voxels when 






Figure 1.10. Calculation of densitometric indices. 
 
 
Example of a density histogram, and how the area under the curve for a given 
threshold is calculated. As shown in the figure, where the 15th percentile point can be 









Table 1.6. Table to summarise studies performed in AATD and COPD directly 
comparing the most accurate measure of CT density. 





RCT x x  -950HU  Parr et al 
2004(132) 
RCT  x x -950HU  and 
PD15 
Parr et al 
2006(133) 
RCT x x x PD15  Parr et al 
2008(36) 
Review x x x PD15 Newell, Hogg 
et al 2004(131) 
COPD 
RCT x x x PD15  Shaker et al 
2004(134) 
Review x  x PD15  Dirksen 
2008(130) 





x X  -950HU Gevenois et al 
1995 (136) 








1.6.3. Other measures of emphysema quantification 
 
Throughout the literature there are numerous other ways of describing or 
quantifying emphysema (see Table 1.7). However these measures are less widely 
used than CT density, which has been pathologically and clinically validated, and 






Table 1.7. Summary of alternative methods of quantifying emphysema 
 
Measure Description CT image Reference 
Core vs Rind 
distribution 
By dividing 50% of pixels into ‘core’ 
and 50% into ‘rind’, those with core 
predominant emphysema have a 
lower FEV1 and a higher BODE 
index.  
 
Mair et al 2009 
Nakano et al 2001 




CT emphysema Ratio (CTR) is a 
measure of the cranio-caudal 
distribution, with a value>2.5 
(representing upper lobe dominant 
emphysema) associated with an 
improved outcome following bilateral 
LVRS. 
 




Zones In order to delineate upper zone from 
lower zone emphysema, studies have 
identified preferable landmarks as cut 
off values. Different studies use 
different anatomical landmarks e.g. 
mid-portion of the intrathoracic 
trachea or arch of the aorta for upper 
zone and therefore not identical 
method. Even within the same 
method there is still inter/intra-
observer variability i.e. at least 4 slices 
include the arch of the aorta.  
 
Soejima et al 2000 
Dowson et al 2001 




Gas trapping Ratio of expiratory CT 
density/inspiratory CT density to 
quantitatively assess lobar air 
trapping.  
 
Nagatani et al 2015 
Mets et al 2012 
Zaporozhan et al 2005 
(144-146) 
Yamashiro et al 2010(147) 
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Uniformity Visual assessment of whether the 
distribution of emphysema is 
homogenous (shown on the right), 
heterogeneous or mixed. Both 
markedly heterogeneous and 
homogenous distributions were 
found to be protective, and therefore 
not an effective method of assessing 
risk prior to lung volume reduction 
surgery (LVRS). 
 
Weder et al 1997 
Hamacher et al 1999  
Boutou et al 2015 (148-150) 
Texture analysis Uses automated software trained to 
identify certain patterns of 
emphysema on a CT scan (regions of 
interest-ROI).   





In order for a new technology such as CT densitometry to be deemed reliable, it 
requires validation against pre-existing methods of measuring emphysema, both 
pathological and clinical.  
1.6.4.1. Pathological correlations 
 
The ability of density analysis to accurately assess the degree of emphysema has 
been validated through pathological studies, using macroscopic and microscopic 
techniques.  Muller et al in 1988 macroscopically assigned an emphysema pathology 
score (1 to 100) to 28 patients who had undergone lobar resection for a lung tumour, 
and showed a strong correlation with simple density mask results (r=0.83, p<0.001) 
(152).  
Gevenois et al measured emphysema macroscopically using two further methods, 
point counting and panel grading, which both require investigators to manually 
estimating the amount of visible emphysema per section (136). Through this 
measure of emphysema, the authors did show -950HU was the only level for which 
no statistical significant difference was found between HRCT and morphometric 
data (p=0.384) 
In 45 patients who had undergone lung resection of peripheral lung tumours, Gould 
et al compared CT density as measured by EMI units (EMI was the historic name for 
CT, Hounsfield was previously a scientist at EMI) with the resected pathological 
specimens. The mean value for the surface area of walls of the distal airspaces per 
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unit lung volume (AWUV) was measured in 1mm*1mm microscopic fields of lung 
from methacrylate-embedded blocks selected from inflation-fixed lobes. There was a 
strong correlation between EMI units and AWUV (r=-0.77, p<0.001), demonstrating 
the ability of CT to quantify emphysema (153).  
Emphysema was measured microscopically by Gevenois et al by measuring the 
perimeter and the inter-wall distances within alveoli and the alveolar duct count on 
surgically resected specimens (137). The selected patients were undergoing resection 
for either primary lung cancer or transplant, and once resected, they were inflated 
with 10% buffer formalin overnight. 2cm*2cm blocks were then embedded in 
paraffin and cut into 5µm thin sections and stained with hematoxylin and eosin. CT 
density was measured and compared across numerous RA (relative area of 
emphysema) thresholds ranging from -900HU to -970HU. There were significant 
correlations with emphysema measured pathologically and CT density, with the 
strongest correlation between MIWD (mean inter-wall distance) and -950HU (r=-0.7, 
p<0.001) (compared with -910HU, r=0.64).  
1.6.4.2. Clinical correlations 
 
Numerous studies have shown significant correlations between CT measures of 
emphysema (PD15 and %LAA 950) and FEV1 and DLCO (154-157), as well as 
measures of exercise tolerance e.g. MRC grade and 6 minute walk distance 
(6MWD)(158-162). There are also significant correlations with frequency of 
exacerbations and ultimately mortality (121, 158, 163-165) (see also chapter 4 for the 
systematic review). In the NELSON trial (Dutch and Belgium Lung Cancer Screening 
47 
 
Trial) Hoesein et al have shown that smokers with normal lung function 
demonstrated evidence of emphysema on CT, concluding that CT is a more sensitive 
in detecting emphysema than PFTs(166, 167).  However, the R2 value between CT 
density and FEV1 even when adjusted for other variables remains 0.3-0.68 indicating 
that the parenchymal disease detected by CT density only contributes for 30 to 68% 
of the total variation(120, 168-170). Therefore other factors including small airways 
disease must additionally contribute to the altered lung function seen.  
1.7. Airways disease 
1.7.1. Quantification 
There are several recognised methods of quantifying airway wall metrics, namely 
measurement of the airway lumen, the airway wall or the wall area expressed as a 
percentage. Semi-automated software programmes measure the luminal area (LA) 
and the wall area(WA) allowing the calculation of %WA (%WA=WA/LA +WA*100) 
(171). Alternatively the bronchial wall thickness (BWT) can be derived as the square 
root of WA adjusted for the internal perimeter (172, 173) (Figure 1.11).  
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Figure 1.11. Airways disease measurements 
 
Diagram to demonstrate various values calculated in assessing either the luminal or 
wall contribution to airway thickening. 
 
Airway wall measurements are often based on the full width at half maximum 
principle (FWHM) and modifications of it (174, 175). This technique estimates 
airway wall measurements by assessing the change of the XR attenuation along a XR 
beam as it travels from the lumen, through the airway wall and into the 
parenchyma. The change in attenuation as the XR enters the inner airway wall and 
leaves into the parenchyma is called the “full width”. The FWHM principle then 
makes an assumption the true airway wall boundary is half the peak value (see 
Figure 1.12) (176).  This method is known to overestimate the value of wall thickness 
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particularly in small airways due to influence of surrounding structures e.g blood 
vessels.  
Table 1.8 summarises various algorithms proposed for quantification of airways 
disease, most of which are modifications of the FWHM principle (177, 178).  
 







Table 1.8. Summary of recognised methods to quantify airways disease. 
Airway 
Measurement 
Algorithm Description Reference 
Airway lumen Threshold-
based 
Uses a luminal seed point, and 








Airway wall manually traced, 






Luminal seed point. Uses voxels 





Full Width at 
Half 
maximum 
Ray measured from inside to the 
outside of airway and the 
changes detected estimate the 
















 Measurement of the slope using 
internal perimeter along the X 
axis, and square root of wall area 
on the y axis 
Grydeland 






Nakano et al measured the airway dimensions of intermediate and large sized 
airways on CT and compared them with measurements taken from histologic 
calculation in resected lung. They concluded that CT could be used to reliably 
estimate the diameter of small airways in vivo (CT airway with an internal diameter 
of greater than 0.75cm accurately predicts the dimensions of small conducting 
airways with an internal diameter of 1.27mm (r2=0.57, p<0.01) (171, 174). Airway 
wall thickening as measured by CT is related to obstructive spirometry(184-187), and 
chronic sputum production is associated with increased likelihood of an 
exacerbation leading to a hospital admission(188), and death from a pulmonary 
infection(189). Chronic bronchitis (cough and sputum production for at least >3 
months in 2 consecutive years)(56) has a greater mean %WA and internal perimeter, 
and is associated with higher exacerbation and mortality rates.(172, 190, 191) Thus 





1.8. CT Quantification Variability 
The potential pitfall of CT analysis is that the various components of the technology 
must all be equal in order to compare study results. These factors include using the 
same software programme (192), the same reconstruction algorithm (193-195), 
appropriately calibrating the scanner (36, 132) and adjusting for volume (130, 135, 
196) (see Error! Reference source not found.). CT phantoms should be used, which 
re models that contain manufactured rods of material which have identical CT 
density to air and water and are therefore used to calibrate the scanner.  If CT 
density logistics are standardised, then scans may be compared longitudinally to 
measure treatment effect, and combined from different centres.  A detailed review of 
CT noise reduction by Dirksen 2008  recommended using a soft reconstruction 





Table 1.9. Summary of CT acquisition variables resulting in noise effects. 
Factor Effects Reference 
Software Programme Significant variations in measurement of 
emphysema (p<0.001) therefore recommend 
when comparing results to use the same 
software  
Wielputz  et al 2014(192) 
Reconstruction Algorithms Trade off to be made between spatial and 
contrast resolution i.e. the sharper the image, 
the more noise and artefact created. In 
addition, selecting the wrong reconstruction 
algorithm can significantly overestimate the 
degree of emphysema 
Shaker et al 2004(193) 
Kemerink GJ et al 1996(194) 
Gierada DS et al 2010(195) 
 
 
Slice thickness Thinner slices e.g. 1mm >5mm will give less 
detailed analysis for that slice and therefore 
values may differ 
Shaker et al 2004(193) 
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Calibration Calibrating for air and with a phantom 
essential as values differ significantly 
longitudinally if not. 
Parr et al 2004(132) 
Parr et al 2008(197) 
Radiation dose Using a low radiation dose technically can 
overestimate the degree of emphysema. 
However the actual numbers are not clinically 
significant, and using low dose scans means it 
is more acceptable in terms of safety 
 
Gierada DS et al 2008 
Volume Volume and level of inspiration must be 
adjusted for either statistically or 
physiologically. Difference of opinion of how 
reproducible a patient’s breath hold is. 
Dirksen 2008(130) 





1.8.1. Volume variability 
 
The principle of CT densitometry is to quantify the amount of alveolated tissue, and 
therefore arguably is a more precise measure of emphysema (lung tissue 
destruction) than pulmonary function tests. The amount of air that is within the 
alveolated tissue would be either due direct loss of alveolar tissue or increased 
inspired air, therefore eliminating the variability of the latter is crucial. Ideally every 
patient would always be examined at full inspiration each time, but especially in 
COPD patients who are already breathless, this is very difficult to do and needs a 
high level of patient compliance. Shaker et al demonstrated during their analyses of 
volume correction that even with patient coaching for deep inhalation, there was still 
a within-subject total lung volume (TLV) SD of 234ml (134). The weight of the lung 
however was more stable as would be expected with a SD of 21g.  
1.8.2. Correction for air 
The importance of air calibration was demonstrated by Parr et al 2004 (132). This 
two-part paper consisted of a validation study in order to propose a correction 
threshold, followed by application to AATD patients. 57 patients were recruited 
with 3 annual scans done 2 years apart and plotted the VI (voxel index) change 
against time, with comparisons made using the uncorrected and adjusted thresholds. 
The method of correction threshold calculation was = (air calibration-water 
calibration/-1000)*index threshold. Using this correction method, there a shift in the 
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observed VI progression from an apparent improvement of %VI before correction to 
no significant progression following correction (see Figure 1.13). By adjusting the 
analysis threshold there was improved detection of emphysema progression over 
the two years, and these results demonstrate the important of scanner and image 
calibration in longitudinal studies of CT density decline.  
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Figure 1.13. Annual progression of CT density with and without air calibration 
(132) 
A) Before air calibration B) After air calibration.  
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1.8.3. Correction for volume 
In theory the lungs may be considered sponge-like, i.e. a reduction in the lung 
volume would consolidate and increase the lung density, as the compression is mass 
preserving. How to adjust CT density for volume using the sponge model, or 
physiological adjustment, was explored by Shaker et al 2004(134). This is necessary 
so CT density may be use confidently in clinical trials and reassured that the changes 
seen are that of the patient and not variability in the instrument.  
In this 2004 study 50 patients underwent 3 CT scans 2 weeks apart. Total lung 
volume (TLV) is the total measure of air and lung tissue combined (assuming air=-
1000HU). In order to assess the variability of lung density for within-subject 
variability of TLV, TLV was plotted against percentile density (PD) and relative area 
of emphysema (RA), with the purpose of assessing the distribution of air at full 
inspiration and therefore how to adjust density measurements accordingly. 
Following double logarithmic transformation, the relationship of TLV against CT 
density was near to linear (see Figure 1.14) .The slope of the linear relationship gives 
a co-efficient, and when the co-efficients across the range of percentile densities was 
calculated, the slope lines were very stable across PD 10-75% whereas this was more 









Figure 1.15. Co-effients for volume adjustment for PD and RA 
(134) 
 
Stoel et al further explored if the sensitivity of lung density could be improved by 
correcting for changes in lung volume based on the estimated relation between 
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density and lung volume (196). Two methods were explored; correcting CT density 
using an estimate for the entire patient group versus individual and patient specific 
volume adjustment. This was done by using a linear mixed effects model with CT 
density as the outcome, volume of lung, and time of CT scans as fixed effects. They 
found sensitivity was improved using repeated CT scans and by applying volume 
correction to individual patient data which decreased the SE of progression estimate 
by a factor of two.  
Regarding the application of volume correction to clinical trials, the EXACTLE study 
used 2 methods to adjust for volume in this RCT of prolastin versus placebo; the 
‘physiological method’ and ‘statistical method’(198). Physiological ‘sponge’ method 
uses TLC-adjusted PD15 as the dependent variable; treatment and centre as fixed 
factors and baseline measurement as covariates. The statistical model used PD15 as 
the dependent variable; treatment and centre as fixed factors; and change in 
logarithm of CT-measured TLV and baseline measurement as covariates. Adjusting 
for volume and the level of inspiration is critical in standardisation of CT 
densitometry whether this be done as a physiological adjustment or statistically.  
 
1.8.4. Clinical Trials using CT as an outcome measure. 
 
CT has been used as an alternative outcome measure in therapeutic trials for patients 
with emphysema. When performing power calculations in the EXACTLE study 
using CT density as a measure of response to alpha one augmentation therapy, the 
author’s calculated 494 patients would need to be recruited in each treatment arm 
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for 3 years using FEV1 as the primary outcome measure (198). In the RAPID trial 
however, they calculated 180 patients distributed over the two treatment arms 
would provide a power of at least 80% using two sided p value of 0.05(92); this was 
possible because their primary outcome was CT density which is more sensitive to 
change. 
CT has been used to measure treatment response in both usual COPD and AATD and a 
summary detailing CT measure used, outcomes and the strengths and weaknesses of each 
study are presented in Table 1.10. Notably, in AATD the recent RAPID trial was the first 
RCT to demonstrate a significant improvement in lung density with alpha one 
augmentation therapy. Stockley et al pooled the data from the two RCTs by Dirksen et al in 
1999 and  2009 (EXACTLE), and with the increase in statistical power , augmentation 
therapy increased the lung density as measured by 2.997 g/L in comparison to the placebo 
arm (95% CI, 0.669 to 3.926, p=0.006)(199).  
1.8.5. Development of reference values. 
 
Now that we know CT density correlates with pathologically measured emphysema, 
lung function tests and other parameters such as mortality, how to we define 
thresholds beyond which we say a patient has clinically important emphysema and 
may need observation or treatment. An isolated value is meaningless without 
knowledge of what defines the healthy population and has the patient’s 
measurement moved outside this. The mission to determine a range of CT density 
values in the normal population has shown there to be significant heterogeneity 
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even in the healthy population. For example, age, gender, ethnicity, BMI and even 
educational attainment are all known to significantly affect a person’s CT density 
(200, 201). Reference or ROC derived intervals limits would be helpful in 
interpreting the sensitivity/specificity of test results and how they relate to our 
patients, and there have been attempts to define this in healthy populations (202, 
203). 
In my opinion there is a question about which anchors should be used to help 
determine a clinically important change in density i.e. quality of life measures or 
exacerbations or mortality are likely more pertinent to the patient than FEV1. A 
reference value would help signpost clinicians towards someone who has 
pathologically more emphysema than a healthy individual and therefore may need 
more observation. The only current treatment for true emphysema progression in 
AATD at an alveolar level is augmentation therapy, and based on the publication by 
Dirksen et al and Chapman et al, one would argue that regardless of the baseline, it 
is the change in CT density over time that denotes a patient declining and in need of 
intervention. Therefore whilst work is in progress by groups such as MESA and 
SPIROMICS to create a reference range for CT density for healthy individuals, what 
we do with a patient who then has an out of range value is yet to be fully decided.  
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Table 1.10. Summary of interventional drug trials using CT measures as an outcome measure 
 
Author Study Design Pt 
N⁰ 






254 2-4 years PD15 and --
910HU. 
Budesonide or placebo Annual fall in PD15 ↑in the placebo 
arm vs budesonide (p=0.09).  
Annual increase in --910HU↓in the 
budesonide arm (p=0.02). 
Hoshino et al 
2014(205) 
RCT 54 16 weeks %WA, LA, 
BWT 
Tiotropium, Indacaterol or both. Combination therapy resulted in a ↓in 
%WA and wall thickness (p<0.01). 
Nordenmark 
2015(206) 
RCT 36 12 weeks BWT, air 
trapping index 
and %WA 
Reversible neutrophil elastase inhibitor 
60mg BD 





23 1 week Airway inner 
luminal area 
Salmeterol/Fluticisone (SFC) Ct detected the significant change in 





Alpha 1 Antitrypsin Deficiency 
Stolk et al 
2012(208) 
RCT 262 1 year PD15 Parlovarotene no benefit on lung density  




20 9 months --910HU ATRA No benefit 




148 9 months --910HU Patients received ATRA either low dose 
(LD), high dose (HD), 13-cis retinoic acid 
(13-cRA) or placebo 
No definitive clinical benefits  
Dirksen et al 
1999(211) 
RCT 32 3 years PD15 Alpha1-antitrysin CT analysis showed a non-significant 
trend towards a favourable effect. CT 
lung density twice as sensitive as PFTs 
Dirksen et al 
2009(198) 
(EXACTLE) 
RCT  77 2-2.5 
years 
PD15 Prolastin CT densitometry more sensitive 
measure for the detection of 
emphysema progression than PFTs or 
health status indices 
Chapman et al 
2015(92) 
RCT 180 2 years PD15.  Alpha 1 proteinase inhibitor Annual rate of density decline at TLC 
↓in treatment group (p=0.03) 
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1.9. Quantifying Emphysema using Magnetic Resonance Imaging (MRI) 
1.9.1. Introduction to MRI 
 
MRI measures the behaviour of protons once a strong magnetic force is applied. The 
lungs have therefore been notoriously difficult to image due to the abundance of air 
and low proton density. However, technology has advanced so that MRI may 
capture changes in a much shorter time window and use inhaled gases (oxygen and 
hyperpolarised helium/xenon) that alter the proton behaviour in different ways, so 
that disease and heterogeneity in the lung may be detected. The benefits of MRI over 
CT and PFTs are the ability to acquire functional information with regards to 
ventilation, perfusion and alveolar diffusion, and any regional differences. MRI 
therefore could offer an attractive solution to evaluating underlying pathology and 
targeting treatment. 
1.9.2. Validation 
1.9.2.1. Clinical Validation 
 
MRI findings from the various modalities have been correlated with lung function 
and CT density in numerous studies (Table 1.11), r values for FEV1 ranging from 
0.61-0.72 and 0.45-0.9 for DLCO.
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Table 1.11. Studies correlating MRI with other clinical variables 
MRI modality FEV1 Gas Transfer CT density 








0.8-0.9 (212, 218) 
 






0.677*(221)   
UTE-MRI**  0.6(222) 0.72(222) 
*: Dynamic contrast measured by the signal intensity perfusion defect (SIpd). 
**: Ultra-short echo time-MRI 
1.9.2.2. Pathological Validation 
 
One of the pathological hallmarks of emphysema is the destruction of alveolar walls 
and dilatation of respiratory bronchioles (223, 224). Histologically this may be 
measured by the surface area to volume ratio (SA/V) and this was compared with 
MRI findings in five patients who had undergone bilateral lung transplant for end-
stage COPD. Using He-MRI and measuring the ADC, the correlation between 
histology and MRI findings was very strong (r=0.96)(225). Morino et al in an animal 
model measured the correlation between dynamic contrast MRI and alveolar 
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enlargement as defined by the mean linear intercept (Lm) and this demonstrated a 
slightly weaker correlation though still significant (r=-0.77, p<0.001)(226).  
1.9.3. Oxygen enhanced MRI 
 
Proton MRI measures the longitudinal and transverse relaxation times (T1 and T2 
respectively) after magnetic force has been applied(227).  Oxygen molecules shorten 
the T1 relaxation time, and mapping the degree of change can depict the 
heterogeneity of ventilation within the lungs(228). The mean wash in time maps of 
oxygen created significantly correlates to FEV1 and FEV1/FVC ratio (-0.74 for both) 
demonstrating its strong relationship to current measures of ventilation (219). The 
degree of altered signal change as depicted by the mean relative enhancement signal 
has a stronger correlation with gas transfer (r=0.83) (220)and therefore as well as 
acting as a map of ventilation, oxygen enhanced MRI may also reflect alveolar-
capillary gas transfer(219). Oxygen enhanced MRI has also been demonstrated to be 
able to separate emphysematous patients from asymptomatic smokers (213).   
The benefits of offering oxygen enhanced MRI over other inhaled gases acting as a 
contrast is that it may be implemented at most centres without the need for specialist 
equipment, although it would still require specialist software(227). No breath 
holding manoeuvres are required, which is preferable in COPD patients, and the 
signal artefacts are relatively low, as is the overall cost. However, the scanning time 




1.9.4. Hyperpolarised MRI 
 
Using spin technology to hyperpolarise inhaled gases such as Xenon (129Xe) and 
Helium (3He) through polarised laser light, the nuclear polarisation is increased up 
to 10,000 times, and therefore can be detected and quantified by the MRI scanner. 
This is then amplified and then measured (228, 230) . The apparent diffusion 
coefficient (ADC) is a reflection of measured molecular movement, being enhanced 
in emphysema where there are larger air spaces and destroyed alveolar walls (Figure 
1.16)(231). For this reason MRI using hyperpolarised gases yields information about 
alveolar anatomy unlike HRCT, and images produced of regional ventilation 
without ionising radiation and therefore no health risk to the patient of performing 
multiple scans.  ADC correlates with lung function, and is sensitive at detecting 
differences between emphysematous and non-emphysematous patients(232).   
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Figure 1.16. Demonstration of Random Brownian Motion and Apparent Diffusion 
Coefficient (ADC) in emphysema 
 
More recently a dwindling supply of helium has forced up the price, rendering it too 
expensive to be used for either clinical or research purposes(230). However, xenon is 
naturally abundant and therefore significantly cheaper; it also outperforms Helium 
in its ability to assess gas exchange and uptake (230, 233). Hyperpolarised 129Xe 
nuclei can remain dissolved in blood for around 4 seconds in venous blood (234) 
(235)(therefore potential use for examining the relationship between ventilation and 
perfusion), and in gaseous form for several hours(236, 237). The stability of 
hyperpolarised Xenon is therefore attractive in planning future clinical trials. 
The main drawbacks of hyperpolarised Xenon and MRI are that the technique 
requires specialist centres with appropriately trained radiologists(227). Patients are 
required to breath hold for around 20 seconds, which is very challenging for patients 
with COPD, and at high doses Xenon has anaesthetic properties and therefore 
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caution following the procedure should be taken (e.g. driving and operating heavy 
machinery(234)). There needs to be the technology available to perform optical 
pumping of rubidium vapour, which in turn is used to excite nuclear spins of 
xenon/helium(234). However, hyperpolarised MRI has no radiation dose and gives 
high spatial resolution. It provides detailed regional information about gas exchange 


















Detecting early changes in the vascularity of patients at risk of developing 
emphysema could potentially act as another early biomarker of disease. Dynamic 
Contrast Enhanced MRI involves injecting contrast and measuring the amount of 
time taken for the contrast to pass through the pulmonary circulation, i.e. the longer 
the time taken, the more flow restriction there must be. Transit time of blood 
through the pulmonary circulation is notoriously rapid, though MRI with ultra-fast 
capabilities is able to capture this (239, 240). Not only is this technique feasible it also 
correlates to clinical parameters. Hueper et al demonstrated this is possible on a 
microvascular scale, and demonstrated evidence of disease in patients with COPD in 





Multiple studies have demonstrated that MRI correlates more strongly with PFTs 
than CT does (Table 1.12). However at this early stage it still remains unclear if MRI 
is more sensitive, as the literature is not as advanced.
74 
 
Table 1.12. Summary of studies comparing MRI and CT in COPD. 
Author Year Pt No Variables Results 
Ley S 
(212) 
2004 13 ADC and EI vs FEV1 ADC vs FEV1, R= 0.7 
EI vs FEV1 R= 0.5 
MLD vs FEV1 R=0.4 
Ohno 
(219) 
2008 71 O2 enhanced MRI 
(mean wash in time and relative enhancement ratio), 
CT defined lung volumes vs lung function 
Mean wash in time vs  FEV1 r=-0.74 
Relative Enhancement Ratio vs KCO r=0.66 
CT lung volume vs FEV1 r=0.61 
CT lung volume vs KCO r=0.56 
Van Beek 
(216) 
2009 94 ADC and MLD vs FEV1/FVC and DLCO ADC vs FEV1/FVC r=0.5 
MLD vs FEV1/FVC r= 0.52 
ADC vs  DLCO r=0.59 





2009 27 ADC and EI vs FEV1 and DLCO ADC vs FEV1 r=0.67 
EI vs  FEV1 r=0.55 
ADC vs DLCO r=-0.82 
PD15 vs DLCO r=0.6 
Quirk 
(242) 
2011 30 Hyperpolarised He vs CT density in at risk smokers Lung morphometry vs 
%LAA 950: 
Significant difference seen in those still smoke, not on CT 
Xia 
(221) 
2014 55 Positive rate of Perfusion defects vs CT changes  Early COPD: MRI detected 8/8, vs CT 3/8 
P=0.003 




2015 144 DCE-MRI vs CT density 
 
PMBF vs %LAA 950: 
Evidence of non-linearity,  p=0.015 
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1.9.7. Phenotyping with MRI 
 
1.9.7.1  Airways Disease 
 
MRI is already used to visualise airway changes in more detail in Cystic Fibrosis 
including inflammation, mucus plugging and bronchiectasis (243). In this capacity, 
MRI is superior over CT with its ability to more accurately differentiate soft tissue 
such as remodelling/inflammation (227, 244). The increased airway resistance seen 
in small airways disease in asthma has also been evaluated by MRI. Where 
bronchoconstriction has resolved clinically MRI assessment of ventilation 
demonstrated focal, fixed obstructive defects that may be reversible with targeted 
therapies e.g. bronchothermoplasty (215).  The ability of MRI to accurately measure 
the resultant degree of hyperinflation and air trapping has obvious potential clinical 
applications in COPD namely endobronchial valves and LVRS.  
1.9.7.2.  Emphysema 
 
 
The ADC measured in MRI is a reflection of the amount of measured molecular 
movement, with more movement in emphysema where there are larger air sacs and 
destroyed alveolar walls(231). Therefore a high ADC indicates more severe 
emphysema and could be used either diagnostically or for assessment 
longitudinally. As there is increased interest in using CT density as a direct measure 
of parenchymal response to augmentation therapy in AATD, ADC would be another 
potential option of measuring alveolar changes.  
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Vascular remodelling secondary to hypoxic vasoconstriction is likely part of a more 
systemic process associated with COPD. Perfusion studies such as dynamic contrast 
enhanced MRI may therefore act as another useful imaging biomarker to detect and 
prevent further disease(245). For example where there is a perfusion defect with 
preserved ventilation, then this maybe a target for bronchodilators. Similarly where 
there is preserved perfusion, up to 20% have emphysematous regions which 
therefore may act as a map for targeted interventional therapies such as BVRS (246). 
Jobst et al showed a moderate relationship between oxygen enhanced MRI and 
contrast enhanced MRI (r value =0.52, p<0.05) therefore there is a link but one is not 
a surrogate for the other(247). A summary of how MRI can help phenotype COPD is 
given in Table 1.13. 
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Table 1.13. MRI modalities to phenotype and treat COPD. 
 





Detailed anatomical information of 
airway inflammation, oedema and 




Regional information re. lung 







Global high ADC(231) 
Low PaO2(213) 
Early disease detection  




↑↓Relative enhancement signal(219, 
220) 
 





Global microvascular reduction 
blood flow(241) 
Lifestyle moderation 
Focal defects, small pulmonary 
emboli 
Anticoagulation 
Increased pulmonary pressure Treat as pulmonary 
hypertension 
Potential treatments based on the phenotypes identified by the technique, but that 
have not yet been tested are noted by * in the table. BVRS=bronchoscopic volume 




1.10. Minimal Clinical Importance Difference (MCID) 
1.10.1. MCID and COPD.  
 
First described by Jaeschke et al, the Minimal Clinically Important Difference 
(MCID) is defined as the minimal amount of change to take place that is relevant to 
the patient (249, 250). Multiple validated MCIDs exist within COPD including health 
status (SGRQ 4 points), exercise capacity (47.5 m for incremental shuttle walk) 
(100ml at trough), dyspnoea (2 units Borg scale or 5-7 units on the UCSD 
questionnaire), and FEV1 (100-140ml) (251-253). MCID are traditionally calculated 
one of two ways: the anchor method and the distribution method, though within this 
broad grouping, there is still upwards of 9 different methods used, and no consensus 
on the optimal technique (250, 254, 255).   
1.10.2. Distribution Method 
 
Distribution-based methods use the spread of the data to calculate the standard error 
of measurement, beyond which a significant change has occurred(250). The 
advantages of this technique are that they do remove some of the random variation. 
However, the disadvantage is that this is a statistically derived estimate and further 
removed from benefits observed by patients. Furthermore, there is a lack of 
consensus over the optimum tool, and there is a degree of lack of understanding in 
the literature between the minimal clinically important difference and the minimal 
detectable difference(250).  
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1.10.3. Anchor Method 
 
Anchor-based methods examine the relationship between scores on the assessment 
instrument and other measures of impaired health (the anchors).i.e. using the 
already known MCID for FEV1 of 100ml (251, 256, 257). Criticisms of this method 
surround using anchors that in themselves are effectively estimations, and that the 
lack of precision in the calculation means using the proposed MCID reduces its 
sensitivity and specificity (false negatives and positives respectively)(250).  
The recommendations are to use a combination of approaches, narrowing down to a 
single figure or range, based on a triangulation process(257). Where triangulation 
cannot be performed then statisticians recommend using a modified Delphi method 
to order to achieve a consensus value. This vague approach to proposing an MCID 
produces a value that is in essence an estimate(251), and patients may describe 
feeling benefit without achieving the MCID.  In summary, an MCID that uses patient 
reported outcomes as one of its anchors, plus multiple methods using the 
distribution technique should be used to give as narrow range of MCID as possible.  
1.10.4. FEV1 
 
Patients do not report an improvement in their FEV1, rather their response to 
treatment will be judged by them by a reduction in breathless, exacerbations and 
mortality. However, these measurements remain relatively subjective, and therefore 
FEV1 has continued to remain an endpoint in clinical trials due to its 
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reproducibility(251). The MCID needs to be beyond the noise of the instrument, and 
the repeatability of FEV1 testing itself can vary up to 150ml, requiring at least 3 
measures are required to account for this variability (253, 258, 259). An American 
study of nearly 6000 patients with repeated spirometry 17 days apart demonstrated a 
difference in FEV1 of 110-123ml, and a larger 2004 study of 18,000 patients showed a 
variability of 120ml (260, 261).  
The regularly cited review by Donohue recommends a proposed MCID for FEV1 of 
100ml which has been used in subsequent trials (258, 262, 263). Using other methods 
of proposing an MCID including the anchor method and that of patient-opinion, 
other MCIDs proposed are 110ml and 122ml respectively(264) (265). However the 
ATS/ERS taskforce suggest a range of 100-140ml may be more appropriate but 
further work continues to needed (253). Of course the baseline FEV1 measurement 
affects the decline over time, i.e. patients with the least and most severe COPD 
decline the least rapidly. Therefore FEV1 change is relative to the baseline, not 
accounted for in the MCID(266). Finally, FEV1 only correlates moderately with its 




As the SGRQ is a validated tool to assess quality of life in COPD, it is more often 
used in COPD trials. Again, using a process of triangulation, the MCID for SGRQ is 
proposed at a decline by 4 units(267). Newer inhaled medications have been shown 
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to reach this MCID e.g. aclidinium (268) and indacterol(269, 270) as opposed to 
ipratropium (251, 271). However, as the SGRQ is a self-reporting technique, it is 
possible that patients will perceive benefit even when on placebo, and are more 





 . Aims and Hypotheses Chapter 2
 
The studies presented in this thesis investigated the utility of CT density as an 
outcome measure in Chronic Obstructive Pulmonary Disease (COPD) and Alpha 
One Anti-Trypsin Deficiency (AATD). The aims and hypotheses are as follows. 
 
Chapter 3 : The aim of the systematic review was to assess the validity of CT 
densitometry as an outcome measure of severity and progression of lung disease 
in emphysema specifically seeking relationship to lung function, mortality, 
hospital admissions and quality of life (QOL).  The null hypothesis was there 
would be no significant relationship between CT density and other clinical 
parameters. 
 
Chapter 4 : To aim was to assess the variability of CT measurements performed 
on the same CT scans by the same observer (intra-observer variability) and 
between observers (inter-observer variability) and between the two leading 
software programs. The null hypothesis was that measurements of the same scan 





Chapter 5 : The aim of this cross-sectional and longitudinal analysis was to assess 
the relationship between CT density and common clinical parameters including 
mortality using the Birmingham Alpha One Antitrypsin Deficiency cohort. The 
null hypothesis was CT density is not associated with other clinical parameters 
including mortality.  
 
Chapter 6 : The aim of this study was to propose and validate an MCID for CT 
density annual decline.  The null hypothesis was that a proposed MCID wouldn’t 




 . Methods Chapter 3
 
3.1. Systematic Review 
 
This systematic review has been conducted in accordance with the Cochrane 
Handbook for Systematic Reviews of Interventions and reported using the Preferred 
Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines.  
3.1.1. Studies Included 
 
This review is registered with Prospero (CRD42015024183). All papers concerning 
patients with clinically or spirometrically defined COPD or AATD which compared 
CT densitometry data with FEV1, gas transfer (DLCO or KCO), quality of life (QOL), 
in the same study population were included. In addition any study in AATD or 
COPD patients which described longitudinal density change, irrespective of whether 
a direct relationship to one of our pre-specified outcomes was included.  
3.1.2. Population 
 
The following databases were searched with no date or language restrictions, 
confined to adults and human studies: MEDLINE (Ovid), MEDLINE In Process 
(Ovid), EMBASE (Ovid), Cochrane Library (Wiley) Cochrane Central Register of 
Controlled Trials (CENTRAL), CDSR, HTA, NHS EED and DARE. In addition 
Conference Proceedings Citation Index (CPCI) via Web of Science and British 
Library’s ZETOC were searched for conference proceedings and abstracts and 
Clinical Trials.gov and WHO ICTRP (International Clinical Trials Registry Platform) 
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searched for ongoing trials. Search terms for COPD and AATD were combined with 




Table 3.1. Search terms 
Row 
Number 
Search Terms Row 
Number 
Search Terms 
1 (Alpha adj2 anti adj2 deficien$).tw. 31 deficien$.mp. or lack$.ti,ab. [mp=title, abstract, heading word, 
drug trade name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword] 
2 A1AT.mp. 32 Smoking-related lung disease*$.mp. 
3 A1AT.ti,ab. 33 Emphysema.mp. or emphysema/ 
4 A1ATD.tw. 34 Computed Tomography.mp. 
5 AAT.mp. 35 Computerised axial tomography.mp. 
6 AAT.ti,ab. 36 Computerised axial tomography.mp. 
7 AATD.mp. 37 computer assisted tomography/ 
8 AATD.ti,ab. 38 ct.mp. 
9 alfa 1 antitrypsin.ti,ab. 39 Tomography, X-Ray Computed.mp. 
10 alpha 1 antitrypsin.ti,ab. 40 X-Ray computed.mp. 
11 Alpha 1-Antitrypsin.mp. 41 Lung density.mp. 
12 Alpha 1-Antitrypsin Deficiency.mp. 42 Densitomet*.mp. 
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13 (Alpha adj2 anti trypsin).mp. [mp=title, abstract, heading word, 
drug trade name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword] 
43 Lung attenuation.mp. 
14 alpha one antitrypsin.ti,ab. 44 Lung densitometry.mp. 
15 alpha one-antitrypsin.ti,ab. 45 Lung function test/ or lung function/ or spirometry/ or forced 
expiratory volume/ or FEV1.mp. 
16 alpha1 antitrypsin.ti,ab. 46 Pulmonary function.mp. 
17 alpha-1 antitrypsin.ti,ab. 47 Lung Volume Measurements.mp. 
18 alpha1-antitrypsin.mp. or alpha 1 antitrypsin/ 48 All alpha 1 terms. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 
11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 
19 alpha1-antitrypsin deficiency.mp. 49 (excluding 31): all COPD terms: 23 or 24 or 25 or 26 or 27 or 28 
or 29 or 30 or 32 or 33 
20 alpha-1-antitrypsin.ti,ab. 50 All CT and CT densitometry terms: 34 or 35 or 36 or 37 or 38 or 
39 or 40 or 41 or 42 or 43 or 44 
21 alpha-1-at.ti,ab. 51 Lung function terms: 45 or 46 or 47 
22 exp alpha 1 antitrypsin deficiency/ 52 alpha one AND CT: 48 and 50 
23 exp Bronchitis/ 53 alpha one AND CT and lung function: 48 and 50 and 51 
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24 exp Pulmonary Disease, Chronic Obstructive/ 54 COPD AND CT: 49 and 50 
25 chronic obstructive airway* disease.mp. 55 COPD AND CT AND lung function: 49 and 50 and 51 
26 Chronic bronchitis.mp. or chronic bronchitis/ 56 Sum of all COPD terms and CT/densitometry terms: 48 or 49 
27 chronic obstructive pulmonary disease.mp. 57 COPD OR alpha one AND CT:  50 and 56 
28 chronic respiratory disorder.mp. 58 COPD OR alpha one AND CT AND lung function: 51 and 57 
29 COPD.mp. 59 Sum of 52 or 53 or 54 or 55 or 57 or 58 
30 chronic obstructive lung disease/ 60 limit 59 to (human and (embase or medline) and (adolescent 
<13 to 17 years> or adult <18 to 64 years> or aged <65+ years>) 
90 
 
3.1.3. Study Selection 
 
Titles and abstracts of search yield were screened for relevance by two reviewers 
(DC and AT) independently and disagreements resolved by discussion, where 
required involving a third reviewer. Relevant articles were obtained and assessed 
against the full selection criteria in a similar manner. Studies which used visual 
scoring only were excluded, as were those that were measured in expiration only.  
3.1.4. Inclusion and Exclusion Criteria 
 
Inclusion 
 COPD/AATD and any reference linking lung density to clinical outcomes.  
Exclusion 
 Case study or studies with participant number less than 8. 
 Surgical studies (i.e. those reporting density before and after surgical 
intervention) 
 Other medical specialities 
 Lab or animal based studies 
 Paediatric studies 





3.1.5. Data Extraction 
 
Data was extracted using the Cochrane model (273), and included general study 
information, specifics of CT acquisition (i.e. reconstruction algorithm, software and 
slice thickness), percentage Low Attenuation Area (%LAA), whether the scan was 
taken in full inspiration, use of bronchodilator during spirometry and a CT phantom 
for quality assurance. This process was performed by one reviewer (DC), and 
checked by another (AMT, EL, MT, MK).  
3.1.6. Risk of bias 
 
3.1.6.1. General Bias Assessment 
 
Table 3.2 summarises the recommended risk of bias tool for each type of clinical 
study following a systematic review of methodological quality assessment tools by 
Zeng et al 2014(274). The majority of the studies we assessed were cross sectional 
with no intervention and therefore the risk of bias tool of choice was the Agency for 
Healthcare Research and Quality (AHRQ) tool. This consists of 11 items which 
examines the study population and the comparability of patients. The fairness of the 
outcome measure and appropriate statistical tests applied are assessed and whether 
there are any possible biases within the discussion. As CT density as an imaging 
biomarker is being compared with other disease measures such as lung function, 
including elements of the QUADAS 2 score allowed for assessment between the two 
tests to be performed i.e. asking questions about the index test plus the flow and 
timing. I created a specifically designed tool therefore to incorporate the strengths of 
92 
 
the AHRQ and QUADAS2 (see Table 3.3). Risk of bias was assessed by one reviewer 
(DC) and independently by another (AT, MR, EL, MK). 
Table 3.2. Choice of risk of bias tool depending on the type of study 
Study Type Risk of Bias Tool Reference 
Randomised Control Trial Cochranes Collaboration 
Tool 
Higgins et al, 2011 (275)  
Cohort and case control 
studies 
Newcastle-Ottawa Scale Stang et al, 2010 (276)  
Non-randomised 
interventional studies 
The Methodological Index 
for Non-Randomised 
Studies (MINORS) 
Slim, K et al, 2003 (277)  
Cross-sectional Agency for Healthcare 
Research and Quality 
(AHRQ) 
Viswanathan, M et al, 
2008. (278) 
Diagnostic accuracy tests QUADAS-2 Whiting et al, 2011 (279) 
Systematic reviews/meta-
analysis 
Assessment of Multiple 
Systematic Reviews 
(AMSTAR) 
Shea, B.J. et al, 2007 (280) 
Clinical practice guidelines Appraisal of Guidelines, 
Research and Evaluation 
(AGREE) 





Table 3.3. Risk of bias tool used in the systematic review 
 
Patient Selection 
Source How well defined was the source of information (survey, record review) 
Inclusion/Exclusion List inclusion and exclusion criteria for exposed and unexposed subjects? 
Patient Selection Was a consecutive or random sample of patients enrolled? 
Applicability Adequate representativeness of the sample: do they reflect all COPD/AATD 
patients rather than just one end of the spectrum e.g. NETT trial and LVRS 
Duration of Study Indicate time period used for identifying patients 
Index and Reference Test 
Blinding Indicate if evaluators of subjective components of study were masked to other 
aspects of the status of the participants: 
CT bias Could conduct or interpretation of CT density have introduced bias? Was CT 
density measurement reliable 
PFT Bias Could conduct or interpretation of PFTs introduced bias: Was it done post-
bronchodilator 
Quality assurance Was a phantom used or calibration performed?  
Flow and Timing 
Flow and Timing Was there an appropriate interval between the CT study and PFTs  (within a 




Description of how confounding was assessed and/or controlled 
Missing variables If applicable, explain how missing data were handled in the analysis 





3.1.6.2. Publication Bias 
 
Publication bias was assessed visually through funnel plots and the Egger test of 
significance applied. The Egger test was chosen to assess publication bias due to its 
high power and suitability for continuous/dichotomous outcomes. It is the most 
frequently used test though is limited by its type one error rate which can increase 
with the degree of heterogeneity (282). 
3.1.7. Data Synthesis 
 
Baseline characteristics are presented as mean (standard deviation), or median 
(interquartile range). Studies where density was taken from a single slice, where 
authors divided the patients into arbitrary thresholds or which only used Mean 
Lung Density (MLD) against clinical parameters were not included in meta-analysis 
as data reliability, quality  or heterogeneity precluded this (283). Where meta-
analysis of the relationship between CT density and one of our chosen outcomes was 
appropriate StatsDirect was used to estimate the Schmidt Hunter for Pearson’s 
correlation coefficient alone, due to its high accuracy in heterogeneous populations 
(284). I2 and Chi square analyses were performed to assess study heterogeneity. A 




3.2. CT Density Validation 
 
3.2.1. Reader variability 
 
3.2.1.1. Intra-observer variability 
 
CT density analysis was performed twice, on two separate occasions three months 
apart by DC for 9 patients with varying severity of COPD as defined by the FEV1. 
Volume, Mean Lung Density (MLD), and emphysema as defined by --910HU, --
950HU and PD15 were measured each time and the correlation coefficient between 
the two sets of measurements calculated.  
3.2.1.2. Inter-observer variability 
 
A further 9 different scans, with a mixed severity of COPD were analysed by DC and 
then independently re-analysed by one of my supervisors (Dr Subramanian) in order 
to determine the level of inter-observer agreement using a correlation coefficient.  
Previously analysed scans performed between 2002 and 2004 as part of a previous 
fellow’s thesis work (DP) were accessed and reanalysed. These scans were 
performed following the SPREAD trial (Software Performance and Reproducibility 
in Emphysema Assessment: Demonstration), where the CT slice thickness and 
increment were found to be inaccurate, and therefore repeated on ‘Parr Protocol’ on 
subsequent scans. The ‘Parr protocol’ was used through the remainder of this thesis 
i.e. B30f reconstruction algorithm, slice thickness 5mm and increment 2.5mm. These 
subsequent analyses by DP and those repeated by myself were compared. Between 
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the 2002/2004 scans and those performed by myself, there has been an update in the 
PULMO software program, which may introduce an element of variability.  
3.2.2. Comparison and Evaluation of CT density analysis between the two leading 
software programs 
 
18 patients with AATD and emphysema underwent CT scanning between May 2014 
and February 2016 at the Queen Elizabeth Hospital Birmingham, recruited to the 
Birmingham AATD registry (processes for assessment being described in detail 
elsewhere and participating in the ongoing NIHR Rare Diseases Consortium). (285, 
286) Informed consent was given and the parent studies approved by the local ethics 
committee. All scans were performed on a Siemens scanner during deep inspiration, 
using a smooth reconstruction filter (B30f) and both 1mm and 5mm slices. Images 
were analysed using PULMO CMS (developed at the Leiden University Medical 
Centre) in the UK and then the images sent by DICOM format to National Jewish 
Health for analysis by Pulmonary Workstation by a researcher blinded to the UK 
results. 
Linear regression was performed on volume and emphysema thresholds -910HU, -
950HU and PD15 from both programs and the correlation coefficient calculated. 
Bland Altman plots were used to assess agreement. The level of significance was set 








The first thoracic CT scan analysed for densitometry within the Birmingham AATD 
registry was in 1994, and since then over 1100 CT scans have been performed and 
analysed. The nature of CT density analysis has evolved greatly over time, with 
modern techniques nearly fully automated and use sophisticated algorithms to 
delineate lung tissue from air (so called the region growing technique). PULMO (and 
Pulmonary Workstation, the second most frequently used software program) both 
use this technique as demonstrated in Figure 3.1. Between two adjacent voxels, the 
software program applies an algorithm to decide whether or not they are of the same 
density or different. If they are the same, the voxels will be connected to create a 
structure now 2 voxels wide. The software runs this program on all adjacent voxels 















A) The algorithm selects two adjacent voxels to determine if they are of the same 
density or not. B) Those voxels that are of the same density are combined to begin to 
create an image. C) This process continues until D) where an image recognisable as 
anatomical is created. 
The slice thickness used by the Birmingham AATD registry changed from 6.5mm to 
5mm in 2002, and for reasons detailed in the introduction, cannot be merged for 
meta-analysis. All scans performed from 2002 onwards were analysed using 
PULMO but prior to this, ‘density mask analysis’ was performed but without any 
further specifics given. Therefore all those scans performed before 2002 could not be 
included. 6 large databases existed with duplicate records and different formatting, 
which required extensive data ‘cleaning’ to finish with the most current version. 203 
patients have had at least one CT scan, with 432 scans in total that have been 
analysed using the correct CT acquisition parameters. These were all performed 
during one of the below studies using  B30f (soft) reconstruction algorithm, slice 
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thickness 5mm and increment 2.5mm on PULMO CMS. REPAIR and EXACTLE 
were RCT’s with placebo and treatment arms; only those patients in the placebo 
arms were analysed.  
 ADAPT (Antitrypsin Deficiency Assessment and Programme for Treatment) 
 REPAIR (Retinoids in Emphysema Patients in the α1-Antitrypsin 
International Registry) 
 EXACTLE (The Exacerbations and Computed Tomography scan as Lung End 
Points) 
 NIHR (National Institute of Health Research) Rare Diseases Consortium. 
3.3.2. CT density Analysis 
 
In order for PULMO to analyse the CT scans they must firstly be converted into 
DICOM (Digital Imaging and Communications in Medicine) format. The density of 
blood in the aorta can be calculated either manually or automatically. Two separate 
points are marked, at the proximal part of the aorta before the arch, and nearer to the 
diaphragm (see Figure 3.2a). The software program calibrates the density of the 
blood in subsequent slices until the standard error no longer changes. The same is 
repeated for air, though a manual scan through the slices is recommended to check 
any of the patient’s clothes haven’t been included in analysis for example (see Figure 
3.2b). The seed point, and the starting point of analysis, is automatically detected by 
PULMO within the trachea and preliminary analysis will highlight the lung 
contours, i.e. boundaries within which it predicts the lungs lie and may be adjusted. 
If the seed point fails to be correctly detected by the software program, it will 
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subsequently fail to detect the lung contours. Common pitfalls during this stage of 
the segmentation include bowel or tracheal air being included and required manual 
deletion before density analysis is performed. The software program finally 
generates a histogram of voxel density, including the values for a given LAA% and 
percentile point (see Figure 3.2c, Figure 3.2d).  
It is noteworthy the impact an incorrect reconstruction algorithm has on the density 
analysis of air. Figure 3.3a demonstrates the grainy quality of the appearance of air 
when a reconstruction algorithm of B50f was used instead of B30f. Figure 3.3b 
demonstrates the dramatic impact this then has on the density histogram with a left 
sided skew, and the results left uninterpretable.  
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Firstly, blood in the aorta is detected B) secondly the density of air is determined. 
C) The software will detect all voxels within a specificied range D) These voxels 




Figure 3.3. The effect of a sharper reconstruction algorithm on the CT density 
histogram.  
 
A sharper reconstruction algorithm e.g. B50f causes the histogram to have a severe 
left sided skew and the results un-analysable. 
3.3.3. Clinical Investigations 
 
3.3.3.1. St George’s Respiratory Questionnaire (SGRQ) 
 
SGRQ is a validated 16 part questionnaire designed to measure quality of life in 
patients with COPD and asthma. Divided into two parts, part one (questions 1-8) are 
designed to assess respiratory symptoms and part two (sections 9-16) designed to 
assess the patient’s activity and the impact this has on their day to day life. Ideally 
this should be completed by the patient in a quiet and undisturbed environment 
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with no input from friends and family. The answers are uniquely weighted and total 
score is out of one hundred, representing the maximum disability a patient may 
experience(287).  
3.3.3.2. Lung Function 
 
Spirometry measurements are performed in accordance with the British Thoracic 
Society (BTS) and the Association for Respiratory Technology and Physiology 
(ARTP) UK guidelines. FEV1 and FVC are determined using a wedge-bellows 
spirometer following a 12 hour period without taking their usual long acting 
medication, and after 5mg nebulised salbutamol. Lung volumes are calculated by 
constant volume body plethysmography and gas transfers measured by the single 
breathe carbon monoxide technique (288). Subjects are trained to hold their breath 
for 10 seconds following deep inhalation, followed by full expiration. KCO 
(diffusing capacity of the lungs for carbon monoxide divided by the alveolar 
volume) was additionally calculated.  
3.3.4. Statistical Analyses 
 
3.3.4.1. Cross Sectional analysis 
 
3.3.4.1.1. Univariate analysis 
 
Baseline characteristics of the Birmingham AATD registry are presented as mean 
and standard deviation (SD) if normally distributed, or median and interquartile 
range (IQR) if non-normally distributed. The cohort was then subdivided into those 
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who have survived and those who have not, and test of significance performed by 
either an independent samples T test or Mann-Whitney U (MWU) test.  
The Pearson’s or Spearman rank correlation coefficient between CT density and 
PFTs was calculated, and analysis of variance (ANOVA) between CT density and 
GOLD stage groups. The strength of the correlation between FEV1 and PD15 
weakens with reduced severity of emphysema, and the scatter plot shows there is 
not a clear linear relationship between the two variables. PD15 may be expressed as 
g/L by the addition of 1000 to the PD15 in HU e.g. PD15 value of -900HU would 
equal 100 g/L (130). By then calculating the natural logarithm, the relationship with 
FEV1 (L) becomes linear and meets the assumptions of linear regression (see figure 
3.4).  
Figure 3.4. Logarithmic transformation of PD15 
 





In the Birmingham AATD registry lung volumes were largely non-normally 
distributed with the exception of Total Lung Capacity (TLC) percent predicted, and 
the Residual Volume (RV)/TLC ratio. Gas Transfer as measured by DLCO and KCO, 
both raw values and the percent predicted of each was correlated with CT density.  
SGRQ is normally distributed and therefore Pearson’s correlation coefficient applied 
where the dependant variable was normally distributed and Spearman rank 
correlation coefficient where the dependant variable non-normally distributed.   
3.3.4.1.2. Multivariate analysis 
 
Forward selection stepwise regression was performed between PD15 and SGRQ, 
KCO and FEV1 (L). The unstandardized beta coefficients with 95% confidence 
intervals are reported plus the level of significance. The r2 value is reported between 
SGRQ and PD15 to demonstrate the amount of variability seen in CT density can be 
attributed to the SGRQ.  
3.3.4.2. Longitudinal Analysis 
 
3.3.4.2.1. Exacerbations and mortality  
 
The annual exacerbation rate was drawn from the patient’s electronic notes, and 
subdivided into those who frequently exacerbate (2 or more exacerbations per year) 
or not. Linear regression was subsequently performed between exacerbation rate 
and CT density to determine the effect of one variable on the other.  
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In order to determine an accurate date of death, patient’s records were also accessed 
and the time to final analysis calculated. 193 patients in whom the CT density for 
each emphysema threshold and survival status was known was subdivided into four 
quartiles (see table 3.4). Kaplan Meier curves were created to demonstrate the 
mortality for each quartile, and tested statistically using the log-rank test.  
 
Table 3.4. Quartiles used in the Kaplan Meier curves for each density measure 
 
Quartile -910HU -950HU PD15 
Q1 <31% <9.5% >-939HU 
Q2 31-45% 9.5-19% -939HU to -956HU 
Q3 46-55% 19.1-27.5% -957HU to -966HU 
Q4 >55% >27.5% <-967HU 
 
Cox regression analysis was subsequently performed in order to adjust survival for 
covariates: age, height, sex, pack years, FEV1 and KCO percent predicted. Multi-
collinearity was assessed by linear regression and the variation inflation factors 
(VIFs). Each density quartile was converted into a categorical variable and separate 








There are two recognised methods of proposing an MCID, the distribution and the 
anchor method. Both have their benefits and criticisms, and there is no clear 
consensus on which method is superior (see section 1.11.2 and 1.11.3). The anchor 
method uses an established MCID from a clinical parameter within the same field 
and plots the change of the known ‘anchor’ against the change in the parameter that 
is under review. In the case of proposing an MCID for CT change in density, the 
MCID of FEV1 (100mls) is plotted against the annual change in CT density (see 
Figure 3.5).  
Figure 3.5. Demonstration of the anchor method to propose an MCID 
 
The distribution method, of which there are upwards of 6 different variations 
suggested, measures the standard deviation at baseline in order to determine a 
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threshold beyond which cannot be attributed to the noise of the instrument. For this 
reason, the distribution method may also be regarded as the Minimal Detectable 
Difference (MDD).  
Statistical assistance and advice was provided by PN, a statistician employed within 
my hospital trust. The concept of proposing and validating a MCID was new to PN 
and therefore I needed to present the data and propose myself how I felt such 
analyses should be performed. A typical consult with the statistician would last 
around 30 minutes whilst we discussed potential techniques, and I would then 
proceed to perform the analysis and the outputs of the more difficult tests were cross 
checked by PN.  
An MCID for CT density will bring clarity to an imaging modality and investigative 
tool that many perceive as potentially useful but uncertain how to interpret the 
result. We aim to propose and validate a MCID for CT density decline in patients 
with AATD using both recognised methods. This value could then be used to judge 
response to AAT, or to identify those declining rapidly in need of intervention.  
3.4.2. Distribution Method  
 
Studies that reported the mean and standard deviation of CT density (as measured 
by the 15th Percentile Point-PD15 g/L-1) at baseline and annual change were sought. 
Table 3.5 summarises each method; the Reliable Change Index (RCI) and the 
Standard Error of Measurement (SEM) both require a test-retest correlation 
coefficient expressed as r. Using a random sample and two independent analysers, 
the calculated r value is 0.99 (see chapter 5). Given the sensitivity of CT density to 
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detect small changes, the MCID was calculated for small effects only. 95% confidence 





Table 3.5. Summary of proposed distribution methods to calculate the MCID 
Distribution Method Equation Adjustments 





X=1 for small 
effect 
1.96 for moderate 
2.77 for large 
Reliable Change Index 
 
MCID=X*SD baseline (154) 
 
X=1 for small 
effect 
1.96 for moderate 












3.4.3. Anchor Method  
 
3.4.3.1. Placebo arms of AAT RCTs 
 
The literature was searched for any papers that reported annual CT density change 
with the relative change in FEV1 as measured in millilitres without exposure to an 
intervention i.e. the placebo arms. FEV1 presented as a percent predicted only could 
not be used as the FEV1 anchor is 100mls, with no alternative for percent predicted. 
We sought any papers that detailed the relationship between the two variables for all 
patients including the spread of data so that the sample variance may be deduced 
(see figure 3.6). After establishing the slope of the regression line, by taking known 
values of x and y at a certain time point (e.g. FEV1 and CT change at one year), the 
regression equation can be built to establish the intercept. With a new estimated 
intercept and slope value, the MCID for CT density (y) can be calculated by knowing 
x (MCID for FEV1, which equals 100mls). Using the sample variance, 95% confidence 
intervals could then be additionally calculated.
111 
 
Figure 3.6. Demonstration of how scatter plots published in the literature differ, 
and what information was required to be able to establish a MCID 
 
 
A) Most commonly a summary statistic is given i.e. overall FEV1 and CT density at 
one year. B) Information regarding the variance of the data using each patient’s 
measured values.  
3.4.3.2. Birmingham AATD registry 
 
423 scans have been performed on over 220 patients recruited into studies such as 
EXACTLE “Exacerbations and Computed Tomography scan as Lung End-points” 
and the ongoing NIHR (National Institute for Health Research) rare diseases 
consortium. These only include patients who had a CT scan as part of an 
observational study, or were in the placebo arm of an RCT. The CT scans have all 
been performed using the approved CT protocol of a smooth reconstruction 




software programme (PULMO) was used throughout, and they were all analysed 
using the PD15 method.  
Patients who had received 2 or more CT scans plus at least 3 FEV1 measurements 
within the same time frame were identified. Annual slope FEV1 (mls) was calculated 
and compared with the respective annual CT density in order to achieve the line of 
regression. Where patients had multiple CT scans performed over the time, the first 
and last scans were used to calculate the decline.  
3.4.4. Validation of MCID 
 
Mortality, time to death and time to transplant was established for each patient, 
alongside age, FEV1, FEV1/FVC, DLCO, KCO and baseline density. The cohort was 
then subdivided in to those that declined faster or slower than the proposed MCID, 
and either a t test (normal distribution) or Mann-Whitney-U (non-normal 
distribution) performed to identify any significant differences. All analyses have 
been reported as two tailed in order to reflect the novelty of this approach and not 
assuming it has a one way hypothesis. All those with a significance level <0.12 were 
then entered into a multivariate cox regression in order to determine to hazard ratios 









The heterogeneity of COPD and AATD is well recognised, as is the need for more 
descriptive biomarkers beyond lung function.(289) CT has been used for many years 
to visually diagnose emphysema, providing the most direct assessment of its 
presence and distribution.(290) Software programs have since been developed which 
can objectively measure the severity of emphysema.(119) Quantitative CT, and in 
particular CT densitometry, is the method of quantifying emphysema using such 
software; its ability to assess emphysema has been validated clinically and 
pathologically (152, 160, 291) However, CT densitometry is yet to be standardised, 
with numerous factors impacting on the measurement of density and affecting 
results (195) Changes seen on CT predate those seen on spirometry, with 
pathological studies demonstrating that up to one third of the lung tissue is 
destroyed in emphysema before spirometry becomes abnormal. This suggests that 
CT densitometry may be a very important technique for detection of early disease, 
an area which is of increasing clinical interest.(292) CT densitometry was the 
primary outcome measure for registration level randomized clinical trials (RCTs) of 
augmentation therapy in AATD, where signals have been seen for this measure, and 
only trends in the same direction for other clinical outcomes(211)  More recently 
large cross-sectional studies in COPD have been established (e.g. COPDGene) which 
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have collected data from quantitative measures on CT as well as extensive 
physiology.(293)  
Understanding the implications of density data is complex for both clinicians and 
regulatory agencies and no systematic reviews of its utility have been undertaken. 
The purpose of our study is to assess the validity of CT densitometry as a measure of 
severity and progression of lung disease in emphysema specifically seeking 
relationship to lung function, mortality, hospital admissions and quality of life 
(QOL).   
4.2. Methods 
 
This systematic review has been conducted in accordance with the Cochrane 
Handbook for Systematic Reviews of Interventions and reported using the Preferred 
Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. 
All papers concerning patients with clinically or spirometrically defined COPD 
which compared CT densitometry data with FEV1, gas transfer (DLCO or KCO), 
quality of life (QOL), in the same study population were included. In addition any 
study that described longitudinal density change, irrespective of whether a direct 
relationship to one of our pre-specified outcomes was included. Studies where 
COPD was secondary to AATD were included. Details of data extraction, data 




4.3.1. Included Studies 
 
The PRISMA flow diagram (Figure 4.1) demonstrates 112 papers were included in 
the overall narrative, and 82 papers could be combined by meta-analysis. 
Characteristics of all included papers can be found in the Table 4.1. 200 papers that 
met the initial inclusion criteria were later excluded followed a more detailed 
review. Clinical parameters that were felt not to be useful and beyond the scope of 
this review included chronic asthma/bronchitis, CPET (cardio-pulmonary exercise 
testing), tracheal and vascular indices or observed racial differences (294-297). A 
total of 35 papers were further excluded where the method of CT quantification was 
felt to be particularly experimental or unique and unrelated to CT densitometry. 
Such examples include those papers which discuss regions of interest (ROI) or image 
registration with biomechanical analysis (151, 298-300).
116 
 



























Records identified through database 
searching: 
 
MEDLINE (Ovid), MEDLINE In Process 
(Ovid), EMBASE (Ovid) N=7748 
CENTRAL n=1709, CDSR n= 245, DARE 
n= 118, CMR=1, HTA=16, EED=92. 
Total=9929 
9078 records removed either not 








Records after duplicates removed 
N =9559   
Potentially relevant records identified 
and screened for retrieval 
n = 481 















Studies included in quantitative synthesis 
N=82 
 
200 Full Text Articles Excluded 
 Not a useful clinical parameter 
(58) 
 Other methods of emphysema 
CT quantification (35) 
 Visual score (19) 
 Unable to translate (14) 
 Airways (13) 
 Not COPD or AATD (10) 
 Lung volumes only (8) 
 Phenotypes (8) 
 Further duplicates (7) 
 Expiration (6) 
 Zones (6) 
 MRI (4) 
 No clinical comparison made 
(4) 
 Smoking only as the 
comparator  (4) 
 Paper unreliable (3) 
 Unable to obtain (1) 
 
Studies included for qualitative synthesis  
N=112 
169 excluded: Did not meet inclusion 
criteria 
370 duplicates removed   
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procedures used  
Agusti, A. et al, 
2010 (301) 
2164 (48) 63.4 (7.1)     -950HU       low dose 
CT; 1mm 
thickness 




smokers from site 
databases and local 
papers. 
Akira et al, 2009 
(154) 
67(55) 70.7 (9.3) 24.4 (3.9)   -950HU Correlation coefficient not mentioned Advantage 
Windows 3D 
1.25mm usual care 
Alberti, P. et al 
2012 (302) 
1831 (66) 63.4(7.0)     -950HU       low dose 
CT 
Via ECLIPSE: 3 year 
prospective non-
interventional study 
in 12 countries 
Atta et al, 2015 
(303) 




thoracic VCAR 5mm usual care 
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Aziz, Z. A. et al, 
2005 (170) 





not mentioned 1-3mm identified 
retrospectively  
Baldi et al, 2001 
(304) 
24 (75) 61 (11) 35 (12)   -950HU Correlation coefficient bone algorithm program 
developed at the 
research service 
branch of National 
institute of health 
1mm usual care 
Barjaktarevic, I. 
et al 2015(305) 
460(57) 64.2 (6.8) 30.6 (8)   -950HU Correlation coefficient B35f Pulmonary 
Workstation 
1.25mm usual care 
Bastarrika, G. et 
al, 2009(306) 
102 (80) 55 (7.5) 103 (23)   -950HU Correlation coefficient B30f  5mm usual care 
Bernspang, E. et 
al, 2011(307) 
19 (61) 32 108(12) 92 (11) PD15 Correlation coefficient B10f Pulmo 5mm   
Camiciottoli, G. 
et al, 2006(160) 
51 (90) 64 52 (20) 68 (24) -950HU Correlation coefficient High resolution  Pulmo 1mm usual care 
Camiciottoli, G. 
et al, 2012 (308) 
72 (73) 66 (8)             5mm   
Castaldi, P. J. et 
al, 2013 (120) 
9313 (54) 60 (9) 77 (25)   -910HU, 
-950HU 









45.79 (17.84)   -950HU Correlation coefficient 
 
B30 MATLAB and in 
house software 




Chapman, K. R. 
et al 2015 (92) 
180 (54%) 53 (7) 43.3 (11.6)   PD15 mixed effects model 
and mITT 
not mentioned Pulmo not 
mentioned 
28 study centres in 
13 countries 
Chen et al, 2014 
(310) 
146 (83.6) 65     -950HU Correlation coefficient not mentioned LungCAD 1mm usual care 
Cheng et al, 2015 
(164) 
103 (84) 75.8 (9.8) 44.77 (13.8)   -950HU Logistic regression Standard algorithm Myrian 1.25mm Usual care 
Chierakul, N. et 
al, 2014 (311) 
23(82) 73 (8) 67.8 (25.4) 56 (28.1) -950HU Correlation coefficient not mentioned Thoracic VCAR not 
mentioned 
usual care 
Coxson, H. O. et 
al, 2013 (312) 




Crim, C. et al, 
2011 (313) 
2054 (65) 63.4 (7.1)     -950HU       1mm ECLIPSE 
Dawkins, P. et 
al, 2009 (121) 
488 (60) 50 (0.48) 55.99 (1.4)   -910HU Hazard Ratio     1mm ADAPT 
De Torres, J. P. 
et al, 2011 (314) 
115 (84) 64 (10) 75 (15) 73 (20) -960HU Correlation coefficient B40f Leonardo 1mm usual care 
Desai et al, 2007 
(315) 
106 (66.9) 61 42.4 (26.7) 48.1 (20.8) -950HU Correlation coefficient not mentioned MagicView 1mm usual care 
Diaz et al, 2009 
(155) 
27 (33) 55 (12) 50 (10) 55 (16) -950HU Correlation coefficient B10f Pulmo 5mm usual care 
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Diaz, A. A et al, 
2015 (161) 
102 (60) 66 (8.8) 68 (23.8) 71.5 (21.6)% -960HU MCID and C-statistic 
 
B45f not mentioned 1mm PELE 
Diaz, A. A. et al 
2010 (291) 
109 (56) 61.2 (7.9)     -950HU        COPDGene 
Diaz, A. A. et al, 
2010 (162) 
93 (57) 66.7 (8.8) 57.1 (24.3)   -950HU Correlation coefficient 
and multivariate 
linear regression 
B46f Airway inspector 1mm LTRC 
Diaz, A. A. et al, 
2012 (316) 





Diaz, A. A. et al, 
2013 (317) 
2500 64 (8) 59 (23)   -950HU       0.75mm COPDGene 
Dijkstra, A. E. et 
al, 2013 (318) 
492 (100) 59.4 (5.2) 98.2 (19.7)   PD15 Multivariate analysis soft reconstruction 
filter (B30f) 
in house software 1mm NELSON 
Dirksen, A. et al 
1999 (211) 
56 (61%) 47.6 (3) 48 (2.8) 60 (3) PD15 random effects 
regression model, 
slope analysis and 
Pearson’s coefficient 
<5/10mm not mentioned 8mm alpha one registries 
in Netherlands and 
Denmark 
Dirksen, A. et al 
2009 (319) 
77 (53%) 55 (9) 46.5 (20) 51.5 (17) PD15 ITT and mITT; slope 
analysis tested by 
linear regression with 
statistical or 
B30f Pulmo 1mm AATD registries 







Dowson, L. J. et 
al, 2001 (143) 






-910 correlation coefficient 
and multivariate 
linear regression 
not mentioned not mentioned 1mm ADAPT 
Garfield et al, 
2012 (320) 
59 (46) 63 (9) 41 (18)   -950HU Multivariate analysis 
and correlation 
coefficient 





Gevenois, P. A. 
et al, 1996 (321) 
37 (78.4)   72 (21) 65 (20) -950HU Correlation coefficient not mentioned pulmo 1mm usual care 
Gevenois, P. A. 
et al, 1996 (137) 
59 (86.4) 62 (8) 73 (20) 66 (17) -950HU Correlation coefficient not mentioned pulmo 1mm usual care 
Gietema, H. A. 
et al, 2013 (322) 
1778 (64) 63 (7) 48.4 (15.7)   -950HU Multiple linear 
regression 




Grydeland, T. B. 
et al, 2010 (159) 
463 (64) 65.2 (9.4) 52.6 (17.4)   -950HU   Standard algorithm Not mentioned 1mm GenKOLs 
Han et al, 
2011(72) 
483 (53) 64 (8.5) 55 (22.7)   -950HU multivariate analysis 








  COPDGene 




Haruna, A. et al, 
2010(323) 
251 (94) 68.7 (7) 50.3 (17)   -960HU Hazard Ratio lung reconstruction 
algorithm 
 
  2mm Kyoto university 
Hong, Y. et al, 
2012 (169) 
213 (96) 66.3 (7.3) 53.4 (16.5) 74 (58.4) -950HU Multivariate analysis standard algorithm 
(??) 
in house software 0.625-
0.8mm 
  
Heussel et al, 
2009 (324) 
102 64     -950HU Correlation coefficient B40f In house YACTA 
software 
1.25mm usual care 
Johannessen, A. 
et al, 2013 (325) 












et al, 2011 (326) 
260 (96.9) 66.2 (7.2) 53.1 (16.3)   -950HU Logistic regression Soft kernel (B30f) Not mentioned 0.75mm KOLD 
Kim et al, 2010 
(168) 
200 (62.5) 64.6 (8.4)     -950HU Multivariate analysis 
and correlation 
coefficient 
different ones used 









Kim et al, 2014 
(327) 
78 65.3 (8.2) 49.6 (16.2)   -950HU Correlation coefficient reconstruction 
algorithm B 
in house software 1mm KOLD 
Kim et al, 
2015(328) 
167 64.8 (8.2)     -950HU Correlation coefficient not mentioned not mentioned 0.75mm usual care 
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Koyama et al, 
2010 (329) 
25 (60) 67.6     -950HU Correlation coefficient FC51 doesn’t specify 0.5mm usual care 
Koyama et al, 
2012(330) 
 
56 42 70.2 (8) 68.9 (19.6)   -950HU Correlation coefficient FC13 MATLAB 1mm usual care 
Kurashima, K. et 
al 2013(331) 
70       -960HU Correlation coefficient from ultrahigh 
resolution (UHR) CT 
and noise reduction 
software 
 
iDose 0.67mm SCGOR 
Kurashima, K. et 
al, 2015 (332) 
62 (100) 70.8 (6.4) 62.9 (30.7)   -960HU Correlation coefficient Interactive 
reconstruction 
algorithm 
Brilliance 0.67mm Usual care 
Lee, J. H. et al 
2010 (333) 
145 (98%) 66 (7) 47 (16) 78 (27) -950HU   reconstruction 
algorithm B 
in house software 1mm KOLD 
Lee, J. S. et al 
2012 (334) 







in house software 0.625-0.8 KOLD 
Lee, J. S. et al, 
2011 (335) 




in house software 1mm KOLD 
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models and Pearson’s 
correlation coefficient 
Lutchmedial et 
al, 2015 (336) 
274 (55) 66.9 
(10.4) 





Martinez, C. H. 






    -950HU       not 
mentioned 
COPDGene 
Martinez, F. J. et 
al, 2006(165) 
609 66.7 (5.9) 26.7 (7) 28.4 (9.7) -950HU Hazard Ratio standard 
reconstruction 
kernel 
custom built   NETT 
Martinez, F. J. et 
al, 2007 (337) 





Matsuoka, S. et 
al, 2007 (338) 
32 (87) 72.8 (8.2) 56.2 (26.9)   -950HU Correlation coefficient not mentioned ImageJ 2mm usual care 
McAllister, D. A. 
et al, 2014 (163) 
521 (51) 68 (6) 76 (23)   -910HU Multilinear analysis B50f Not mentioned 10mm NLCST 
Mets, O. M. et al, 
2011 (339) 
1140 62.5 (5.2) 94.8 (17.6)   -950HU Multivariate analysis smooth 
reconstruction filter 




(B filter) Screening Trial. 
Mets, O. M. et al, 
2013 (340) 
442 61.3 (5.5) 96.5 (18)   -950HU Multivariate analysis soft reconstruction 
filter (B30f) 
in house software 1mm NELSON 
Mohamed 
Hoesein, F. A. A. 
et al 2013 (341) 




        from NELSON 
Mohamed 
Hoesein, F. A. A. 
et al, 2011 (342) 






in house software 1mm NELSON 
Mohamed 
Hoesein, F. A. A. 
et al, 2011 (343) 
2085 (100) 59.8 (5.3)     PD15 Multivariate analysis B30f in house software 1 NELSON 
Mohamed 
Hoesein, F. A. A. 
et al, 2012 (344) 
2003 (100) 59.8 (5.3) 98.5 (18.5)   PD15 Multivariate analysis soft reconstruction 
filter (B30f) 
in house software 1mm NELSON 
Mohamed 
Hoesein, F. A. A. 
et al, 2012 (345) 
587 (100)   97.7 (18.1)   PD15 Multivariate analysis soft reconstruction 
filter (B30f) 
in house software 1mm NELSON 
Mohamed 
Hoesein, F. A. A. 
1108 (100) 60.4 
(19.9) 
94.8 (17.6)   -950HU 
and 
Multivariate analysis soft reconstruction 
filter (B30f) 
in house software 1mm NELSON 
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et al, 2013 (346) PD15 
Mohamed 
Hoesein, F. A. A. 
et al, 2015 (187) 
2021 (100) 59.8 (5.3)     PD15 Multivariate analysis B30f Cirrus Lung 12.03 1.0mm nelson 
Mohamed 
Hoesein, F. A. et 
al, 2014 (347) 




Cirrus 1mm nelson trial, 
prospective 
Motohashi, N. et 
al, 2009 (348) 
125 (89) 71 (8) 51.5 (17.8)   -940HU Correlation coefficient     1.25mm 
collimation 
  
Nakano, Y. et al, 
1999(49) 






2mm usual care 
Nakano, Y. et al, 
2000 (174) 






2mm usual care 
Nambu et al, 
2015 (349) 








not mentioned VIDA Diagnostics 0.625mm COPDGene 
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Nishio, M. et al, 
2014 (350) 
30 (83.3) 70.1 
(12.2) 
65.3 (20.6) 66.1 (23.6) -900HU Correlation coefficient standard kernel FC 
13 
in house prototype 
software 
1mm not mentioned 
O'Donnell, R. A. 
et al, 2004 (351) 
65 55 (7) 56 (16) 56 (16) -950HU Correlation coefficient not mentioned not mentioned 1mm usual care 
Ogawa, E. et al, 
2009 (352) 
239 (100) 71 (7) 46 (18)   -960HU Correlation coefficient lung algorithm 
(FC38) 
custom software 




2mm usual care 
Orlandi et al 
2005 (353) 
42 (88) 63 49.09 (19.44) 67.57 
(24.69) 
-950HU Correlation coefficient not mentioned Pulmo 1mm usual care 
Orlandi et al, 
2004 (354) 
11 (81) 68     -950HU Correlation coefficient not mentioned Pulmo 1mm usual care 
Paoletti, M. et al 
2015 (355) 







0.75mm usual care 
Park, M. J. et al 
2014 (356) 
98 (100)       -950HU         retrospectively 
recruited 
Parr et al, 2004 
(119) 
100 52 (10.2)     -950HU Correlation coefficient smooth filter Pulmo 5mm ADAPT 
Parr, D. G. et al 77 (53%) 55 (9) 46.5 (20) 51.5 (17) PD15, mITT and sensitivity not mentioned ?on Pulmo 5mm alpha one registries 
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from Demark, UK 
and Sweden 




60.7 (20.27)   -950HU Correlation coefficient not mentioned "Lung 
Emphysema" 
application 
2mm usual care 
Rambod, M. et 
al 2012 (359) 
2256 (52) 61.3 (9.3) 88.1 (24.3) 56.5 (21.5) -950HU       1mm COPDGene 
Roth, M. D. et al, 
2006 (210) 
148 (58.1) 65.8 
(7.45) 
42.5 (13.7) 37.1 (12) -910HU ANOVA, chi square       from five university 
hospitals 
Saitoh et al, 2000 
(360) 
50 68 (6) 54.9 (21.5) 66.4 (17.6) -950HU Correlation coefficient Bone algorithm a density mask 
program' 
10mm usual care 
Sandek, K. et al, 
2002 (361) 
20 (40) 60 (8) 38.2 (15.5) 43.6 (23) -910HU Correlation coefficient not mentioned density mask-not 
specific software 
1.5mm usual care 
Schroeder, J. D. 
et al, 2013 (362) 












M. et al, 1998 
(363) 
21 (61.9) 48 (2) 44.7 (3.3) 55.3 (4.1) -950HU Correlation coefficient not mentioned not mentioned 1mm usual care 
Shaker, S. B. et 
2009 (364) 
254 (58%) 63.6 (7) 52 (11)   PD15 mixed effects 
regression model 
low spatial (soft) 
frequency 




Shaker, S. B. et 
al 2009 (156) 
184 (59) 64.9 (7.1) 53 (13) 59 (17) -910HU Correlation coefficient soft algorithm pulmo 5mm usual care 
Shaker, S. B. et 
al, 2005 (157) 
42 (38) 63 (7) 48 (13) 49 (16) PD15 Correlation coefficient low spatial 
resolution (soft) 
Pulmo 5mm   
Stolk, J. et al 
2012 (365) 
227 (72%) 54 (8.7) 46.6 (16.7) 48 (14.8) PD15 ANCOVA, Least 
mean squares, ITT, 
correlation coefficient 
not mentioned Pulmo not 
mentioned 
From 10 AAT 
registries 
Stolk, J. et al, 
2003 (366) 




Correlation coefficient     
Stolk, J. et al, 
2007 (367) 
87 (50.6) 58.6 
(10.4) 





pulmo 5mm advertisement 
Sverzellati, N. et 
al, 2012 (368) 
1159 (68) 57.5 (6) 97.1 (19.6)   -950HU Multivariate logistic 
regression 
B30f MevisPULMO 5mm MILD 
Tanabe, N. et al 
2012 (369) 





  -960HU Multivariate analysis FC56 (sharp kernel) custom designed 5mm kyoto university 
ongoing study 
Tanabe, N. et al, 
2011 (370) 




  -910HU, 
-930HU 
and -





Tanabe, N.et al, 
2013 (371) 
131 (100) 70.7 (8.8) 57.9 (19.8)   -960HU Multivariate analysis not mentioned not mentioned not 
mentioned 
  
Timmins, S. C. et 
al, 2012 (372) 
26 (61.5) 69.6 (55-
85) 






osiriX 1.25 volunteer database 
and advertisements 
in newspaper 
Tsushima, K. et 
al, 2010 (373) 
48 61.1 (9.3) 77.5 (19.2)   -960HU Correlation coefficient not mentioned not mentioned 5mm lung screening 
cohort 
Van der Lee et 
al, 2009 (374) 
263 60.3 (5.4) 97.7 (16.8) 87.4 (16.1) -950HU Correlation coefficient not mentioned not mentioned 1mm usual care 
Vijayasaratha, K. 
et al, 2012 (375) 
 
21 (81) 52.5 (2.1) 38.4 (3.1)   PD15 Multivariate analysis Not mentioned Pulmo 5mm ADAPT 
Wang et al 2015 
(376) 
46(80.4) 67 (10.84) 72.56 (31.15) 69.38 
(25.39) 
-950HU Correlation coefficient standard algorithm Thoracic VCAR 
software 
 
0.625mm usual care 
Wang et al, 2013 
(377) 
573 (36.6) 63.9 (5.4) 74.8 (28.5)   -950HU Correlation coefficient bone kernel, due to 
its ability to analyse 
airways and 
parenchyma 
in house software 0.625mm SCGOR 
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Washko et al, 
2008 (378) 




Xia et al, 2014 
(221) 
51(100)       -950HU Correlation coefficient not mentioned extended brilliance 
workspace 
1mm usual care 
Yamashiro et al, 
2010 (147) 
46 (56.5) 67.7 (7.9) 57.9 (24.6)   -950HU Correlation coefficient bone algorithm Airway Inspector 1.25mm lung tissue research 
consortium 
Yuan, R. et al, 
2009 (379) 
143 (53) 59.5 (6.4) 99.4 (12.8)   -950HU Multivariate analysis Standard 
reconstruction 
kernel in 36 cases 
(25%) and B35f in 













4.3.2. Cross-sectional studies of CT Density  
 
4.3.2.1. Baseline Characteristics 
 
LAA% at --950HU was the most commonly used emphysematous threshold, with a 
total of 46 studies reporting a correlation coefficient and 23 of which were from 
larger cohort studies (e.g. COPDGene(293), KOLD(380)). The vast amount of papers 
in this particular sub-section was primarily due to the high number of publications 
produced whilst the knowledge base of the methodology and applicability of CT 
density was rapidly expanding. Eight papers were published in radiology journals 
exploring the optimum density analysis technique (e.g. factor analysis, histogram 
skewness/kurtosis)(309, 354, 381-383). The difference in the correlation between 
FEV1 using a high or low radiation dose was explored and the density results pre 
and post volume correction (329, 384). 5 papers examined the difference between 
inspiratory and expiratory CT scans (147, 154, 321, 328, 338), and 3 were assessing 
the additional impact of airway thickness or presence of bronchiectasis (330, 353, 
362).  
CT density was added to other clinical variables such as airway measures and lung 
function to try to use density measures to build effective prognostic models. (120, 
355, 379) 4 studies adjusted CT density for airway wall thickness (AWT) so to elicit 
the contribution of parenchymal change over airway changes on PFTs, (170, 346, 347, 
385)and a further three used a similar concept but simply used the 
inspiratory/expiratory ratio(169, 320, 386).  
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Table 4.2 summarises the baseline characteristics of studies and patients included in 
meta-analyses. Notably there were no two studies using the same statistical 
technique and emphysema threshold for mortality, exacerbations and all quality of 





















N° studies N°  patients Age FEV1pp DLCOpp KCOpp 
Correlation 
Coefficients 
900 7 551 66 (10) 54.96 (20.19) 65.47 (20.97) 63.73 (20.13) 
910 2 69 64.67 (8.34) 58.93 (24.27) 57.46 (19.63) 61.59 (22.47) 
950 46 10764 62.45 (10.77) 58.04 (33.59) 59.90 (31.43) 85.19 (21.86) 
960 6 639 67.96 (8.76) 54.86 (23.75) --- --- 
PD15 7 4544 60.91 (9.22) 53.99 (24.52) --- 67.16 (24.58) 
Multivariate 
Regression 
910 3 425 62.04 (8.93) 64.17 (27.27) --- --- 
950 14 18984 60.59 (9.56) 78.71 (26.29) 66.23 (23.44) 87.06 (18.07) 
960 2 161 70.33 (8.69) 54.81 (20.13) --- --- 
PD15 8 7251 59.89 (9.51) 93.06 (20.63) --- 85.19 (18.86) 
Trials 
ICS+/-LABA 
950 2 482 64.50 (7.37) 50.50 (12.21) 75.15 (29.50) 46.70 (39.08) 
ATRA PD15 2 375 58.83 (9.91) 44.99 (15.70) 43.82 (14.79) 43.70 (13.57) 
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Studies of lung function, sub-divided by statistical techniques used to assess relationship to CT density, followed by trials, and 
those using quality of life measures. All quantitative measures are shown as mean (SD).  
Prolastin PD15 4 369 51.83 (7.39) 47.39 (12.35) 36.14 (23.39) 54.70 (11.77) 
Mortality mixed 6 3584 61.66 (9.68) 69.39 (31.27) ---- ---- 
Exacerbations Mixed 7 2637 66.10 (8.22) 60.54 (25.44) ---- ---- 
SGRQ Mixed 8 4864 58.82 (13.75) 45.01 (19.03) 35.68 (18.17) 60.40 (22.22) 
BODE Mixed 4 2440 65.58 (6.44) 44.43 (21.19) 35.08 (19.87) ---- 
6MWT Mixed 3 2481 61.63 (9.38) 56.03 (48.57) ---- ---- 






A total of 36 studies compared FEV1 percent predicted to CT density. The forest plot 
in Figure 4.2 demonstrates the correlation between FEV1 percent predicted with CT 
density at--950HU and the variation seen within the included studies. The ranges of 
correlation coefficients are from -0.33 to -0.67; the pooled correlation coefficient is -
0.53 (95% CI -0.57, -0.49) (p<0.0001).  This data is further summarised in Table 4.3, 
which shows the meta-analyses of other CT parameters against FEV1. The level of 
heterogeneity remained high in all sub-group analyses except 900HU v FEV1 percent 














Figure 4.2. Forest plot of all studies included in the meta-analysis that correlated 
FEV1 percent predicted with -950HU. 
 
*X2 test for heterogeneity=591, and I2 score for inconsistency 97.2%. Pooled 







Table 4.3. Summary of meta-analyses performed on all studies using Pearson’s 













P I2 X2 p 
FEV1 
 
950 6 -0.37 -0.53 -0.21 <0.0001 90.7 48.54 <0.0001 
960 3 -0.33 -0.43 -0.22 <0.0001 46.9 3.78 0.15 
PD15 4 0.40 0.20 0.59 <0.0001 84.9 18.90 0.0003 
FEV1pp 
900 3 -0.53 -0.63 -0.43 <0.0001 0 1.96 0.37 
910 9 -0.29 -0.38 -0.20 <0.0001 80.5 36.45 <0.0001 
950 13 -0.54 -0.57 -0.49 <0.0001 97.2 591.46 <0.0001 
960 4 -0.35 -0.51 -0.19 0.0003 84.5 17.70 0.0005 
PD15 4 0.53 0.49 0.57 <0.0001 0 0.768 0.857 
 
Further investigation into the cause of heterogeneity revealed major differences in 
the choice and combination of reconstruction algorithm, slice thickness and software 
program used by included studies. When the meta-analysis was restricted to 3 
studies that used the same CT acquisition parameters, the forest plot became more 
uniform and heterogeneity as measured by X2 decreased (Error! Reference source 
ot found.). Of note, in the Schroeder et al study, the box is larger than the line drawn 
through it. This can be explained as the size of the box over the stratum-specific 
point estimate (correlation coefficient) reflects the weight that study has on the 
pooled estimate. The confidence intervals for the point estimate are reflected by the 
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width of the line, and so for a study of larger power due to patient size for example, 
the box may be larger to reflect this and the CIs narrow.  
 
Figure 4.3. Forest plot to demonstrate the effect on the forest plot once the same 
reconstruction algorithm, slice thickness, and software program are used. 
 
Schmidt hunter (SH) weighted mean correlation coefficient=-0.66, I2=91.8%, X2=33.59 
 
7 studies performed multivariate linear regression between FEV1 and CT density 
(Table 4.4). However, for each density variable, all studies adjusted for different 





Table 4.4. Studies performing multivariate linear regression to examine the relationship between FEV1 and CT density 
Density 
Measure 
Study Variables adjusted for Results for adjusted FEV1. 95 % Confidence Intervals 
(CI) 
950 
Kim et al, 2013(168) 
Mean Wall Area 
Visual score of 
emphysema 
Visual score of lobe  
ᵦ =-0.4726 -0.8215, -0.1238 






ᵦ =-0.252 --- 
Hong et al, 
2012(169). 
LAA% -950HU 
Mean Lung Density 
Mean Wall Area 
Smoking status 
ᵦ =-0.24 --- 
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1 point change in PD 15 results in  -0.824ml 3 year 
change FEV1 
-1.473 to -0.0174 






Years in Study 
1 HU change in PD 15 results in  -4.75 ml 3 year change 
FEV1 
- 3.3 to -6.1 










Akin to FEV1, there was a significant correlation between each density variable and 
FEV1/FVC (p<0.0007; Table 4.5). The forest plot demonstrating the meta-analysis of 
correlation co-efficients for PD15 and FEV1/FVC is shown in Figure 4.4.  
Table 4.5. Summary of studies comparing FEV1/FVC with CT density, divided into 



















910 5 -0.33 -0.49 -0.16 <0.0001 95.5 75.72 <0.0001 
950 19 -0.56 -0.63 -0.49 <0.0001 86.2 114.35 <0.0001 
960 3 -0.48 -0.71 -0.25 <0.0001 88.9 18.73 <0.0001 














Figure 4.4. Forest plot of all studies comparing FEV1/FVC with PD15. 
 














4.3.2.2.3. Gas Transfer 
 
A total of 23 studies compared DLCO percent predicted to CT density. These studies 
tended to be as part of larger cohort studies examining the relationship between all 
PFTs and CT density (160, 311, 355). 4 studies reported the correlation between 
DLCO and CT density in order to help identify CT defined phenotypes and airways 
versus parenchymal disease (170, 353, 387).  When exploring the utility of 
hyperpolarised helium and emphysema, DLCO was compared with the ADC from a 
MRI study that also quoted CT density (155). The pooled correlation coefficients 
were universally significant across individual density values, albeit slightly weaker 
than for FEV1 and CT density (Table 4.7). The same pattern was seen regarding 
heterogeneity of results, with I2 dropping from 91.5% to 0 once CT algorithm was 
taken into account (Figure 4.5 and Figure 4.6).  
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Figure 4.5. Forest plot demonstrating correlation co efficient confidence intervals 
and pooled correlation coefficient for those studies comparing DLCO percent 
predicted with PD15.  
 
Schmidt hunter (SH) weighted mean correlation coefficient=0.3, I2=91.5%, X2=40.98 
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Figure 4.6. Forest plot of those studies comparing PD15 and DLCO percent 
predicted once all studies using the same CT variables has been re-analysed.  
 
















p I2 X2 p 
DLCO 950 5 -0.42 -0.53 -0.32 <0.0001 77.8 15.538 0.0036 
DLCOpp 
910 3 -0.31 -0.40 -0.22 <0.0001 83.6 10.46 0.005 
950 16 -0.43 -0.52 -0.34 <0.0001 88 100.34 <0.0001 
PD15 5 0.29 0.15 0.42 <0.0001 92.2 33.79 <0.0001 
KCO 
 
950 3 -0.63 -0.71 -0.54 <0.0001 49.9 4.43 0.1091 
PD15 3 0.38 0.15 0.61 0.0012 96.4 45.67 <0.0001 
KCOpp 
910 3 -0.61 -0.63 -0.59 <0.0001 0 0.29 0.8658 




4.3.2.2.4. Lobar analyses 
 
Table 4.7 summarises the results of three papers that subdivided the correlation 
between LAA --950HU and FEV1/FVC into the individual lobes in patients with 
usual COPD (303, 360, 376). The total number of patients included was 189, and 
there remained a significant correlation between spirometry and CT density, though 
no stronger than whole lung density. The lower lobes appeared to have a stronger 
correlation than the upper lobes.  
Table 4.7. Summary of studies which subdivide the correlation between CT 
density (--950HU) and FEV1/FVC into individual lobes. 
 
Lobe Pooled correlation 
coefficient 
95% CI I2 (%) X2 p 
LLL -0.70 -0.83 to -0.57 86.20 10.00 0.0067 
LUL -0.33 -0.62 to -0.04 87.80 15.55 0.0004 
RUL -0.38 -0.56 to -0.20 71.20 6.60611 0.0368 
RML -0.33 -0.52 to -0.14 70.10 6.32 0.0424 
RLL -0.62 -0.69 to -0.54 20.80 2.21 0.3314 
4.3.2.2.5. Quality of Life, symptom and composite scores 
 
SGRQ was the most frequently reported QOL compared with CT density. 2 studies 
recruited patients with AATD (genotype PiZZ); Stolk et al found that when those 
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patients with normal lung function were removed from analysis, the correlation 
coefficient improved from 0.56 to 0.74 with CT density as measured by PD15, 
highlighting the same change was not seen with --950HU and that the former 
method is better able detect early emphysema changes than --950HU (366). Of the 4 
studies comparing SGRQ to COPD, Motohashi et al was the only publication to 
detail the relationship across each sub-component i.e. impact, activity, symptoms 
and total score (348).  
2 out of 5 studies using correlation coefficients showed no relationship between the 
two measures, whilst the other 3 showed a strong association (p<0.003) (Table 4.8). 
There was variability in the density threshold and patient groups used (e.g. cancer 
screening populations or those being considered for lung volume reduction surgery), 
thus precluding meta-analysis. Nevertheless, studies that performed multivariate 




















Statistical technique Results 
P 
value 




-950HU 0.6 0.003 
Dowson et al, 
2001(143) 
AATD -910 Spearman’s CC 0.39 <0.001 
Barjaktarevic, I. et al 
2015 (305) 
COPD -950 Pearson’s CC 0.028 0.572 
Motohashi, N et al, 
2010 (348) 
COPD -940 Pearson’s CC 0.501 <0.001 
De Torres, J. P. et al, 
2011 
(314) 
COPD -960 Pearson’s CC -0.12 0.39 
Martinez, C. H. et al, 
2012(68) 
COPD -950 
Un-normalised and Normalised (value-
















Studies comparing BODE (BMI, Airflow Obstruction, Dyspnoea, Exercise Capacity) 
with CT density were particularly heterogeneous in their methods and analyses. 
Camiciolotti et al compared CT density as measured by --950HU with the modified 
BODE index (mBODE), Martinez et al presented all their results as parameter 
estimates, and De Torres et al compared BODE indexes across those with 
predominant core versus rind disease and upper versus lower predominance(68, 
160, 314).  
2 studies examined the relationship between CT density and MRC grade using 
multivariate analysis. Camiciolotti et al performed logistic regression in order to 
establish an odds ratio for presence of dyspnoea using inspiratory and expiratory CT 
scans. (308)Haruna et al assessed MRC grade whilst examining CT defined 
emphysema and mortality from cardiac and respiratory causes (323). The 
relationship between MRC, BODE and CT density was particularly significant once 










Adjusted for Age, pack years and 
FEV1%predicted 
Beta value=-7.69 (95% CI 
-14.09, -1.3) 
0.02 





Adjusted for Gender, Age, smoking status, pack 






Table 4.9. Summary of studies that compare BODE and MRC with CT density.  














LAA% Statistical technique Results P value 
Camiciottoli, G. 
et al, 2012(308) 
COPD BODE -950 Pearson’s CC R=0.58 <0.0001 
Camiciottoli, G. 
 et al, 2006 (160) 
COPD MRC -950 Odds ratio 
1.41 (95% CI 1.11-
1.78) 
<0.005 
Martinez, C. H. 
et al, 2012(68) 
COPD BODE -950 
Un-normalised and 
Normalised (value-
mean/SD) parameters in 
univariate analysis 
Unnormalised 





1.23 (95% CI 1.2-
1.26) 
<0.001 
De Torres, J. P. 
et al, 2011(314) 
COPD BODE -960 Pearson’s CC R=-0.08 0.53 
Haruna et al, 
2010 (323) 
COPD MRC -960 Pearson’s CC R=0.41 <0.05 
De Torres, J. P. 
et al 2011 (314) 




4.3.3. Longitudinal studies of CT density 
4.3.3.1. Introduction 
 
Understanding the nature and prognostic value of CT density decline is imperative 
if it is to be used in the future as an imaging biomarker.  For this reason, studies 
which reported longitudinal outcomes such as exacerbations and mortality were 
sought in addition to cross-sectional studies. These clinically relevant end points 
allow for appreciation of how an intervention is like to impact patient’s quality of 
life, as opposed to a decline in FEV1(or other physiological measures) which patients 
may not perceive as important for them(388). As interventional trials of alpha one 
augmentation therapy report annual change in lung function and CT density, these 











Adjusted for Age, pack years and 
FEV1%predicted 
Beta value=0.01 
7.69 (95% CI 
0.005, 0.02) 
0.002 





Adjusted for FEV1, BMI, MRC, 
6MWT 
R=0.61 <0.0001 












6 papers reported the relationship between CT density and mortality, 3 of which 
reported a hazard ratio (HR) for all-cause mortality (Table 4.10) generated by multi-
variable logistic regression. However, it was inappropriate to combine them 
statistically due to differing emphysematous thresholds and confounding variables 
included in their models. Emphysema as defined by CT density remained a 
significant independent predictor for mortality throughout. 
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Table 4.10. Studies reporting an all-cause mortality HR for emphysema as defined by CT density. 
Reference Patient 
Source 
LAA%  Statistical 
technique 



















Univariate analysis therefore N/A 
 
↑LAA% significantly related to 
mortality  
1.52 1.2 1.91 <0.001 
Upper lung field 1.55 1.22 1.95 <0.001 
Lower lung field 1.41 1.09 1.78 0.009 
Age, BMI, FEV1, RV/TLC and KCO 
LAA% independent predictor of 
mortality  










N/A Whole lung %emphysema not 
associated with mortality 
1.14 0.85 1.52 0.38 
Lower zone emphysema associated 
with ↑mortality 
1.39 1.04 1.85 0.02 
Age, LTOT, Hb, BODE, RV%, TLC%, DLCO%, maximal 
CPET workload, lower lung emphysema and nuclear 
perfusion scan result.  
Difference between upper and 
lower lungs% emphysema 
remained predictive in multivariate 
model 








Age. Hazard ratio for  mortality (Exp B) comparing 
those with FEV1 >80pp with FEV1<30pp. 
Survival curves indicate a 
relationship of ↑VI to ↑mortality  
    





4 studies investigated severity of emphysema, as measured by CT density, as a risk 
factor for COPD exacerbations, using multiple regression analyses in order to 
independently attribute exacerbations to density loss (Table 4.11). Due to different 
regression methods, variables and presentation a statistical meta-analysis could not 
be performed. All but one study showed a significant relationship between CT 
density and exacerbations; Yoo et al found that the ability for emphysema index to 
predict exacerbations did not remain significant when multiple variables including 
age and exercise tolerance were adjusted for.(326) Cheng et al performed a 
multivariate ordinal logistic regression to demonstrate a LAA%>7.5 was associated 
with worse performance status and MRC grade if they presented to Accident and 




Table 4.11. Summary of papers describing the association between CT density and exacerbations. 




Statistical technique Variable adjusted for Results 
p 
value 












Age, gender, current smoker, exacerbation leading to hospitalisation in 
past year; Charlson index, BMI, MMRCS, 6MWD, SGRQ, FEV1%, CT wall 
area %, CT air trapping index 
OR=1.01  
(95% CI 0.987-1.034) 
0.39 






FEV1, FEV/FVC, KCO% predicted, delay in treatment initiation in days, 
Anthonisen criteria, cold symptoms 
PD15 associated with 
exacerbation length and  
 (r=-0.361) 
0.003 
PD15 associated with 





Multivariate rate ratios 
(RR) 
Age, sex, race/ethnicity and cotinine 
%emphysema predicts 
episodes of care  
RR1.45 (95% CI 1.04-2.03) 
0.03 
↑hospital; admissions  










Statistical technique Variable adjusted for Results 
p 
value 
Han et al 
2011(72) 
-950 
multivariate analyses and 
forward selection regression 
Scanner model, age, sex, smoking status 
and FEV1 
>35% emphysema associated with a 1.18 fold 
increase in exacerbation 
 
0.047 
5% ↑ in emphysema associated with a 0.86 
fold ↑ in exacerbation frequency 
0.001 
Cheng et al 
2015(164) 
-950 ANOVA  
No difference in CT density before and after 
exacerbation 
(13.38%+/-9.04% vs 11.43%+/-7.1%) 
0.135 
Tanabe et al 
2011 (370) 
-960 Multivariate regression 
Exacerbations, change in CT derived lung 
volume and baseline LAA% 
exacerbations independently contributed to 
changes in LAA (R2=0.41) 
0.0001 
Significant change in %LAA in those that 
exacerbated and those that didn’t 
0.0001 
Baseline scan result made no difference to 




4.3.3.4. Interventional studies reporting CT density 
 
4.3.3.4.1. Alpha One Augmentation Therapy 
 
3 RCTs used CT density as an outcome measure for augmentation therapy in AATD 
patients (92, 198, 211). The first two, “A randomized clinical trial of alpha 1-
antitrypsin augmentation therapy” and “Exacerbations and Computed Tomography 
scan as Lung End-points” (EXACTLE) trial both by Dirksen et al in 1999 and 2009 
respectively followed by “Randomized Placebo-controlled Trial of Augmentation 
Therapy in Alpha-1 Proteinase Inhibitor Deficiency” (RAPID) by Chapman et al in 
2015. The annual change in CT density was a secondary outcome in the first RCT by 
Dirksen et al, and the primary outcome in subsequent 2 studies. A final paper was 
not included in the quantitative synthesis as it simply explored statistical approaches 
in data from the EXACTLE trial (357). In all papers CT density was log transformed 
and volume adjusted (see table 4.1 for CT acquisition parameters), study duration 
was 2-3 years, and the rate of density decline was measured in g/l-1 per year. A 
recent meta-analysis of this data by our group has been reported separately (389), 
which demonstrates slower density decline in those receiving augmentation therapy 
than those receiving placebo (p=0.002). The 3 papers analysed also report overall low 
to moderate correlation coefficients between CT density and FEV1, KCO and exercise 
tolerance (0.31, 0.47 and 0.21 respectively).  
4.3.3.4.2. All-trans-retinoic acid (ATRA) 
ATRA was shown to promote alveolar repair in animal models by upregulating 
RARƴ leading to decrease in alveolar area by up to 50% through improved alveolar 
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septation and a subsequent increase in oxygenation (390). In 2011 Stolk et al 
randomised 262 patients with AATD to either Palovarotene or placebo, using 
volume adjusted CT density as their primary outcome(391). The results of this study 
showed no significant benefit in the treatment arm, and the authors postulated that 
perhaps due to the severity of the patients selected, there was little available tissue to 
repair, or that perhaps a larger study was required. However, retinoids have not 
been further investigated since this RCT.   
4.3.3.4.3. Inhaled LABA/ICS 
2 studies from South Korea and the KOLD study collected longitudinal data on 
spirometric change over 3 months with ICS/LABA treatment and demonstrated a 
significant correlation between FEV1 and baseline CT density, using--950HU as the 
emphysematous threshold (333, 392). Shaker et al performed annual CT 
densitometry in a RCT conducted in patients with COPD which demonstrated 
significantly slower decline in emphysema (using --910HU; p=0.02) in those 
randomised to budesonide compared to placebo (364)).  
4.4. Standardising studies for equal CT variables 
Since there were clear differences in the meta-analyses regarding the relationship 
between CT density and outcome when stratified by CT acquisition parameters, a 
separate summary was performed to illustrate the extent of the heterogeneity.  
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4.4.1. Software Programs 
PULMO was the most frequently used software program (used in EXACTLE and 
RAPID trials), and the same number of publication again used an ‘in house’ software 
program (see Figure 4.7)(324, 377). Many papers did not report which program they 
had used, with a staggering 23 different programs reported. Pulmonary Workstation 
is the principle software program used by COPDGene and does use the same ‘region 
growing technique’ as PULMO (72, 120). This heterogeneity of software programs is 
likely be a frequently recurring problem in respiratory imaging (e.g. in other 
conditions such as Interstitial Lung Disease (ILD)) as there is a shift towards 




Figure 4.7. Frequency Histogram to demonstrate the variety of software programs 
reported  
4.4.2. Reconstruction Algorithms 
There is a clear consensus that a soft or smooth reconstruction algorithm is most 
appropriate for parenchymal/density analysis whereas a sharper algorithm is more 
suitable for airways analysis (130, 194). There is however no global definition for the 
exact reconstruction that constitutes a ‘soft filter’ with algorithms used varying 
between B10f and B45f. The most frequently reported algorithm was a ‘standard 
algorithm’ followed by ‘soft’ and then ‘smooth’ with no more detail regarding the 
resolution given. To add to the heterogeneity, ‘B’ algorithms are used by Siemens 
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scanners and ‘FC’ by Toshiba. Figure 4.8 summarises the different reconstruction 
algorithms reported throughout this review.  
Figure 4.8. Frequency Histogram to demonstrate the variety of reconstruction 
algorithms reported 
 
4.4.2. Slice Thickness 
Varying slice thicknesses were used throughout with 1mm or less being the most 
commonly reported. 1mm is the choice of slice thickness used by Pulmonary 
Workstation which allows for airway and parenchymal measurement and is likely 
the reason why many other authors have chosen to use the same thickness. PULMO 
on the other hand uses 5mm as it is solely used to measure CT density. Thinner 
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slices however sacrifice the accuracy of the emphysema due to the fewer number of 
pixels, broadening the density histogram and over estimating the severity of 
emphysema(130). Figure 4.9 demonstrates the variety of slice thicknesses reported.  
Figure 4.9. Frequency Histogram to the demonstrate variety of slice thicknesses 
reported  
 
4.5. Bias assessment 
4.5.1. Study Quality 
Risk of bias is detailed in Table 4.12. Risk bias for all included studies and a 
summary is provided in Figure 4.10. Risk of Bias Summary The risk of bias tool was 
designed to ascertain the CT acquisition parameters and those relating to lung 
























function (e.g. were the PFTs performed before or after bronchodilation). Where there 
was no concern across each subheading, the paper was considered to be at low risk 
of bias. If two or more domains were determined to high risk, then the paper was 
described as high risk of bias, and then a pragmatic decision was taken on the 
remainder of papers whether they were felt to be medium risk. Two reviewers 
independently assessed the risk of bias for all 112 papers; none were considered to 
be high risk for all 4 domains and therefore were all included in the overall bias 
assessment. A key finding was that less than 40% of the papers reported the CT and 
PFT acquisition method adequately. Flow and timing was of high concern in 20% of 
the papers analysed. Ideally the two diagnostic tests, that is, CT and another clinical 
parameter, should be measured on the same day but there were a large number of 
papers where this could not be ascertained. 
Table 4.12. Risk bias for all included studies 
Author, Year Patient Selection Index and Reference Test Flow and Timing Reporting 
Nakano, Y. et al, 2000 high medium high high 
Wang et al 2015 low medium high high 
Chapman, K. R. et al 2015 low medium high high 
Koyama et al, 2012 low high medium high 
Schroeder, J. D. et al, 2013 low medium low high 
Castaldi, P. J. et al, 2013 low medium low high 
Dijkstra, A. E. et al, 2013 low medium low high 
Bernspang, E. et al, 2011 low medium low high 
Haruna, A. et al, 2010 low medium low high 
Diaz, A. A. et al, 2010 low low low high 
Shaker, S. B. et al, 2005 high medium high medium 
Stolk, J. et al 2012 high medium high medium 
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Kim et al, 2010 medium medium high medium 
Stolk, J. et al, 2007 medium medium high medium 
Johannessen, A. et al, 2013 low medium high medium 
Garfield et al, 2012 low medium high medium 
Pauls et al, 2010 low medium high medium 
Mohamed Hoesein, F. A. A. et al, 2011 low low high medium 
Stolk, J. et al, 2003 low low high medium 
Diaz, A. A et al, 2015 medium medium high low 
Lee, J. S. et al, 2011 medium medium high low 
Nambu et al, 2015 medium medium high low 
Chierakul, N. et al, 2014 medium medium high low 
Nakano, Y. et al, 1999 low medium high low 
Lee, J. H. et al 2010 low medium high low 
Lutchmedial et al, 2015 medium low high low 
Haruna, A. et al, 2010 low low high low 
Koyama et al, 2010 low low high low 
Aziz, Z. A. et al, 2005 low low high low 
Nishio, M. et al, 2014 high high low medium 
Parr et al, 2004 high high low low 
Gevenois, P. A. et al, 1996 medium high low medium 
Mohamed Hoesein, F. A. A. et al, 2015 medium high low low 
Kim et al, 2014 high medium medium low 
Saitoh et al, 2000 medium medium medium medium 
Washko et al, 2008 medium medium medium medium 
Diaz et al, 2009 low medium medium medium 
Matsuoka, S. et al, 2007 low medium medium medium 
Martinez, C. H. et al 2012 low medium medium medium 
Diaz, A. A. et al, 2013 low medium medium medium 
Diaz, A. A. et al, 2012 low medium medium medium 
Roth, M. D. et al, 2006 low medium medium medium 
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Kim et al, 2015 low low medium medium 
Jung-Wan Yoo et al, 2011 low low medium medium 
Shaker, S. B. et 2009 low low medium medium 
McAllister, D. A. et al, 2014 medium medium low medium 
O'Donnell, R. A. et al, 2004 medium medium low medium 
Dowson, L. J. et al, 2001 medium medium low medium 
Park, M. J. et al 2014 medium medium low medium 
Barjaktarevic, I. et al 2015 low medium low medium 
Atta et al, 2015 low medium low medium 
Mohamed Hoesein, F. A. A. et al, 2012 low medium low medium 
Han et al, 2011 low medium low medium 
Yamashiro et al, 2010 low medium low medium 
Desai et al, 2007 medium low low medium 
Gietema, H. A. et al, 2013 low low low medium 
Tanabe, N. et al 2012 low low low medium 
Chae et al, 2010 low low low medium 
Camiciottoli, G. et al, 2006 low low low medium 
Cheng et al, 2015 medium medium medium low 
Mohamed Hoesein, F. A. A. et al, 2013 medium medium medium low 
Vijayasaratha, K. et al, 2012 medium medium medium low 
Mets, O. M. et al, 2011 medium medium medium low 
Hong, Y. et al, 2012 low medium medium low 
Akira et al, 2009 low medium medium low 
Baldi et al, 2001 low medium medium low 
Gevenois, P. A. et al, 1996 low medium medium low 
Crim, C. et al, 2011 low medium medium low 
Dirksen, A. et al 1999 low medium medium low 
Paoletti, M. et al 2015 medium low medium low 
Xia et al, 2014 medium low medium low 
Mohamed Hoesein, F. A. A. et al, 2012 low low medium low 
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Mohamed Hoesein, F. A. A. et al, 2011 low low medium low 
De Torres, J. P. et al, 2011 low low medium low 
Huessel et al, 2009 low low medium low 
Orlandi et al, 2004 low low medium low 
Atta et al, 2015 medium medium low low 
Mohamed Hoesein, F. A. et al, 2014 medium medium low low 
Coxson, H. O. et al, 2013 low medium low low 
Mets, O. M. et al, 2013 low medium low low 
Motohashi, N. et al, 2009 low medium low low 
Shaker, S. B. et al 2009 low medium low low 
Ogawa, E. et al, 2009 low medium low low 
Dawkins, P. et al, 2009 low medium low low 
Martinez, F. J. et al, 2006 low medium low low 
Orlandi et al 2005 low medium low low 
Rambod, M. et al 2012 low medium low low 
Albert, P. et al 2012 low medium low low 
Mohamed Hoesein, F. A. A. et al 2013 low medium low low 
Martinez, F. J. et al, 2007 low medium low low 
Chen et al, 2014 medium low low low 
Schwaiblmair, M. et al, 1998 medium low low low 
Camiciottoli, G. et al, 2012 medium low low low 
Kurashima, K. et al, 2015 medium low low low 
Nishio et al, 2014 medium low low low 
Kurashima, K. et al 2013 low low low low 
Tanabe, N.et al, 2013 low low low low 
Wang et al, 2013 low low low low 
Timmins, S. C. et al, 2012 low low low low 
Sverzellati, N. et al, 2012 low low low low 
Tanabe, N. et al, 2011 low low low low 
Tsushima, K. et al, 2010 low low low low 
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Grydeland, T. B. et al, 2010 low low low low 
Yuan, R. et al, 2009 low low low low 
Bastarrika, G. et al, 2009 low low low low 
Van der Lee et al, 2009 low low low low 
Sandek, K. et al, 2002 low low low low 
Agusti, A. et al, 2010 low low low low 
Diaz, A. A. et al 2010 low low low low 
Dirksen, A. et al 2009 low low low low 
Parr, D. G. et al 2009 low low low low 
Lee, J. S. et al 2012 low low low low 
 
Figure 4.10. Risk of Bias Summary 
 
4.5.2. Publication bias 
The funnel plots for --950HU versus FEV1 percent predicted and DLCO percent 
predicted are presented in Figure 4.11and Figure 4.12, chosen as these were the most 
frequently reported values. Both show a significant degree of publication bias on 
initial inspection, though one study with a low standard error and large population 
(Washko et al 2008) causes the funnel to shift to the right.(378).  Without this study, it 
stands to reason that the funnel would be more inclusive of the studies within the 
plot and would result in statistically less publication bias.  
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Figure 4.11. Funnel plot for studies correlating --950HU with FEV1 percent predicted 
 





The purpose of this review was to summarise all the currently available literature 
regarding CT density and its association with commonly used clinical parameters to 
develop a clear understanding of for the utility of CT density measures for current 
and future clinical practice. This is particularly important as CT density has been 
used as a primary outcome in registration level clinical trials in AATD, but doubt 
has been cast by some authors as to its relevance as a surrogate outcome. (92),(93) 
Our data showed that association between CT density and other clinical parameters 
deemed suitable as outcomes for airways disease trials (e.g. FEV1, SGRQ) was 
consistently significant, and furthermore there was a clear and consistent 
relationship to mortality. This suggests that CT density is an appropriate surrogate 
outcome measure in studies of emphysema, like those conducted in AATD. 
However, publication and other biases as well as study heterogeneity makes it more 
difficult to draw conclusions regarding the precise strength of each relationship. 
Over half of the included studies were from larger cohort studies and subsequent 
retrospective/cross sectional analysis. The nature of these cohorts introduces 
heterogeneity in the types of patients recruited, i.e. lung cancer screening studies 
(NELSON)(395), alpha one cohorts, (319) COPD (e.g. COPDGene,KOLD(380, 396)), 
and end stage disease (e.g. NETT) (397).The consistency of direction of the 
relationship between density and lung function across diverse patient groups is 
reassuring and suggests density could be a valid surrogate outcome across the 
spectrum of disease severity. However, the wide range of values seen for the CT 
versus FEV1 correlations meant that defining the exact level of CT density that 
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relates to, for instance, the Minimally Clinically Important Difference (MCID) for 
FEV1 was difficult.  
The chosen CT parameter (eg --950HU, PD15), software programme, reconstruction 
algorithm and slice thickness varied widely throughout. This level of heterogeneity 
was far greater than we had anticipated and made combination of all data via meta-
analysis potentially less valid. The broad range of published correlation coefficients 
seen between --950HU and FEV1% (Figure 4.2) (-0.1 to -0.8) demonstrated this well, 
and when variables during the CT acquisition process were adjusted for, the level of 
heterogeneity fell dramatically.  
Besides the previously mentioned 3 variables, there are others that we did not 
account for. For example, the current and age of the XR tube, methods of volume 
adjustment or table height (132, 196). These further factors are known to have a 
significant impact on density values. To account for all possible variables would 
have been overly cumbersome and beyond the scope of this review which has 
demonstrated the impact parameter heterogeneity has on density analysis. However, 
it should be noted that whether emphysema is measured by PD or RA, without 
detailed description of corrections made, for example for volume, there must remain 
a reservation when considering the validity of CT density data.  
This implies that future CT density studies should have a standardised approach.  
Despite PD15 being established as the most reliable and sensitive measure, we have 
seen many studies that do not use this parameter, and would encourage authors to 
report this value so that data can be combined and our knowledge can grow. 
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The most appropriate CT algorithm would be a soft reconstruction algorithm (e.g. 
B30f), slice thickness 2.5-5mm and a software programme that yields reliable and 
repeatable results. This algorithm and slice thickness is optimal due to minimal 
technical noise. Sharper algorithms and thinner slices have been demonstrated to 
overestimate the amount of emphysema.(194) Many publications used in-house 
software that, whilst producing useful data, may not be comparable to one 
another.(192) For example, Pulmo and Pulmonary Workstation are two of the most 
commonly used software programs (used in RAPID trial and COPDGene cohort 
studies respectively), and if identical and repeatable results can be produced by both 
programmes then cohort studies using them can then be combined and meta-
analysed to increase power (92, 396). This requires direct comparison of the software 
on the same scans; a similar approach would be needed for slice thickness, 
reconstruction and so on. There are limited studies of this nature to date (195).  
There was a paucity of longitudinal CT density data in the included studies, which 
precluded conclusions about the sensitivity and specificity of CT density change 
over time with respect to our chosen outcomes. This has meant we are unable to 
assess the relationship between CT density and clinical parameters over time for 
which there a known MCID (e.g. FEV1 of 100mls), and therefore a proposal of a 
MCID for CT density was not possible. This would be of particular use for 
registration level trials which have used or intend to use this as their primary 
outcome. (398) 
The key strengths of this review are that it was very broad; therefore all potential 
papers were captured. Rigorous checking of data extracted from the large number of 
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included studies occurred, and the statistical analyses were conducted with help 
from an experienced statistician.  
Limitations were largely centred on the quality and heterogeneity of the included 
studies. There are other CT scanner variables we did not examine in more detail as 
their impact was considered less relevant, e.g. scanner type and radiation dose. 
Finally, there were 14 papers in languages to which we did not have access to a 
translator such as Japanese and Korean. This was due to funding limitations, and 
ideally all studies would have been translated. In some cases the abstract alone was 
translated by the publisher, so we can be reasonably confident that no major 
omissions have resulted from this limited assessment of the data. 
4.7. Conclusion 
This evidence synthesis has demonstrated that CT density relates significantly to all 
commonly used clinical parameters. However, the large amount of heterogeneity 
and lack of longitudinal data means that how sensitive and specific CT density is to 
change relating to time or interventions is not clear. We recommend that 





 . Exploration of the variability between observers analysing Chapter 5
CT density and between the two leading software programs 
5.1. Introduction 
Quantitative Computed Tomography (qCT) exemplifies how pulmonary imaging in 
is evolving towards precision medicine for assessment and treatment of emphysema. 
The sensitivity index of qCT is greater than that of lung function or Quality of Life 
(QoL) questionnaires, and the ability to demonstrate the type and distribution of 
emphysema is an attractive feature not possible with other modalities (142, 399). 
However, in order to have confidence in the results generated there needs to be 
proven reliability and repeatability of the instrument. The lack of consensus over the 
optimal CT acquisition parameters, and the lack of standardisation currently stands 
in the way of qCT being used in clinical care.  
There is an important difference to distinguish between repeatability measured by 
the intra-class correlation coefficient (ICC) and the level of agreement. The ICC 
measures the relative consistency of the measure and any differences may be 
ascribed to the error of measurement process (400). To put this into context of other 
respiratory investigations, the ICC for FEV1 (L) is 0.97 and MRC grade is 0.82(401). 
Agreement quantifies how similar the two measurements are and the precision of 
the instrument. This ‘true variance’ reflects associated factors including biological 
noise, error on behalf of the subject or the examiner and so on(400).  
Ensuring equal results are produced when the same scan is analysed repeatedly will 
evidence the reproducibility of CT densitometry. There will always be an element of 
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technical noise associated with a measurement tool, but this variability should 
remain within the set confidence limits. The intra-observer variability has not been 
reported for thoracic CT density specifically but a study measuring diameter and 
attenuation of renal cell carcinomas reported the intra-class correlation coefficient 
(ICC) as 0.998 (402). Inter-observer variability has been investigated to a greater 
extent in the literature and an ICC >0.9 reported(292).  
By assessing the intra- and inter observer variability within our cohort we will in 
parallel validate my own analyses of CT scans. One of my supervisors (DS) 
reanalysed a subset of CT scans in order to determine the correlation coefficient and 
the level of agreement. In addition, CT scans analysed by a previous fellow (DP) in 
2002-2004 were sourced and reanalysed, and the results of his comparisons and mine 
compared. Providing the results of the analyses were equal, we would have 
confidence in my ability to accurately analyse the CT scans and proceed further.  
The software programs used for CT density measurement have recently been 
reviewed in chapter 4. We found that most frequently the software programme was 
either not mentioned, or was ‘custom built’. Wielputz et al previously compared the 
analyses of three software programmes (YACTA, LowATT and Pulmo 3D) finding 
marked differences between the measurements of emphysema, concluding that this 
hampered qCT becoming an accepted biomarker in COPD (192).  
Since this time 2 density analysis programs are emerging as leaders in the field. The 
most frequently reported program PULMO has been used in the “Exacerbations and 
Computed Tomography scan as Lung End-points” (EXACTLE) trial and 
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“Randomized Placebo-controlled Trial of Augmentation Therapy in Alpha-1 
Proteinase Inhibitor Deficiency” (RAPID) (92, 319). Both trials reported change in CT 
density as their primary outcome measure, and used CT slices of 5mm thickness. 
Pulmonary Workstation, a product of VIDA diagnostics founded at the University of 
Iowa, is designed to analyse airways and parenchymal density. Used by the 
COPDGene authors to analyse CT scans, numerous publications have arisen that 
cross-sectionally examine the associations between CT density and lung physiology 
or quality of life (72, 349, 378). Pulmonary Workstation uses 1mm slices which 
allows for airway and parenchymal measurement, whereas PULMO is used solely to 
measure CT density. Thinner slices sacrifice the accuracy of the emphysema due to 
the fewer number of pixels, broadening the density histogram and over estimating 
the severity of emphysema. 
5.2. Methods 
 
5.2.1. Internal Validation and the generation of an intra-class correlation coefficient 
 
CT density analysis was performed on 15 scans twice by myself (DC) on two 
separate occasions three months apart, from patients with COPD with varying 
severity as defined by the FEV1. 9 CT scans were analysed by DC and then 
independently re-analysed by one of my supervisors (DS) in order to determine the 
level of inter-observer agreement.  A further 17 CT scans previously performed and 
analysed by a previous fellow (DP) between 2002 and 2004 studies were additionally 
accessed. They were analysed by a previous fellow (DP), and the results from these 
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historic analyses and those repeated by myself were compared. Between the 
2002/2004 scans and those performed by myself, there has been an update in the 
PULMO software program, which may introduce an element of variability.  
The mean and SD, or median and IQR, depending on the normality of each variable 
was calculated and expressed as percent predicted for age, sex, race and height (see 
appendix). Bland Altman plots were created using SPSS (version 22) by establishing 
the mean difference between the sets of results and 95% confidence intervals. If the 
true differences between two sets of measurements have a normal distribution, 95% 
of differences will lie within 1.96*standard deviations of the mean. In general 
though, the 95% limits of agreement from a Bland-Altman analysis will not contain 
95% of true differences, because both the mean and standard deviation used in the 
calculation of the limits of agreement are estimates rather than true values. Therefore 
in order to determine confidence in the findings, Monte Carlo methods were used to 
establish the true limits of agreement.  
5.2.2. Comparison and Evaluation of CT density analysis between the two leading 
software programs 
50 patients underwent CT scanning between May 2014 and February 2016 at the 
Queen Elizabeth Hospital Birmingham, recruited to ADAPT programme and 
participating in the ongoing NIHR Rare Diseases Consortium. (285, 286) All scans 
were performed on a Siemens scanner during deep inspiration. A smooth 
reconstruction filter (B30f) was used and both 1mm and 5mm slices created.  Air and 
water calibration are performed on a daily basis as part of routine CT conduct. 
Images were analysed using PULMO CMS (developed at the Leiden University 
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Medical Centre) in the UK and then the images sent by DICOM format to National 
Jewish Health for analysis by Chest Imaging Platform (CIP). Linear regression was 
performed and the correlation coefficient calculated. Bland Altman plots were used 
to confirm any agreement. A t test or a Mann Whitney U depending on normality 
distribution was performed and the level of significance set at p<0.05. 
5.3. Results 
5.3.1. Internal Validation 
5.3.1.1. Intra-observer validation 
  
Table 5.1 details the clinical characteristics of the 17 patients included in the analysis. 
The mean FEV1 percent predicted was 52.97% (GOLD stage 2), with evidence of 
hyperinflation within the cohort confirmed by the elevated TLC and RV percent 










Table 5.1. Patient Characteristics Table 
Clinical Parameter Mean (SD) 
Age 62.34 (11.3) 
 
Sex 9 M 8 F 
FEV1pp 52.97 (22.53) 
FEV1/FVC (%) 39.15 (13.4) 
KCOpp  70.3 (8.05) 
TLCpp 117.4 (18.1) 
RVpp 117.19 (18.22) 
 
Figure 5.1 demonstrates the Bland Altman plots for repeated measurements by the 
same observer and show that nearly all measurements lay within the expected levels 
of agreement, with only one or two outliers within each CT density parameter. As 




Figure 5.1. Bland Altman plots of the intra-observer variability 









5.3.1.2. Inter-observer validation 
 
The correlation between these analyses performed by DC and DS was very strong 
with r values for -910, -950 and PD15 of 0.981, 1.0 and 0.995 respectively. The Bland-
Altman plots in Figure 5.2 demonstrate good agreement between the results between 
observers, with just one outlier on each plot, and no proportional bias. 
Figure 5.2. Bland Altman plots to demonstrate the inter-observer agreement 










5.3.3. Comparison of the two leading software programs 
5.3.3.1. Patient Characteristics 
 
It was not possible to analyse 3 out of 50 scans due to issues with automatic 
segmentation. For the remaining 47 patients, a summary of the baseline patient 
characteristics is shown in Table 5.2. The mean FEV1 percent predicted was 63.89% 
(GOLD stage 2), with evidence of hyperinflation within the cohort confirmed  by the 
elevated TLC and RV  expressed as percent predicted for age, sex, race and height 
(259).  
Table 5.2. Patient Characteristics Table 
Clinical Parameter Mean (SE) 
Age 61.53 (11.3) 
 
Sex 26 M 21 F 
FEV1pp 63.89 (6.93) 
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FEV1/FVC (%) 44.87 (20.08) 
KCOpp  70.2 (3.04) 
TLCpp 111.35 (3.85) 
RVpp 107.03 (6.19) 
 
5.3.3.1. 1mm slices Pulmonary Workstation versus PULMO 
 
Table 5.3 demonstrates the overall mean assessment of density and inspiratory 
volume for the two programs. There is an average (though non-significant 
difference) of 110ml difference in the inspiratory volume and no significant 
difference between the two programs for each measure of emphysema. 
 
Table 5.3. Comparison of lung volume (inspiratory) and emphysema estimation 
between PULMO and CIP using the same slickness 
 
 PULMO 1mm CIP 1mm P value 
-910HU (%) 51.85 (15.51) 49.96 
(15.75) 
0.554 
-950HU (%) 27.36 (14.37) 25.57 
(13.98) 
0.49 
PD15 (HU) -970 (31.18) -969 (-32) 0.631 




Figure 5.3 demonstrates the Bland Altman plots for the two programs. For volume, -
910HU and -950HU all but two data points are within the limits of agreement. The 
mean difference for PD15 estimation was 1.8HU and 66ml for volume estimation 
performed on CT. These similar results indicate that a correction could and should 
also be made for these parameters. There were 4 out 47 data points beyond the limits 
of agreement for PD15 though no significant bias and the outliers did not have 
extremes of lung function or disease.  
 
Figure 5.3. Bland Altman plots between the two software programs for volume 













5.3.3.2. 1mm Pulmonary Workstation vs 5mm PULMO 
 
Table 5.4 demonstrates larger differences in the emphysema assessment between the 
two programs for the different slice parameters used especially for PD15 (p=0.005). 
Figure 5.4 shows the Bland Altman plots for each emphysema measurement and 
volume with the slice differences. There is clear proportional bias demonstrated for 
emphysema measurement with one of the programmes consistently overestimating 
the degree of emphysema especially at the extremes of measurement.  
 
Table 5.4. Comparison of mean assessment of volume and emphysema between 
PULMO and CIP using different slice thicknesses 
 
 PULMO 5mm CIP P value 
-910HU (%) 43.37 (18.94) 49.96 
(15.75) 
0.66 
-950HU (%) 19.31 (13.7) 25.57 
(13.98) 
0.60 
PD15 (HU) -957 (-35.3) -969 (-32) 0.005 






Figure 5.4. Bland Altman plots between the two software programs for volume 













The results of the validation work for both intra and inter-observer analyses 
demonstrated there was strong agreement and therefore appropriate to proceed with 
further analyses. The Bland Altman plots in Figure 5.1 and Figure 5.2 show the 
agreement, with one or two outliers’ only and no proportional bias. By using Monte 
Carlo technique, there was an 80% chance that the 95% limits of agreement estimated 
from a sample of 17 pairs of measurements will contain 90% or more of the true 
differences. It would be arguably inappropriate however to calculate power at this 
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point, as with no reasonable prior knowledge of the relationship between the two 
sets of analyses then estimates cannot be built in to the calculation.  
The summary ICC for each CT density threshold based on the observed variability is 
0.99 which can be used for future work applying the standard error of the mean 
(SEM) calculations. That is when assessing CT density, there is only 1% error that 
can be attributed to the noise of the instrument and the remainder is that reflective of 
disease.   
The software comparison data compares the 2 most widely used software 
programmes for assessing pulmonary emphysema quantitatively(91). We have 
demonstrated that analysing CT scans with either programme but with the same 
slice thickness, produces comparable results for volume and for emphysema 
estimation as -910HU, -950HU and PD15 with only minor and insignificant 
differences. For emphysema estimation, based on our results we would recommend 
a minor correction factor of 2.47% for -910HU, 1.18% for -950HU, or 1.8HU for PD15.  
However, when using the different slice thicknesses the Bland Altman plots showed 
consistent proportional bias in emphysema quantification and therefore no suitable 
agreement. This is consistent with the previous literature recommending use of the 
same slice thickness due to the recognised over-estimation of emphysema with 
thinner slices (195). There is currently an international consensus to address this 
(Quantitative Imaging Biomarker Alliance) (403) which may address this issue as 
raised in the recent CT density systematic review and is clearly essential for 
acceptance of this biomarker as a key outcome measure for future treatments. .   
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The most recent similar publication to our analyses was that by Wielputz et al in 
2014 (192) that compared 3 different software programmes (YACTA, lowATT and 
Pulmo3D). These 3 programs are, however, infrequently used in the literature and it 
was only possible to analyse 43% of scans for CT density with all 3 programs due to 
segmentation errors(404). The authors found a significant difference in both the 
emphysema and volume estimation between each of the three programs (p<0.001). 
By comparison we were able to analyse 94% scans using PULMO and CIP, 
demonstrating better reproducibility. PULMO and CIP produced similar results for 
volume and emphysema estimation using both the same and different slice 
thicknesses, with the exception of PD15 comparing 1mm vs 5mm slices (p=0.005). 
This difference is likely due to higher sensitivity of PD15 for emphysema 
quantification as previously described(131). Both PULMO and CIP showed identical 
and significant correlations of density to lung function not seen by Weilputz et al 
providing further support for the results reported here. The strength of the current 
study is that the scans were analysed independently by physicians with a specialist 
interest in quantitative CT and a depth of experience in the field. A wide range of 
severity (as defined by FEV1) was included and therefore the results are 
generalizable for all stages of emphysema. One minor limitation of our study was 
perhaps the sample size, although the tight correlations seen suggest confidence in 
the result. Inter-observer variability invariably exists, though the published literature 
regarding the test retest intra-class correlation coefficient for qCT analysis suggests 




In conclusion, the ICC for CT density analysis using --910HU, --950HU and PD15 is 
0.99. Emphysema and volume estimation between PULMO and CIP using the same 
slice thickness is comparable and could be combined using the recommended 
adjustment factors. However, attention must be paid to the slice thickness used in 





 Evaluation of the relationship between CT density and Chapter 6
common clinical parameters using the Birmingham Alpha one 
Antitrypsin Deficiency cohort.  
 
6.1. Introduction 
The Antitrypsin Deficient Assessment and Programme for Treatment (ADAPT) was 
established in 1996, recruiting patients with AATD into the research registry in order 
to further understanding and management of the disease. Research that has arisen 
from the registry spans multiple sub-specialities including neutrophil studies, lung 
physiology and small airways disease, and COPD biomarkers. Quantitative CT has 
been performed as an imaging biomarker of emphysema severity by the ADAPT 
group since 2002, with 423 scans have been performed on over 220 patients. These 
included patients recruited into studies such as EXACTLE (Exacerbations and 
Computed Tomography scan as Lung End-points) and NIHR Translational Research 
rare disease consortium. Prior to 2002, density mask analysis had been performed on 
a small number of scans, but was done so on a software program and slice thickness 
incomparable with scans performed post 2002. All scans included in subsequent 
analyses have all been performed using the approved CT protocol of a smooth 
reconstruction algorithm (B30f), slice thickness 5mm and an increment of 2.5mm. 
The same software programme (PULMO) was used throughout, and they were all 




The systematic review (chapter 4) concluded that despite an overall significant 
association between CT density and clinical parameters, there was marked 
heterogeneity throughout, meaning a meta-analysis was only possible for those 
studies reporting a correlation coefficient. With regards to mortality, there were 
three studies which reported a hazard ratio for %LAA and risk of death, but none of 
them reported mortality with respect to PD15. Several publications regarding 
mortality and PD15 once divided into upper and lower zone have been produced 
from the ADAPT group, but none regarding whole lung PD15.  
6.2. Methods 
Multiple databases have produced independently by different clinical fellows over 
the past 10 years, and therefore the first hurdle to overcome was to combine these 
and then ‘clean’ the database so that one up to date comprehensive database now 
exists. Added to these previous analyses were all those analysed by myself as part of 
the NIHR rare diseases consortium, and scans analysed during the validation work, 
where the results were previously either not reported or were in paper format. In 
order to describe the cohort with regards to the associations with clinical parameters 
such as lung function and mortality, the results have been subdivided into cross 
sectional analyses and longitudinal analyses. Full details on the statistical methods 




6.3.1. Cross-Sectional Analysis 
6.3.1.1. Baseline Characteristics 
 
204 patients have received at least 1 CT scan using the recommended CT acquisition 
parameters (i.e. smooth reconstruction algorithm, 5mm slice thickness with 2.5mm 
increment). Table 6.1 summarises the patient characteristics as assessed within a 
mean of 63 days of their baseline scan. FEV1 measured in litres and as a percent 
predicted was found to be significantly different between survivors and non-
survivors, as was the FEV1/FVC. KCO was significantly lower in non-survivors as 
was (RV and pack year history. All 3 measurements of CT density (-910HU, -950HU 










Table 6.1. Baseline Characteristics Table 
 Whole Group Alive  Dead Significance 
Age 64.8 (11.48) 62.18 (10.7) 72.18 (10.26) 0.0001 
FEV1 1.58 (1.11) 1.67 (1.21) 1.55 (0.85) 0.032 
FEV1% 55.39 (38.34) 57.86 (39.03) 46.94 (29.79) 0.007 
PD15 -957.1 (26.65) -954.64 (28.46) -958.8 (25.45) 0.446 
-910HU 43.13 (19.41) 43.06 (18.28) 43.28 (16.67) 0.949 
-950HU 19.41 (13.11) 19.06 (13.5) 20.14 (12.34) 0.53 
FVC 4.13 (1.22) 4.08 (1.18) 4.21 (1.31) 0.851 
FVC% 107.3 (20.72) 107.55 (20.1) 106.76 (22.13) 0.473 
FEV/FVC 44.02 (17.73) 46.17 (17.91) 39.39 (16.54) 0.005 
TLCO 5.72 (2.28) 5.68 (2.18) 5.8 (2.47) 0.994 
TLCO% 61.83 (20.55) 62.27 (20.39) 61.02 (21.02) 0.603 
KCO 1.03 (0.34) 1.09 (0.36) 0.97 (0.3) 0.036 
KCO% 64.76 (19.08) 67.39 (20.65) 61.66 (16.69) 0.08 
RV 2.42 (1.1) 2.29 (0.95) 2.78 (3.47) 0.028 
RV% 115.16 (40.67) 110.46 (32.24) 127.74 (43.42) 0.036 
TLC 7.24 (1.68) 6.98 (1.55) 7.55 (1.8) 0.117 
TLC% 112.48 (17.26) 110.98 (17.5) 115.50 (16.5) 0.095 
RV/TLC 36.81 (11.3) 36.20 (10.07) 38.02 (13.47) 0.338 
RV/TLC% 102.4 (41.8) 99.671 (36.68) 109.14 (54.26) 0.158 
Pack Years 19.48 (13.62) 17.22 (12.98) 24.06 (13.87) 0.004 




6.3.1.2.1. Univariate Analysis 
Table 6.2 summarises the correlation coefficients between the three measures of CT 
density and spirometric measures. The strongest correlation can be seen between 
PD15 and FEV1 percent predicted, with 87.8% of the variability of FEV1 percent 
predicted accounted for.  
 
Table 6.2. Summary of correlation coefficients between spirometry and CT 
density 
 
Variable PD15 p value 950 p value 910 p value 
FEV1 0.604 <0.0001 0.59 <0.0001 0.570 <0.0001 
FEV1pp 0.937 <0.0001 0.646 <0.0001 -0.663 <0.0001 
FVC 0.093 0.101 -0.07 0.166 0.063 0.195 
FVCpp 0.144 0.023 0.179 0.007 -0.084 0.123 
FEV/FVC 0.712 <0.0001 0.697 <0.0001 0.774 <0.0001 
 
Figure 6.1 demonstrates the significant differences in CT density between each of the 
GOLD stage groups. Figure 6.2 shows the individual scatter plots between FEV1 (L) 




Figure 6.1. Box plots to demonstrate differences in CT density as subdivided into 
GOLD stage groups. 
 




























6.3.1.2.2. Multivariate analysis 
 
Table 6.3 demonstrates the sequential adjustment of FEV1 against PD15 for age, 
height, sex and pack years, which remains significant throughout. The r2 value for 
PD15 and FEV1 strengthened with each variable included (r2 for FEV1 adjusted for 




































FEV1 0.155 1.372 0.125 0.185 <0.001 
Adjusted 
for age 
0.151 1.458 0.120 0.182 <0.001 
Adjusted 
for age and 
sex 
0.162 1.233 0.132 0.192 <0.001 
Adjusted 
for age, sex 
and height 
0.17 1.958 0.14 2.01 <0.001 
Adjusted 
for age, sex, 
height and 
pack years 






6.3.1.3. St George’s Respiratory Questionnaire (SGRQ) 
6.3.1.3.1. Univariate Analysis 
 
There is a significant relationship between CT density and SGRQ as measured by 
Pearson’s correlation coefficient (Figure 6.4). The association is marginally stronger 
between PD15 and SGRQ though all are significant, with a p value <0.001.  













6.3.1.3.2. Multivariate Analysis 
The relationship between SGRQ and PD15 remained significant following 
adjustment for age, sex, height and pack years (table 6.4). In the same manner as 
FEV1, the r2 value improved once adjustments had been made.  
Table 6.4. Summary of the r2 values between SGRQ and PD15 following 
sequential adjustment 
 Adjusted r2 value P value 
SGRQ 0.196 <0.001 
Adjusted for age 0.189 <0.001 
Adjusted for age and height 0.190 <0.001 
Adjusted for age, sex and height 0.184 <0.001 






6.3.1.4. Gas Transfer 
 
There is a significant correlation between each of the measures of gas transfer and 
CT density, albeit slightly less significant than for FEV1 (see table 6.5). The 
relationship between KCO and PD15 remains significant even after adjustment for 
FEV1 (L) and the adjusted r2 value of 0.44 indicates CT density can explain 
approaching 50% of the variability seen in KCO (see table 6.6). 
Table 6.5. Summary of correlation coefficients between gas transfer and CT 
density 
Measurement PD15 P value --950HU P value --910HU P value 
TLCO 0.513 <0.001 0.532 <0.001 0.482 <0.001 
TLCOpp 0.604 <0.001 0.640 <0.001 0.608 <0.001 
KCO 0.679 <0.001 -0.606 <0.001 -0.677 <0.001 

























KCO 0.402 1.291 0.301 0.495 <0.001 
Adjusted for age 0.421 1.182 0.319 0.523 <0.001 
Adjusted for age 
and sex 
0.415 1.179 0.307 0.523 <0.001 
Adjusted for age, 
sex and height 
0.416 1.341 0.308 0.525 <0.001 
Adjusted for age, 
sex, height and 
pack years 
0.419 1.617 0.299 0.539 <0.001 
Adjustment for 
age, sex, height, 
pack years, FEV1 
0.222 2.023 0.086 0.359 0.002 
 
 
6.3.1.5. Lung Volumes 
 
RV and TLC both significantly correlated with CT density, though this appears to be 
the weakest association of the clinical parameters thus far (see table 6.7). Both TLC 
measured as percent predicted, or RV/TLC percent predicted had no association 




Table 6.7. Summary of correlation coefficients between volumes and CT density 
 PD15 p value --950HU p value --910HU p value 
RV 0.417 0.000 0.424 0.000 0.508 0.000 
RV% 0.347 0.000 0.349 0.000 0.413 0.000 
TLC 0.246 0.003 0.240 0.005 0.393 0.000 
TLC% 0.018 0.411 -0.029 0.361 -0.019 0.405 
RV/TLC -0.014 0.430 0.049 0.271 0.022 0.393 




FEV1 measured as a percent predicted showed the strongest correlation with CT 
density, and in particular FEV1 (r=0.937) (see figure 6.5). Measures of volume 
including FVC demonstrated the weakest relationship with CT density, with either 





Figure 6.4. Summary of the correlation coefficients between each CT density 
measure and clinical parameters 
 
6.3.2. Longitudinal analysis 
6.3.2.1. Mortality 
6.3.2.1.1. Kaplan-Meier Plots 
The ADAPT cohort was subdivided into 4 quartiles of worsening emphysema 
severity as measured by PD15. These quartiles were (1) >-940HU (2) -940 to -956HU 
(3) -957 to -966HU and (4) <-967HU. Table 6.8 demonstrates the Kaplan Meier plot 
with each quartile shown. The estimated time to death for those in the 4th quartile is 
9.9 years, compared with 13.1 years for those in the first quartile (Log Rank chi 
square value 13.691, p=0.003). 































Table 6.8. Kaplan Meir plots to demonstrate the influence of CT density on mortality 
Emphysema 
threshold 





























































6.3.2.1.2. Cox Regression 
Out of 193 patients that were included in the longitudinal analysis there were 57 
deaths that occurred. 6 variables were adjusted for: Age, height, sex, pack years, 
FEV1 and KCO percent predicted, none of which demonstrated multi-collinearity 
with one another (VIF collinearity statistic remained <2.0 throughout). Considering 
PD15, each of the first 3 quartiles remained significantly different to the fourth and 
final quartile (see table 6.9). The fourth quartile, i.e. those with PD15 < -967HU does 
have a strikingly worse time to death than the other three quartiles. Therefore, if a 
patient’s baseline CT scan shows a <-967HU there is a significant faster time to death 
than those with less emphysema (see figure 6.5). This pattern held true when the 
cohort was divided into quartiles for -950HU with same adjustments including FEV1 
and KCOpp. There was a significant difference between quartile 2 and quartile 4 
using -910HU, there was no difference between quartile 4 and 1 or 3. Therefore 
following adjustment, -950HU and PD15 quartiles remained significant with regards 
to predicting time to death, but -910HU did not. In those with a CT density measure 
of -967HU or lower as measured by the 15th percentile point, there is an estimated 





Table 6.9. Summary of multivariate cox regression analyses for each CT density 
measure 







Quartile 4 (control) 
Quartile 3 -1.76 0.172 0.043 0.688 0.013 
Quartile 2 -2.768 0.063 0.014 0.277 0.000 
Quartile 1 -2.013 0.134 0.021 0.866 0.035 
-910HU 
Quartile 4 (control) 
Quartile 3 -0.942 0.390 0.072 2.111 0.274 
Quartile 2 -1.99 0.137 0.022 0.846 0.032 
Quartile 1 -1.181 0.307 0.024 3.956 0.365 
-950HU 
Quartile 4 (control) 
Quartile 3 -1.847 0.158 0.037 0.667 0.012 
Quartile 2 -2.84 0.058 0.012 0.285 0.000 





Figure 6.5. Survival plots for each PD15 quartile once adjusted for age, sex, height, 


















There was no significant difference in CT density as measured by -910HU, -950HU 
or PD15 between those with 1 or no exacerbations per year versus 2 or more (p=0.94, 
0.47, 0.87 respectively).  
6.4. Discussion 
This study of CT scans performed and quantitatively analysed on 204 patients 
recruited to ADAPT has shown for the first time CT density as measured by PD15 is 
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significantly associated with mortality, including after adjustment for FEV1 and 
KCO. Previous studies have shown such an association with other CT measures i.e. -
910HU and -950HU, and upper zone PD15 but not whole lung. Age, height, sex, 
pack years, FEV1 and KCO percent predicted were all included in the adjusted 
multivariate analyses. FEV1 and KCO were both included as they predominantly 
represent predominant airways versus emphysematous disease and therefore a 
statistical conclusion regarding mortality adjusted for each of the predominant 
phenotypes was felt to increase the applicability. As lung function declines naturally 
with age, and is accelerated by the number of pack years their impact on mortality 
was adjusted for. With the addition of age and height, 6 variables were adjusted for 
in this model, which slightly surpasses the traditional recommendation of adjusting 
for one variable per every event. However, given the impact each variable is likely to 
have on mortality, it was felt appropriate to include a 6th variable, and a highly cited 
publication by Charles McCulloch suggests the rule of 10 can be relaxed to 5-9 events 
per predictor variable (EPVs) (405). Furthermore, the absence of multicollinearity 
between each of the independent variables means a 6th variable is unlikely to have 
had a detrimental statistical effect.  
The analyses performed showed a higher correlation with FEV1 and FEV1pp than the 
pooled correlation coefficient form the systematic review (0.64 and 0.937 
respectively). By taking the unstandardized coefficient and constant reported 
following the multivariate linear regression, in a similar manner to the Hoesein et 
2015 paper, a 10HU difference in PD15 would results in a 0.46L change in FEV1 
(following adjustment for age, height, sex and pack year history) (187). Alternatively, 
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a 0.1L change in FEV1 would results in a 2.153HU change in PD15. The association 
with gas transfer and PD15 was stronger within the ADAPT cohort than the pooled 
correlation coefficient from the systematic review, likely related to the homogeneity 
of the patient cohort. For KCO, in the review the overall CC was reported as 0.38 in 3 
studies, but the results from this stud show a CC of 0.679. For KCO percent 
predicted, 0.42 (from 6 studies) was the pooled correlation coefficient, but in this 
analysis the CC is 0.598.  
These results confirm the significant relationship between CT density and other 
clinical parameters seen in the systematic review. In a large study with the same CT 
acquisition parameters used throughout and therefore any heterogeneity 
minimalised, these results should add further to growing appreciation of CT density 
as a biomarker of measure of emphysema progression. Exacerbations were not 
significantly associated with patient’s baseline CT scan and therefore should not at 
present be used as part of a predictive model. A CT scan before and after an infective 
episode would allow for a greater understanding of the impact on parenchymal 
change, but the risks from the radiation dose probably outweigh the benefits.  
 
Patients included in this cross sectional analysis were participating in either an 
observational cohort study or in the placebo arm of a RCT. This usually involved 
multiple patient visits, and where ideally all of their investigations would be done 
on the same day, this was not always possible. The radiology department and lung 
function department used for CT scans and lung function tests respectively are not 
exclusive research facilities, and therefore it is difficult to coordinate investigations 
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such as the CT scan and lung function to happen on the same day. This is less than 
ideal, and a mean time of 63 days between the two investigations in this cohort is 
longer than we would like. The mean FEV1 percent predicted is 55% (GOLD stage 2) 
and FEV1 (L) 1.58. The mean decline in FEV1 in GOLD stage 2 patients with AATD 
and COPD may be as rapid as 4.7%/year (406). Over the 63 days that our patients 
were seen, it stands to reason that over 2 months (one 1 sixth of a year), even in a 
rapid declining population, there could be a loss 0.8% FEV1 percent predicted in this 
time. This is not an insignificant amount, and over time would accumulate to a 
damaging loss of lung function. However, in the context of this population over this 
amount of time, whilst I accept there could have been some change in lung function 
between visit days I do not feel it is enough to warrant removing these values from 
the analysis.  
The limitation of this study is that these results are only comparable for those 
patients with AATD and more work needs to be done to help understand the 
relationship in COPD. However, the size and the robust conduct of this study add 
gravity to an argument for using CT density in the management of AATD, and 
particularly so alpha one augmentation therapy. The alpha one augmentation 
therapy systematic review recommended mortality should be used as an outcome 
measure in future studies. By dividing the cohort into quartiles, we have shown CT 
density at baseline may be used as a prognostic measure. However, by dividing the 
cohort into quartiles, I recognise that this does reduce the statistical meaningfulness. 
Further work still needs to be done with regards to longitudinal CT scans so that 
density change and how it relates to clinical parameters maybe further understood. 
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In conclusion, PD15 at baseline is significantly associated with all clinical 




 Proposal and validation of a Minimal Clinically Important Chapter 7
Difference (MCID) for Annual CT density decline. 
7.1. Introduction 
CT densitometry offers a precise method of quantifying emphysema that would 
enable tailored treatment of emphysema in patients with AATD. It is more sensitive 
to disease change than PFTs or QoL questionnaires, is objective, and highly 
repeatable (167, 343). Alpha one augmentation therapy (AAT) improves the deficient 
levels of alpha one antitrypsin, to boost the neutrophil elastase activity and prevent 
(or at least reduce) further parenchymal damage(90). Placebo-controlled RCTs have 
demonstrated improvement of CT measured density with AAT, with the recent 
RAPID-OLE (Randomized Placebo-controlled Trial of Augmentation Therapy in 
Alpha-1 Proteinase Inhibitor Deficiency-Open Label Extension) trial showing that 
even when previously on the placebo arm, once patients are switched to AAT, their 
CT density decline slows down (95). The 2010 systematic review of AAT 
recommended the future outcome measures of augmentation trials be simply 
mortality(93). Power calculations demonstrate the length of time to power a study 
for FEV1 is at least three years and 494 patients, nearly three times that required that 
of CT density, and inevitably outcomes such as time to transplant or death would be 
even longer(319). This makes such studies highly unlikely to occur due to cost 
limitations and recruitment difficulties. 
An MCID is defined as “the smallest change in an outcome that a patient would 
identify as important”(407). It represents a move away from simply being 
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statistically significant towards a threshold beyond which patients would notice an 
improvement.  
7.2. Methods 
Two methods were used to propose the MCID for CT density decline; the anchor 
method and the distribution method. The anchor method observes the line of 
regression between the change in one variable versus another, and where the MCID 
for FEV1 is known (100mls or 0.1L), the corresponding MCID for CT density can be 
determined. The line of regression was calculated by using the slope and/or 
intercept with relation to CT density and FEV1 that had been previously been 
reported, and replace the x value with the MCID for FEV1 (100ml). The relationship 
and the line of regression were additionally calculated using Birmingham AAT 
registry’s CT data (section 6.3.1.1. for a description of the cohort). All patients who 
had received 2 or more CT scans on the same CT protocol were sought and their 
annual decline calculated. Where there was more than one CT scan, the first and last 
CT scan were used, and the difference in density calculated. Annual decline in FEV1 
was determined by calculating the slope which requires at least 3 measurements 
within the same time period(258). By plotting one against the other, the linear 
regression equation was calculated, into which the known MCID for FEV1 is 
inputted to determine the corresponding decline in CT density.  
The distribution method is better termed the “minimal detectable difference” 
(MDD), and is designed to predict a threshold based on the variance of the sample 
beyond which any changes seen cannot be attributed the noise of the instrument. 
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There are numerous proposed methods of calculating the MCID using the 
distribution method; the three most applicable methods may be found in section 3.4. 
95% confidence intervals for each proposed MCID were calculated and then each 
proposed value plotted for illustrative purposes.  
The proposed value for the MCID was then used to subdivide the ADAPT cohort 
into those above or below it to determine if there was any survival differences using 
Kaplan Meier plots and Cox regression. In addition any changes in the time to 
transplant were calculated and if there were any differences in the exacerbation 
rates.  
7.3. Results 
7.3.1. Anchor Method 
7.3.1.1. Reported annual change between FEV1 and CT density 
 
Only one study reported the FEV1 change in litres against CT density decline for all 
participants, including the spread of the data. Dirksen et al produced a figure that 










Figure 7.1. Correlation between change in PD15 and FEV1 (L) for Prolastin and 
placebo groups combined 
  
However, this was a combined scatter plot for all patients regardless of whether they 
were receiving Prolastin or placebo, and therefore certain assumptions needed to be 
made. Firstly, by referring to the RAPID RCT, Chapman et al 2015 showed there was 
approximately a 50% faster decline in density in those receiving placebo versus those 
receiving Prolastin (figure 7.2) (92).  
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Figure 7.2. Rates of density decline in patients receiving Prolastin and placebo. 
  
The slope from the graph in the Dirsken et al 2009 paper shows an approximate 
slope of the line of regression of 8.5. From here, in order to deduce how two lines 
may appear with a 50% difference between them, and solving simultaneous 
equations, the intercept of the placebo and treatments arms would be 6.8 and 10.2 
respectively. By inputting the new slope, and using two known values of x and y 
into the linear regression equation y=a+bx we can calculate the intercept. In the 
Dirksen 2009 paper, the annual change in FEV1 and CT was 0.023 L/yr-1and 
1.3848g/L-1 respectively. Below is the bullet pointed demonstration of how the 

















Regarding confidence intervals, the correlation coefficient of 0.316 and therefore the 
r2 value and the amount of variability on CT density attributed to FEV1 is 0.098 
(rounded up to 0.1). The total variance in the sample, i.e. SD of CT density change 
squared is 30.25 (5.5362). Therefore the residual variance is 30.25*0.9=27.225, and the 
residual standard deviation the square root of this (5.218). By then converting to the 





7.3.1.2. Changes between FEV1 and CT density within the ADAPT cohort 
 
39 patients received at least 2 CT scans analysed using identical CT parameters and 
PD15, plus at least 3 FEV1 measurements within the same time frame. Figure 7.3 
demonstrates the resultant correlation and line of regression, and the MCID for CT 
density using our cohort would be -1.59HU. This is over 1 HU less than our 
proposed MCID from the literature. However, table 7.1 highlights how different the 
two cohorts are, particularly with regards to age and baseline FEV1.
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Figure 7.3. Proposal of MCID using ADAPT data 
 
A) Scatter Plot between 
FEV1 and PD15 
 
B) Calculation of MCID Y=a+bx 








Table 7.1. Comparison of baseline characteristics from the placebo arms of AAT 
RCTs and the ADAPT cohort. 
 
 ADAPT cohort (n=39) AAT RCTs* (n=67)  
Variable Mean  SD Mean  SD p value 
Age 69.72 11.41 50.74 9.41 <0.0001 
FEV1 (L) 1.76 0.87 1.51 2.55 0.556 
FEV1/FVC (% 
predicted) 
47.1 1.23 --- ---  
DLCO 
mmol/min/kPa 
5.89 1.77 5.39 1.88 0.181 
KCO 
mmol/min/kPa/VA 
1.00 0.26 0.91 0.26 0.089 
Baseline Density 
(PD15) 
-945.12 27.05 -934.4 22.47 0.03 
*Dirksen et a 1999 and 2009 
7.3.2. Distribution Method 
Three studies reported the baseline and annual change in CT density (See table 7.2). 
The overall baseline density SD was 20.399 g/L, and annual change SD 3.402. The 
95% confidence limits for the baseline standard deviation using n=154 were 18.347 





Table 7.2. Summary of baseline CT density and annual change in the 3 AAT 
RCTs. 
 















28 73.0 25.29 -2.57 2.17 
Dirksen et 
al 2009 
39 45.48 16.95 -1.38 5.5 
Chapman 
et al 2015 
87 48.9 15.5 -2.19 2.33 
Average 154 52.42 20.399 -2.0552 3.402 
 
 
Table 7.3 details how each proposed MCID was reached using the 3 different 
methods. The 95% confidence intervals were calculated by simply replacing the 
standard deviation with the confidence limits. 
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Table 7.3. Summary of proposed MCIDs through Distribution method. 
 
Distribution Method Description Results 










-2.04 (-1.83- -2.3) 
(small effect) 
 




95% CI= X*CI{sqrt[2*(1-r)]} 
=1*-18.347sqrt[2*(1-0.99)] 
=1*-22.972sqrt[2*(1-0.99)] 

















7.3.3. Proposal of MCID 
Figure 7.4 illustrates each MCID and their confidence intervals. The first three are 
each of the distribution methods and the final MCID derived from the anchor 
method.  
Figure 7.4. Summary of each MCID and corresponding 95% confidence intervals 
 
The 95% confidence intervals from the anchor method encompass those of the 
standard error of measurement (SEM) and reliability change index (RCI) with the 
effect size being outside of this range. Given that a proposed MCID should originate 
from a variety of methods, it is reasonable to propose the MCID for CT density as -
2.89g/L-1, as this is the middle estimate from the three distribution methods, and still 
within the confidence intervals of the anchor method.  
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Table 7.4 summarises the patient characteristics from the cohort once they have been 
subdivided into those with CT decline faster or slower than the MCID. Variables that 
were different between those above/below each MCID as determined by the 
threshold of p<0.12 are highlighted in bold, which were then used as part of the 
multivariate cox regression analysis.  The univariate and multivariate cox regression 
models showed no effect of the proposed MCID on determining mortality (Table 
7.5).  
Table 7.4. Demonstration of the differences in clinical parameters for patients 
with CT density decline faster or slower than the proposed MCID 
 
Variable MCID decline 
slower than -
2.89g/L-1/year 
MCID decline greater 
than -2.89g/L-1/year 
p value 
Age 69.93 65.84 0.117* 
FEV1 (L) 1.53 1.70 0.23 
FEV1/FVC (pp) 43.8 4.13 0.417 
DLCO 
(mmol/min/kPa) 
6.19 6.30 0.849 
KCO 
(mmol/min/kPa/VA) 





-959.45 -938.45 <0.001* 
*p values less than 0.12 used in the cox regression model.  
Table 7.5. Summary of univariate and multivariate cox regression analyses to 
establish the prognostic benefit of the proposed MCID. 
Univariate Analysis 
Variables HR Lower 95% CI Upper 95% CI p value 
 1.12 0.616 2.037 0.711 
Multivariate analysis 
Variables HR Lower 95% CI Upper 95% CI p value 
Age 0.879 0.466 1.646 0.68 
Age and KCO 0.696 0.344 1.408 0.313 
Age, KCO and 
Baseline density 





Using a multivariate linear regression, each MCID had no impact on exacerbation 
rate following adjustment for age and baseline density (Hazard Ratio=0.116). 
7.3.4.3. Time to transplant. 
 
By altering the outcome in a cox regression analysis to time to death or time to 
transplant instead of time to death alone, this made no significant impact on the 
survival analysis.  
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7.4. Implications of MCID for future trial design 
7.4.1 Utility of MCID 
Through a variety of methods we have proposed an MCID of -2.89g/L and therefore 
density change beyond this may represent a change that is clinically appreciable by 
the patient. The MCID value proposed with the reliable change index uses the 
density at baseline and therefore any change beyond this is likely due to actual 
changes rather than the noise of the instrument. This represents an absolute value 
which can be used to design a trial and establish how long it should last and how 
many patients would be recruited.  
7.4.2. Study length 
We can assume the natural density decline in AATD patients is approximately -
2.06g/L/yr (standard deviation 3.40g/L/yr) based on the known density decline in 
in the placebo arms of augmentation trials (table 7.2). For a trial including AATD 
patients who are ‘rapidly declining’ (i.e. more than expected) who are potential 
candidates for augmentation therapy, it would be important to know the natural rate 
of decline. There have been no specific studies that have reported data for rapid 
decline in AATD patients. In order to determine a reasonable estimate, it is possible 
to define a rapid decliner if the mean and SD of the whole group are known. In 
figure 7.5, the marked area under the curve represents those who have CT density 




Figure 7.5. Normal Distribution Bell Curve 
 
The hashed area under the curve represents those patients with density greater than 
the mean +1 SD 
 
By estimating those within the top 16% of the overall natural decline, we can define 
rapid density decline in an untreated AATD population. The annual rate of decline 
in this ‘rapid group’ would be 2.06+3.40=5.46g/L. If the mean rate of ‘natural 
decline’ is subtracted (-2.06g/L), the remaining rate of change would be 
approximately 3.40g/L. (As this is derived from the same population, we can 
assume the SD remains constant).  
Using the MCID -2.89g/L plus natural rate of decline (total -4.95g/L), it would take 
a “rapid decliner” as defined here approximately 1.4 years to reach the MCID. This 
would be assuming 100% power and rapid decliners in the top 16%, therefore it 
would probably be more reasonable to suggest at least a 2 year study. 
7.4.3 Sample Size 
A power calculation was performed to estimate the required sample size required to 
demonstrate this difference.  ‘Group A’ is mean density of natural decliners (-
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2.06g/L/yr), ‘group B’ the mean density of ‘rapid decliners’ (3.46g/L/yr), and the 
SD is 3.46g/L. Using a power of 0.8, a type 1 error rate of 5% and sampling ratio 1:1, 
the study would require 93 participants.  
7.5. Discussion 
CT densitometry is undoubtedly an attractive solution to quantifying emphysema 
due to its objectivity, repeatability and sensitivity. Understanding how it can be used 
in a clinical context or as an outcome measure in clinical trials is still not fully 
appreciated. The proposal and validation of an MCID offers a threshold to which 
investigators can power studies, and clinicians can use to identify those rapid 
decliners. This is the first time a MCID has been proposed for CT density, and 
validation work performed. Though the validation failed to show a difference in 
mortality for the MCID, perhaps this is not entirely unexpected. Given the sensitivity 
of the tool to small changes not seen with other clinical parameters such as lung 
function over a short space of time, it is perhaps not surprising that the MCID failed 
to show prognostic value with regards to survival. Furthermore, as the MCID 
should, in theory, relate to a parameter that patients appreciate a difference in. 
Therefore there is an argument that it would be better to relate to QOL score or other 
patient reported outcomes (PROs). However, lack of longitudinal data on these over 
the same time period as CT scans were done limited my ability to conduct such 
analyses. Notably QOL and the other measures assessed have been related to one 
another in prior studies. The 2011 systematic review by Westwood et al quoted an r 
value between FEV1 and SGRQ of -0.46, and the relationship seemed to strengthen 
with a larger increase in FEV1 associated with a greater improvement in the 
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SGRQ(263). Therefore, although we were unable to use SGRQ to propose a MCID, its 
significant relationship to FEV1 means there is still likely to be an impact of 
achieving the MCID and QOL features.  
 
Within the ADAPT cohort, most patients who had 2 or more scans performed had 
them done so between 2002 and 2004 as part of the ADAPT project and REPAIR 
(Retinoids in Emphysema Patients in the α1-Antitrypsin International Registry) 
studies (143 out of 155 scans performed 2004 or earlier). Although quantitative CT 
has been performed within the ADAPT group on many patients particularly as part 
of the NIHR rare diseases collaboration, most of these patients did not have a 
previous scan to compare to. Only 12 scans used in this longitudinal analysis were 
performed and analysed since 2014. In a bid to reduce the impact of the time 
between scans, only those which used the same CT acquisition parameters were 
used. At least 2 different versions of PULMO have been used over time and a change 
in CT scanner will have inevitably introduced some changes differences difficult to 
account for. As demonstrated in table 7.1 there are significant differences between 
our cohort and those patients used within the two trials by Dirksen et al, namely age 
and FEV1. Our patients were more likely to be older with worse COPD as measured 
by FEV1. However, the MCID proposed sits between those receiving placebo in 1999 
Dirksen et al study and our cohort, which is likely to indicate this value relevancies 




The strengths of this study include the uniformity with regards to CT acquisition 
parameters, the importance of which was outlined in section 1.8. Care and time have 
been spent with help of a statistician to ensure the methods and results are robust, 
and a variety of methods to propose an MCID employed. One limitation would be 
that the MCID proposed using the distribution method was done primarily from 3 
studies, all of which were placebo controlled RCTS of alpha one augmentation 
therapy. The proposed MCID -2.89g/L represents one of four calculated values, and 
the true value is likely to lie within the proposed range of values (2.04g/L - 4.08g/L, 
95% CIs -0.41to -4.59). Each method used has both inherent strengths and 
weaknesses, and the RCI which we used in the analyses is a distribution method and 
therefore signifies the minimal detectable difference (MDD). In order to increase 
confidence in the proposed MCID we should re-evaluate the value with the results 
of other such RCTS if and when they are published. The current MCID is taken from 
AATD patients and therefore is not generalisable to the usual non deficient COPD 
population. There is no equivalent parenchymal therapy in usual COPD, but we 
would urge caution in using this value outside -an AATD population.  
 
7.6. Conclusion 
In conclusion, the proposed MCID for CT density in patients with AATD is -2.89g/L. 
This value is derived but may act as guidance for powering trials assessing 
therapeutic interventions to alter CT density decline, and identifying patients who 
may benefit from alpha one augmentation therapy.  
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 Overall conclusions from this thesis relating to the original Chapter 8
hypotheses 
 
Chapter 4 : The systematic review demonstrated that CT density relates 
significantly to all commonly used clinical parameters. The large amount of 
heterogeneity and lack of longitudinal data means that the sensitivity and 
specificity of CT density change, relating to time or interventions is not clear. 
International consensus is required to standardise CT conduct and analysis in 
future emphysema studies. The null hypothesis was rejected. 
 
Chapter 5 : There was no significant inter-observer variability detected, and 
therefore CT density analysis technique by DC successfully validation. 
Following assessment of intra-observer variability, the intra-class correlation 
coefficient for future work within this thesis in 0.99. As all repeated scans were 
comparable, the null hypothesis was rejected. 
 
Chapter 6 : Volume and PD15 when analysed using the same slice thickness 
were identical for the two most frequently used software programs in CT 
densitometry (Pulmonary Workstation and PULMO) and can be directly meta-
analysed. The difference between results for -910HU and -950HU using the 
same slice thickness is negligible, and all measurements using different slice 
thicknesses require application of a correction factor. The null hypothesis is 
236 
 
rejected for both analyses of CT scans using the same and different slice 
thickness as a correction factor can be applied.  
 
 
Chapter 7 : Each measure of CT density i.e. RA-910HU, RA-950HU and PD15 
was significantly associated with lung function and quality of life measures. 
Following adjustment for variables including age and lung function, RA-
950HU and PD15 were both predictive of mortality but RA-910HU was not. 
Given the clear strongly significant association between CT density and other 
clinical measures, the null hypothesis was rejected.  
 
Chapter 8 : The proposed MCID for CT density in patients with AATD is -
2.89g/L-1/year and may act as a guide for those patients under CT surveillance. 
However, the MCID failed to identify those patients more likely to die and 
therefore the null hypothesis is accepted.  
Where there is appropriate standardisation of CT acquisition parameters 
heterogeneity between CT density analyses may be eliminated, and the inter-reader 
variability is negligible. CT density is strongly associated with clinical parameters 




 General discussion and future directions Chapter 9
 
Chronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and 
mortality.  The pathophysiology is increasingly recognised as complex, with some 
patients remaining stable whilst others show more rapid decline. The most used 
biomarker for disease change in COPD remains the FEV1, but has been 
demonstrated to only detect disease once a third of the lung has been affected by 
COPD(292). Evidence presented in this thesis has demonstrated that the relationship 
of CT density to all other clinical parameters deemed suitable as outcomes for 
airways disease trials (e.g. FEV1, SGRQ) was consistently significant, and 
furthermore there was a clear and consistent relationship to mortality. This suggests 
that CT density is an appropriate surrogate outcome measure in studies of 
emphysema, like those conducted in AATD.  However, the large amount of 
heterogeneity and lack of longitudinal data means that how sensitive and specific CT 
density is to change relating to time or interventions is not clear. Further 
international collaboration is required to reach a unified consensus regarding CT 
standardisation in order to reduce the heterogeneity that is currently hampering its 
development as a biomarker within COPD.  
The systematic review presented in the chapter four demonstrates statistically the 
reduction in heterogeneity once the same reconstruction algorithm, slice thickness 
and software program is used. In chapter five we showed that where the same slice 
thickness and reconstruction algorithm are used, the agreement between the two 
leading software programs is strong and identical values for volume and PD15 are 
238 
 
produced. However, whether the 1-3% difference in relative area seen for 
emphysema thresholds --910HU and --950HU is clinically significant or not remains 
to be determined. When 1mm and 5mm slice thicknesses are compared, the 
difference in values is greater again and if/how to adjust for this needs further 
consideration. These two slice thicknesses used by the two most frequently software 
programs (PULMO and Pulmonary Workstation), and realistically unlikely to 
change in the near future.  
Through the analyses performed using patients recruited to the Birmingham AAT 
registry, chapter six shows we were able to validate the association between CT and 
clinical parameters presented in the literature. Each measure of CT density i.e. RA-
910HU, RA-950HU and PD15 was significantly associated with lung function and 
quality of life measures. Furthermore, for the first time CT density as measured by 
PD15 is significantly associated with mortality, including after adjustment for FEV1 
and KCO 
Taking the concept of CT density and its clinical utility forward, in chapter 7 we 
proposed an MCID of -2.89g/L-1/year for CT density decline in patients with AATD. 
Am annual density decline value beyond this may indicate patients who are 
declining rapidly and could possibly benefit from alpha one augmentation therapy. 
This value was proposed using available data from three alpha one augmentation 
trials that use CT density as an outcome measure, and patients who had received 2 
or more CT scans as part of the Birmingham AAT registry. Further work is still 
required to fully understand the utility of CT density longitudinally and its role as 
an outcome measure.  
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The problem with CT as a biomarker and its use in serial repeat measurements is the 
associated radiation dose. At 80 times the radiation dose of that associated with a 
plain chest x-ray, the combined dose over 2 or more CT scans is not negligible 
therefore MRI as a non-ionising imaging modality has been considered(408). The 
lungs have historically been notoriously difficult to image but by hyperpolarising 
inhaled gases to alter the proton behaviours accordingly, direct visualisation of the 
airspaces can be obtained. There is renewed interest in therapeutic options available 
in advanced COPD such as endobronchial valves (EBV)/coils for the purpose of 
lung volume reduction, which remains an attractive option for AATD patients in 
whom standard Lung Volume Reduction Surgery (LVRS) is not currently 
recommended due to adverse outcomes in the National Emphysema Treatment Trial 
(NETT ) (140). MRI has the potential to define patients who could benefit from 
valves/coils by defining the areas of ventilation more accurately than CT and 
therefore offering prospects for direct and imminent patient benefit. A small pilot 
study has been organised in collaboration with the University of Nottingham who 
are already performing MRI with hyperpolarised Xenon in patients with usual 
COPD. Our aim is to conduct the first study of the utility of lung imaging by 
hyperpolarised xenon MRI for quantifying emphysema in AATD patients. To date 
10 AATD patients have been successfully recruited with a view to start scanning in 
October 2017.  
 
We plan to perform functional MRI scans in Nottingham using inhaled 
hyperpolarised xenon to produce novel and clinically relevant data regarding 
240 
 
emphysema in AATD identified from the UHB data base. All patients already have 
PFTs, Quality of Life (QoL) scores and CT scans for comparison with the MRI scans. 
Understanding regional gas trapping in AATD will likely enable therapeutic 
interventions that target hyperinflation, such as endobronchial valves and coils, to be 
targeted in appropriate patients. Thus our specific objectives are: 
 
1. Acquire 129Xe MRI in AATD patients to estimate lung volumes and regional 
ventilation to provide baseline data for future clinical studies 
2. Use the images obtained to establish standard sequencing protocols, define 
algorithms and inform power calculations for future interventional studies 
3. Compare MRI results with routine PFTs, composite health scores (e.g. SGRQ)  
4. Validate MRI emphysema quantification by comparison to emphysema 
severity determined from CT density, measured using the software program 
Pulmo (including, but not limited to the most standardised PD15 assessment). 
In summary, this MD thesis has proven the clinical utility of CT density as a 
biomarker in COPD but more work needs to be done to understand its role 
longitudinally, and to standardise the technology to reduce heterogeneity. 
Functional MRI may offer an attractive non-ionising alternative that images 







Reference equations that generate predicted lung function values are available from 
the Association for Respiratory Technology and Physiology in the UK 
(www.artp.org.uk). These were generated using regression models from a cohort of 
subjects aged 18-60, and include height, age and gender components. The equations 
are as follows. 
 Unit Regression equation 
Male Female 
FEV1 l 4.30H - 0.029A - 
2.49 
3.95H - 0.025A - 
2.60 
FVC l 5.76H - 0.026A - 
4.34 
4.43H  - 0.026A - 
2.89 
TLC l 7.99H - 7.08 6.60H - 5.79 




11.11H - 0.066A - 
6.03 
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